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T ZONE LYMPHOMA: CELLULAR ORIGIN AND FUNCTION 
 The lymphoid system is exceedingly complex with specialized subsets of lymphocytes 
involved in both the innate and adaptive immune response. Lymphocytes are subdivided into T 
cells and B cells with lymphoproliferative disorders comprising a heterogeneous group of 
diseases arising from various lymphocyte subsets. Dogs are a natural model for studying cancer 
in humans with overlapping subtypes of lymphoproliferative disease seen in both species. We 
were particularly interested in characterizing lymphoma subtypes in dogs as a model for 
studying human disease progression. We believe characterization of lymphoma subtypes in 
dogs will contribute to enhanced understanding of the pathogenic mechanisms leading to the 
development of malignancy in both humans and dogs.  
 T zone lymphoma (TZL) is a subtype of peripheral T cell lymphoma (PTCL) occurring in 
both humans and dogs. Determination of the cell-of-origin of PTCLs in humans has pointed to a 
subset of the larger disease, but up to half of these lymphomas cannot be further classified and 
are referred to as PTCL – not otherwise specified (PTCL-NOS). TZL has unique phenotypic 
characteristics including absence of the pan-leukocyte transmembrane protein, CD45, allowing 
for reliable identification by flow cytometry. CD45 has been found to be critical for T cell 
signaling through the T cell receptor (TCR).  
We hypothesized TZL has been derived from an activated, mature T cell. We used gene 
expression in an attempt to classify the cell-of-origin in TZL. Then we used in vitro systems to 
identify proliferative mechanisms, cytokine production, and immunosuppression at play in this 
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disease. We determined TZL cells express genes associated with T helper 2 (Th2) and T 
regulatory (Treg) cells. We further confirmed that TZL cells do not proliferate through the TCR, 
likely due to their lack of CD45. We identified IL-2 may be involved in TZL signaling mechanisms.  
There are reports of TZL occurring with an opportunistic follicular mite infection, 
suggesting a component of immunosuppression with this disease. We thus anticipated TZL cells 
would have an immunosuppressive phenotype and inhibit normal T cells. Using in vitro 
methods, we were unable to confirm immunosuppression through production of TGF-β, 
inhibition of proliferation and inhibition of IFN-γ production. Finally, we observed older Golden 
retrievers having a higher frequency of cells with the same aberrant phenotype as TZL, but 
without evidence or suspicion of lymphoproliferative disease. We believe this finding resembles 
clonopathies of unknown significance in older human individuals, also with rare progression to 
disease.  
We now believe TZL is derived from a Th2 or Treg-like mature T cell which may be 
responsible for the indolent nature of this disease due to the tolerant behavior of those T cell 
subsets. Furthermore, inducing proliferation in this disease was challenging, which is consistent 
with slowly progressive biologic behavior. Expression of immunosuppressive molecules may 
also contribute to the indolent nature of this disease. While we were not able to observe 
immunosuppression in vitro, it is reasonable to assume there may be in vivo mechanisms of 
immunosuppression resulting in clinical manifestations seen in TZL. Characterization of cell-of-
origin of this disease, neoplastic cell function, along with recognition of a pre-neoplastic state, 
contributes to enhanced understanding of the pathogenesis of lymphoproliferative diseases in 
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Cancer hallmarks   
Cancers are an extremely heterogeneous group of diseases but fundamentally share the 
feature of uncontrolled cell growth by a number of mechanisms.1,2 This common growth 
advantage shared by all cancers and its recurring features has become the focus of study for 
many involved in the discipline of oncology research.2  Uncontrolled proliferative signaling from 
growth factors leads to a loss of homeostasis and disruption of tissue architecture.1 For 
example, CD28, a prominent co-stimulatory receptor on T cells involved in T cell proliferation, 
was found to have a recurrent mutation in 11.3% of angioimmunoblastic T cell lymphomas 
sampled and 1 case of peripheral T cell lymphoma not otherwise specified.3  Another important 
mechanism, programmed cell death has been well established as a natural protection from 
cancer development,4 yet cancer cells are able to evade internal apoptotic signals generated by 
cellular stress.1 BCL2 has a prominent role in blocking apoptosis and has a well-known gene 
translocation within the immunoglobulin loci in follicular lymphoma.5,6 Similarly, this 
translocation can also be found in 20 - 30% of diffuse large B cell lymphomas.7 For 
transformation to occur, there must be multiple ‘hits’ or mutations effecting regulation of the 
cell cycle. Likewise, tumors do not develop in isolation and also depend on the 
microenvironment for pathogenesis.1 Inflammation within tumors can have opposing effects, 
either tumor eradication or tumor promotion. Inflammation may promote production of 
growth factors leading to cell proliferation, enhanced survival factors, or enzymes which can 
facilitate invasion.8,9 Immunomodulation can also have a growth promoting effect. The immune 
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response may be altered to release cytokines which support tumor-promoting macrophages 
and neutrophils while suppressing the inflammatory response.8,10 Our work was focused on the 
cell-of-origin and cellular functions related to mechanisms of proliferation, evasion of 
apoptosis, and shifting of the microenvironment as means to cancer development in a subtype 
of peripheral T cell lymphoma. 
Peripheral T cell lymphoma  
 Lymphomas are a broad group of diseases encompassing a number of different 
subtypes with highly variable prognoses. Categorization of the specific subtype entails a 
number of diagnostic tests in order to accurately predict survival and identify the best 
treatment options. The most often employed classification system is the World Health 
Organization (WHO) classification of lymphoid neoplasms. Classification relies on using all 
available information including cellular morphology, immunophenotype, genetic features, and 
clinical presentation.11 This classification system has been adapted to canine lymphomas with 
an overall accuracy of 83% between 17 international veterinary pathologists.12 The first step in 
classification requires determining if the neoplasm is derived from an immature or mature cell 
and then determining B or T; or non-B, non-T cell lineage. T cell lymphomas are a diverse group 
of non-Hodgkin lymphomas (NHL) accounting for the minority of hematopoietic neoplasms 
compared to B cell lymphomas. Peripheral T cell lymphomas (PTCLs) are composed of a variety 
of subtypes of mature T cell lymphomas accounting for 15% of all NHL in humans11 and 15% - 
30% of all lymphomas in dogs.12-16 Up to 50% of PTCLs cannot be further characterized in 
humans and are referred to as PTCL – not otherwise specified (PTCL-NOS).11 Heterogeneity of 
PTCLs hinders identification of molecular mechanisms of disease. Furthermore, their relative 
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rarity in humans limits pharmaceutical interest from a cost benefit standpoint resulting in an 
absence of tumor models.17 T cell signaling through the T cell receptor leads to proliferation 
and a functional immune response through production of cytokines, cell receptor upregulation, 
and transcription of genes involved in survival, death, and signaling. It is not surprising that in 
humans many T cell lymphoma subtypes are associated with signaling molecules that interact 
with these imperative TCR pathways.18-20 The pathogenesis of PTCL in humans is slowly 
becoming more well-defined, but the cell-of-origin for several PTCLs remains to be identified.17 
An in depth understanding of T cell biology is needed to determine the cell-of-origin and 
possible underlying mechanisms of pathogenesis in these diseases.  
T cell Development  
T cells develop in the thymus where positive and negative selection occurs to prevent 
autoreactive T cell responses. From the bone marrow, thymic seeding progenitors arrive in the 
thymus as the earliest stage of the T cell.21 T cells begin their development without expression 
of either subset marker, CD4-CD8- T cells (double negative T cells; DN), or the T cell receptor 
(TCR).22,23 TCR rearrangement begins in the DN2 stage with gene rearrangement occurring in 
the TCR γ, δ, and β loci.24  Rearrangement continues and if the cell ultimately has a γδ 
arrangement, T cell fate commitment occurs at this point, whereas, αβ T cells continue 
development through the β-selection check point.25 A pre-TCR is formed with a rearranged 
TCRβ chain and an invariant preTα chain.26 After pre-TCR signaling, thymocytes upregulate both 
subset markers, CD4 and CD8, to the double positive (DP) stage.27 The TCRA recombination 
originates with re-expression of the RAG gene resulting in an αβ TCR in which specificity and 
binding strength for MHC determines positive and negative selection thymocyte fate.25 Self-
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peptide-MHC complexes are presented by thymic epithelial cells, dendritic cells, and fibroblasts 
to be positively selected for commitment to the single positive (SP) stage of either CD4+ or 
CD8+ cells.28  Negative selection follows in the medulla and thymocytes continue on as MHC 
class I or MHC class II restricted T cells.29 During selection, SP cells are negatively selected if 
their TCR shows high-affinity for self-antigens,28 however, this process is imperfect and there 
are  mechanisms to lessen the degree of auto-reactivity in the periphery.30 Many transcription 
factors and signaling molecules are responsible for T cell development involving different stages 
and compartments of the thymus including Notch-signaling in T cell lineage commitment and 
development,31,32 IL-7 in growth and development,33,34 and GATA3 expression is required for T 
cell development.35 The transcription factors: ThPOK, TOX, and GATA3 are involved in CD4 
lineage fate, whereas RUNX3 is required for the CD8 lineage commitment.36 After successful 
TCR recombination and progression through positive and negative selection, CD4+ T helper (Th) 
or CD8+ cytotoxic T lymphocytes (CTLs) leave the thymus in a resting, naïve state to circulate 
through the periphery.36   
T cell Activation  
T cell activation occurs when an antigen presenting cell (APC) containing the antigen 
bound to major histocompatibility complex (MHC) class I or class II is recognized by the TCR.37 
APCs include macrophages, dendritic cells, and B cells. In addition to the interaction between 
the MHC and TCR, there are a number of co-receptors involved. Activation only occurs  when 
there is both antigen recognition and a second signal.38 The costimulatory signal is transmitted 
through distinct receptors on the cell surface, CD28 being a well-recognized co-receptor. CD28 
binds to receptors on antigen presenting cells via CD80 and CD86.39 Engagement of CD28 
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generates phosphorylation of tyrosine motifs of the cytoplasmic tail of CD28 through Src-family 
kinases. Downstream proteins are recruited and activated including PI3K.40 This signaling 
cascade is similar to TCR activation which suggests synergy with TCR signaling, rather than being 
a distinct pathway.41   
Peptide-MHC recognition by the TCR facilitates phosphorylation of CD3 chains.42 The Src 
Kinase leukocyte-specific kinase (Lck) is associated with CD4 or CD8 and phosphorylates 
immunoreceptor tyrosine-based activation motifs (ITAMs) contained in the CD3 chains.43 
Phosphorylation of ITAMs enables sites for the Syk family kinase, Zeta-activated protein 70 kDa 
(ZAP-70); recruitment is also initiated by Lck-mediated phosphorylation. The membrane 
anchored protein, linker for the activation of T cells (LAT) and cytosolic adapter protein Src 
homology (SH2) domain are targets of ZAP-70 and once phosphorylated function as protein 
docking sites.44,45 Effector molecules, such as phospholipase Cy1 (PLCy1) can be incorporated 
into these docking sites stabilizing communication between the APC and the T cell.46 Activated 
PLCy1 has the ability to hydrolyze phosphatidylinositol 4,5–bisphosphate (PIP2), a membrane 
phospholipid, leading to the production of second messengers: inositol trisphosphate (IP3) and 
diacylglycerol (DAG).47 There are a number of transcription factors activated through the TCR 
including the nuclear factor of activated T cells (NFAT), nuclear factor of kappa-light-chain 
enhancer of activated B cells (NF-kB) and activator protein-1 (AP-1).48  The NFAT pathway 
requires Ca2+ which comes from PLCy1 mediated IP3 generation leading to Ca2+ influx when Ca2+ 
channel receptors increase permeability in the endoplasmic reticulum.49 Ca2+ is a universal 
second messenger and increased intracellular Ca2+ levels lead to activation of Ca2+ and 
calmodulin-dependent transcription factors through the phosphatase, calcineurin.50 Calcineurin 
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can dephosphorylate proteins of the NFAT family, allowing for access to the nucleus and gene 
expression.49 AP-1 proteins can partner with NFAT, which can result in particular gene 
expression patterns.51 The production of DAG leads to activation of the rat sarcoma (RAS) and 
protein kinase C theta (PKCθ) pathway. Activated RAS induces the mitogen-activated protein 
kinase (MAPK) cascade, which can result in the activation of the AP-1 complex.52 DAG 
production can also lead to the activation of NF-kB signaling through PKCθ.52 NF-kB can regulate 
a wide variety of genes involved in the immune response and T cell growth, survival and 
differentiation.53  Normally NF-kB is resting in the cytoplasm associated with (inhibitor of kB) 
IkB. Phosphorylation of IkB leads to degradation of IkB and release of NF-kB to allow for nuclear 
localization and gene transcription.54 AP-1, NFAT, and NF-kB behave in concert, resulting in the 
expression of interleukin-2 (IL-2).55 TCR signaling resulting in IL-2 production provides both 
autocrine and paracrine signals for T cell proliferation through the IL-2 receptor (IL-2R) and 
JAK/STAT pathways.56,57  
During the proximal TCR signal, the process is regulated via inhibitory phosphates. CD3 
is not directly involved in antigen recognition, but is involved in transmitting the TCR signal 
through ITAM phosphorylation by the Src-family protein tyrosine kinases such as Lck, Fyn and 
Zap-70. Phosphorylation of Y505 by C-terminal Src kinase (Csk) maintains Lck in an inactive 
conformation.58 Dephosphorylation of this inhibitory Y505 residue of Lck by CD45 tyrosine 
phosphatase yields auto-phosphorylation at Y394, resulting in the activation of Lck.58 In some 
circumstances CD45 can inhibit Lck and other molecules though dephosphorylation of 
activating residues.59 The fine tuning of T cell response by CD45 has yet to be completely 
elucidated,55 but CD45 does appear to be essential for the TCR response.60-62 Proliferation and 
7 
 
cytokine production has been shown to be impaired in CD45-deficient T cell clones; however 
proliferation could be rescued through TCR independent mechanisms such as IL-2 signaling or 
through exogenous mitogens.60,63 Additional impairment in CD45-deficient clones included their 
inability to produce cytokines, and in CD8 T cells, cytolysis has also been shown to be 
hindered.60,64 
 
Figure 1. Schematic of T cell activation. T cell activation begins with antigen recognition. The 
TCR has affinity for antigen presented by the antigen-presenting cell (APC). Costimulation 
through CD28, along with sustained interaction between the T cell and APC, is facilitated by 
other connections including CD4 or CD8. These interactions form an immune synapse 
promoting activation of phosphorylation cascades and docking sites involving Lck, Fyn, ZAP-
70 and LAT. PLCγ produces secondary messengers including IP3, DAG, and Ca2+ with 
subsequent activation of multiple pathways such as RAS and MAPK. Ultimately there is 
release or activation of transcription factors (NFAT, NF-kB and AP-1) in the nucleus for 
transcription of genes involved in proliferation and effector functions. Upregulation of IL-2 
and the high affinity IL-2 receptor propagates the response. IL-2 can act upon the IL-2R and 





T cell differentiation 
Naïve T cells in the peripheral lymphoid tissue undergo differentiation in order to 
produce an appropriate immune response. The two main branches of T cells are CD4+ Th cells 
and CD8+ CTLs, which interact with MHC II and MHC I, respectively.65 The T helper subsets 
include Th1 and Th2, which were the first discovered T helper subsets,66 Th17 and Th9 which 
produce the cytokines IL-17 and IL-9,67-69 follicular helper (Tfh) with functions in the lymph node 
follicle70 and regulatory (Treg) T cells regulate the immune response and control self-
tolerance.71 CTLs are activated by cells that are infected with intracellular pathogens.72   
Virus or intracellular bacteria can promote Th1 and CTLs through type I IFNs and IL-12 
produced in response to these pathogens.73,74 The expression of the transcription factor, T-bet, 
which is the master transcription factor for Th1 cells,75,76 is elicited in these responses. Mice 
deficient in the IL-12 or the IL-12 receptor have a poor Th1 response and reduced ability to 
produce the classic Th1 cytokine, IFN-γ.77,78 T-bet/TBX21 controls expression of IFN-γ and can 
repress production of the Th2 cytokines, IL-4 and IL-5.76,77 Similarly Th2 responses are more 
prominent in mice lacking IL-12,77 which illustrates the reciprocal nature of promotion and 
inhibition of Th1 and Th2 cells. Similarly, IFN-γ has been shown to directly inhibit Th2 cell 
proliferation,79 as well as to boost Th1 programming through up regulation of IFN-γ receptor 
mediated STAT1 generated T-bet expression.80    
Th2 cells are elicited in response to parasites and allergic disease, and are induced by IL-
4.81-83 Th2 cells also produce IL-4, IL-5, and IL-13, inducing alternatively activated macrophages 
(IL-4, IL-13)84 recruitment of eosinophils (IL-5),85 and initiating B cell production of IgG and IgE 
(IL-4).86 GATA3 is the major transcription factor of Th2 cells and is upregulated by IL-4 though 
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STAT6 mediation.87,88 STAT6 phosphorylation results in gene induction of GATA3.89 STAT6 has 
been identified as a requirement for activation of 77% of enhancers specific for Th2.90 However, 
GATA3 expression can direct Th2 differentiation independently of IL-4 and STAT6.91 GATA3 can 
also inhibit Th1 differentiation; for instance, ectopic GATA3 expression in Th1 cells leads to IFN-
γ repression and expression of Th2 cytokines.92  GATA3 expression is induced by IL-2/STAT593 
and through Notch pathways,94 which are also involved in Th2 differentiation. Another 
important Th2 transcription factor is c-Maf, which contributes to peak IL-4 production and 
increased levels of CD25 in emerging Th2 cells.95,96  
Th9 cells develop in conditions characterized by TGF-β and IL-4 and they produce IL-9,97-
99 which is a common γ-chain cytokine involved in parasitic infection100,101 and allergy.102 Th9 
responses are often in accordance with Th2 cellular reactions delaying identification of this 
subset. There are several transcription factors that have been identified to be involved in Th9 
cells, however, PU.1 appears to be required.67 GATA3 involvement in Th9 differentiation has 
shown variable results. GATA3 mRNA is increased during differentiation, but retroviral 
expression of GATA3 repressed IL-9 production in Th9 cells;103 additionally, GATA3 expression 
was absent in Th9 cells in some studies98,104 but was identified with intracellular staining in 
others.103  
Th17 cells are involved in the clearance of organisms which Th1/Th2 cannot combat 
successfully. For instance, fungal and extracellular pathogens have been shown to elicit a Th17 
response.105-107 TGF-β and IL-6 have been found to induce naïve T cells to produce IL-17.108,109 In 
humans, TGF-β is necessary to induce RORγt which is the major transcription factor for this 
subset. IL-6 and IL-23 or IL-21 are necessary to allow RORγt to upregulate the transcription of 
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IL-17.110 RORγt is necessary for Th17 differentiation and transduction of T cells with this 
transcription factor induces production of IL-17 in naïve T cells.111 STAT3 has also been found to 
be important in Th17 differentation.112,113 IL-17A and IL-17F produced by Th17 cells leads to 
activation and recruitment of neutrophils to areas of infection.114,115 Although TGF-β is 
necessary for Th17 cell differentiation, high concentrations of TGF-β will shift the environment 
away from Th17 cells and induce T regulatory (Treg) cell differentiation through the 
transcription factor, Forkhead box P3 (FoxP3).116 
Treg versus Th17 cell development has been found to be mutually dependent on 
communication from the innate immune system.109 With TCR stimulation in the presence of 
TGF-β, a naïve cell can express Foxp3 leading to Treg differentiation; however if IL-6 or IL-21 is 
also present, Th17 cells develop instead.116 Th17 cells have been implicated in autoimmune 
disease,68,69,117 whereas Treg cells inhibit autoimmunity.71 Treg cells actively downregulate the 
activation and proliferation of self-reactive T cells; Treg cells are also involved in suppressing 
excessive inflammation in other immune responses, including T cells recognizing infectious 
antigens.71,118-120 Treg cells develop both in the thymus and in the periphery; naïve T cells can 
differentiate into Treg cells in the presence of IL-2 and TGF-β.121 Thymus and peripheral derived 
Treg cells express the master transcription factor, Foxp3,122-124 which is induced in naïve T cells 
by high levels of TGF-β.125 TGF-β has also been shown to inhibit Th1 and Th2 differentiation 
through down regulation of the differentiation transcription factors, T-bet and GATA3, 
respectively.126,127 
Follicular helper T cells (Tfh) are identified as a T cell subset, independent of Th1, Th2, 
and Th17 with reliance on the master transcription factor, Bcl6.128-131 The other T helper cell 
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subsets express high levels of Blimp-1,128,132,133 which is an antagonist of Bcl6 and vice 
versa.133,134  After antigen recognition, T and B cells migrate to the T cell zone-B cell zone border 
where their interactions increase.135-138 T cells express high levels of CXCR5 in order to maintain 
follicular center localization and continued contact with B cells.128,139,140 Tfh cells are involved in 
development and maintenance of the germinal center (GC), along with the production of 
plasma cells and memory B cells.70,141 This process involves a number of signaling pathways, 
including survival signals necessary for generating GC B cells dependent on somatic 
hypermutation with eventual downregulation of proliferation, and replacement by signals for 
plasma cell differentation.70 IL-6 and IL-21 have also been implicated in TfH cell 
development.129,130 IL-21 is expressed by Tfh cells139,142-144 but not exclusively.142,145-147 IL-21 
expression leads to plasma cell differentiation and GC B cell proliferation.148,149 IL-4 is also 
produced by Tfh cells for the process of B cell help139,144 and may be involved in B cell survival.   
CD8+ T cells interact with MHC class I expressing cells which present cytosolic peptides 
that have been degraded by proteasomal mechanisms and transported to the endoplasmic 
reticulum where they are bound to MHC class I molecules and presented on the cell surface.150 
CD8 T cell response in acute infection includes clonal expansion with differentiation into 
effector and memory cells. CD8 T cells mediate defense against intracellular organisms through 
secretion of INF-γ, TNF-α151 and cause cytolysis through perforin and granzyme delivered to 
target cells.152,153 Additionally, upregulation of FasL allows for ligation via Fas-FasL causing cell 
death.154 After cell expansion and clearing of the pathogen, CD8+ T cells enter a contraction 
phase whereby < 10% survive to become memory CD8+ T cells with phenotypically increased 
expression of the IL-7 receptor-α, CD27, BCL2, and decreased expression of killer cell lectin-like 
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receptor G1 (KLRG1).155-158 Memory cells are further characterized as central memory CD8+ T 
cells, which occupy secondary lymphoid organs with proliferative capacity; and effector 
memory CD8+ T cells which inhabit non-lymphoid tissue and continue to have cytotoxic 
function.159  T-bet and eomesodermin (EOMES) are vital transcription factors for function of 
CD8+ T cells 156,160-162 and are reciprocal in their expression in differentiation. T-bet expression is 
the highest in early effector CD8+ T cells and then declines, whereas EOMES is upregulated in 
early effector cells but expression increases with memory differentiation.156,162 Additional CD8+ 
effector T cell subsets are non-cytotoxic and promote a Th2 response. There is evidence that IL-
4 can induce CD8+ T cells with Th2-like effector functions.163 Furthermore, CD8+ T cell subsets 
in human peripheral blood were identified by high expression of IL-6R, expression of GATA3, 
along with production of IL-5 and IL-13; in patients with asthma, there was increased 
prevalence of this subset.164 Additionally, this subset also expresses low levels of terminally 
differentiated CD8+ T cell genes including T-bet, EOMES, and Blimp-1 with a possible Th2-like 
polarized state.164 
Cell-of-origin in lymphoma  
In humans, identification of the cell-of-origin for various lymphoma subtypes has shown 
biologic165 and prognostic significance,166,167 as well as elucidating potential interventions for 
therapy.168,169 Peripheral T cell lymphomas (PTCLs) lack many of the definitive diagnostic and/or 
cytogenetic markers found in B cell lymphomas complicating the classification and subsequent 
investigation of this branch of lymphoid neoplasms.167 While there are several subtypes of 
PTCLs including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma 
(ALCL), and adult T-cell leukemia/lymphoma identified by WHO classification, 30 - 50% of PTCLs 
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cannot be further defined and are categorized as PTCL-not otherwise specified (PTCL-NOS).11 
PTCL-NOS are considered a heterogeneous cohort of multiple entities with no reliable criteria 
for delineating these neoplasms.16  Gene expression profiling (GEP) of T cell lymphomas has led 
to advances in classification170 and identification of the cell-of-origin in some subtypes. For 
example, AITL and follicular T cell lymphoma (FTCL) have been identified to have a similar GEP 
leading to a common lineage for these two subtypes, compatible with a T follicular helper 
cell.170,171 There is evidence that adult T cell leukemia/lymphoma is derived from a T regulatory 
cell with expression of CD25 and FoxP3,172 the T regulatory cell transcription factor. Recently, 
GEP has identified two major categories of PTCL-NOS with high expression of either GATA3 or 
TBX21 (T-bet), 167 the transcription factors responsible for Th2 and Th1 differentiation, 
respectively. Expression of these transcription factors was not only useful for categorization of 
PTCLs-NOS, but was also prognostically important.167 Through gene expression, most PTCLs-
NOS have been more closely related to a mature CD4+ Th cells with a marginal number of cases 
with gene patterns more similar to CD8+ CTL.173 Derivation from mature T cells is supported by 
variable function and expression of the αβ T cell receptor (TCR).171 
In dogs, investigation into the cell-of-origin of lymphoma subtypes has been limited. 
Gene expression profiling of canine diffuse large B cell lymphoma (DLBCL) revealed a similar 
pattern to that seen in human diffuse large B cell lymphoma.174 In humans, DLBCL is derived 
from germinal center B cells and activated B cells.175,176 The gene expression pattern in canine 
DLBCLs was consistent with germinal center B cells and post-germinal center B cells similar to 
the findings with humans.174 T cell lymphomas are more common in dogs than in humans, but 
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are still less common that B cell tumors, accounting for nearly 30% of all lymphomas in dogs.12 
Still, molecular investigations involving canine T cell tumors is very limited.177,178 
Dogs as a natural model for cancer  
While mice are a common model for studying human disease genetics because of the 
ease and degree to which these animals can be modified; for cancer, this model is hindered by 
the lack of spontaneous disease development compared to humans.179 Dogs, on the other 
hand, live in the same environment as their humans with > 40% of households in the US having 
at least one dog.180 Further, dogs receive a high level of health care. In dogs over 10 years old, 
cancer is the leading cause of death.181,182 Dogs provide an obvious system for studying 
spontaneous disease development and cancer growth within an intact immune system.183 
Many types of naturally occurring cancers in dogs overlap with human disease in 
histomorphology, genetics, biologic behavior, and therapeutic response.184 There are nearly 
400 dog breeds with variable affinities for specific diseases and their associated 
mutations.179,185 In fact, 41 naturally occurring dog diseases have homologous human genes 
associated with similar disease phenotypes in humans.186 Canine genome mapping has also 
identified marked genetic similarities between dogs and humans.187,188 Breed associated 
diseases suggests there is a limited number of loci involved in each disease, which presents an 
advantage for determining underlying genetic susceptibility, when compared to humans.189,190 
Lymphomas are one of the more common tumors in dogs191 and several breeds have been 
identified to have a higher relative risk for developing various lymphoma subtypes.192 For 
instance, Boxers have a predisposition to the developing an aggressive CD4 T cell 
lymphomas,193-196 while American Golden Retrievers have a high incidence of T zone 
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lymphomas.197 The incidence of canine non-Hodgkin lymphoma is similar to that seen in 
humans.198,199 Canine lymphomas have similar morphology to their human counterparts with 
high reproducibility and adaptability of the human WHO classification scheme for lymphomas in 
dogs.12-14 
T zone lymphoma in dogs  
While PTCL in dogs is likely a heterogeneous groups of diseases, specific characterization 
of several T cell lymphomas in dogs has aided in the identification of distinct subsets of T cell 
lymphomas in dogs.15,194,196,200,201 The most common types of T cell lymphomas in dogs are 
PTCL-NOS and T zone lymphoma (TZL).12,16 TZL occurs rarely in humans, but shares a similar 
histomorphology with the canine disease.202,203 In dogs, TZL accounts for 4-13% of all 
lymphomas.12,15 TZL has a unique histologic pattern with compression of follicles by the 
expanded paracortex (T zone) and infiltration of the medullary cords by neoplastic cells with 
maintenance of nodal architecture.203 The cells are small to intermediate in size with folded or 
indented nuclei and indistinct nucleoli; mitoses are rare.12,203 Because the histologic evolution 
associated with this disease retains follicles and the pattern is nodular,204 accurate diagnosis 
may be challenging in the earlier stages and fine needle aspiration may be equivocal in 
distinguishing malignant TZL from benign lymphocytes.12 Due to phenotypic abnormalities, this 
disease can be reliably diagnosed using flow cytometry.197 The neoplastic cells can express 
either or both subset antigens, CD4+ and CD8+, or neither,197,200,205 but consistently do not 
express CD45 protein which has been verified by flow cytometry197,205 and histopathology 
recognizing multiple CD45 clones.206 Additionally, CD45 gene expression206,207 is absent in TZL, 
even though CD45 DNA can be found.206 Other aberrant phenotypic characteristics include 
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increased expression of the activation markers: CD21,178,197,205 CD25,197,208 and class II MHC.197 
Clinically, systemic lymphadenopathy is reported,208,209 even when clinical illness is absent.12,203 
The median age at diagnosis is 9 -10 years old in dogs197,200,203,204 and peripheral blood 
involvement is common.197,200,204 In a study on nodal TZL, all cases with available blood had 
evidence of aberrant TZL cells in the peripheral blood even when there was a normal 
lymphocyte count.197 TZL is considered indolent and survival times of 622 to >1000 days have 
been reported.15,197,200,204 This disease has also been reported extranodally, in the tongue, with 
most cases also showing indolent behavior.210  The best treatment for this disease has not been 
systematically determined. There is evidence that the common multidrug chemotherapy used 
in many types of canine lymphoma does not improve survival.15  In a couple of case series, 10-
50% of dogs with TZL also had demodicosis204,208 which has been associated with 
immunosuppressive diseases in adult dogs.211 Additionally in 10% of cases of TZL, a separate 
tumor was reported,200 suggesting there is a clinically significant degree of immunosuppression 
in at least a subset of TZL patients. 
Although TZL appears to be relatively rare in humans,212 the phenotypic features and 
indolent clinical course in dogs provide an opportunity for studying early and late phases of 
pathogenesis of a lymphoid neoplasia. In humans, there are multiple B and T cell clonopathies 
identified by their phenotypic abnormalities even though progression to disease is rare. These 
include monoclonal gammopathy of undetermined significance (MGUS), monoclonal B cell 
lymphocytosis (MBL), and T-cell dyscrasia of undetermined significance or T cell clones of 
undetermined significance (TCUS). MGUS is found in ~4% of Caucasian individuals over the age 
of 50 and there is an average risk of developing multiple myeloma of 1% per year.213,214 In 
17 
 
MGUS, the phenotype includes expression of CD138+/CD38+, which is expressed on normal 
plasma cells but there is usually one or all of the following additional, aberrant phenotypic 
characteristics: CD19-, CD45-, or CD56+.215,216 MBL is also an age related asymptomatic 
phenomenon characterized as an expansion of B cells with the same phenotype as CLL (CD5+, 
CD19+, CD23+, CD20+, and sIg dim), with an overall risk of transformation to CLL of 1 – 2% per 
year.217 A possible precursor or benign counterpart to cutaneous T cell lymphoma was 
identified as a monoclonal expansion of CD3+CD4+CD7-CD26- lymphocytes in the peripheral 
blood in patients with erthroderma.218 In another T-cell dyscrasia, clonality was defined by Vβ 
expression. T cell subset markers were varied, similar to canine TZL, with cases being either 
single positive CD4+ or CD8+, having co-expression of CD4+ and CD8+, or negative for both 
subset markers: CD4-CD8-; the most common feature was decreased or absent CD5.219 These 
phenotypic aberrancies allow for screening for these syndromes and prompt investigation into 
risk factors associated with disease development. Distinct, early pathogenic events have been 
identified in MGUS and multiple myeloma but how these events contribute to different stages 
of disease is still not well understood.220 Prediction of disease development in MBL has 
improved by stratifying individuals into high and low B cell count subgroups.221 High-count MBL 
individuals have a higher risk of serious infection than progression to CLL,222 highlighting the 
need for investigation of cellular function and pathogenesis in this syndrome in order to 
optimize patient management. Genetic factors in familial diseases play a role in determining 
relative risk for both MBL and MGUS.223-225 TZL has been identified to be highly prevalent in 
American Golden retrievers;197 this breed susceptibility suggests an inherited component for 
this disease.  TZL may have a similar pre-neoplastic state and genetic risk as these human 
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entities and phenotypic abnormalities afford the prospect for early identification and 
investigation of pathogenic stages of this disease.  
Conclusion 
 A fundamental principal of cancer development is uncontrolled cell growth. The 
pathogenesis of PTCL is still under investigation but various TCR signaling mutations have been 
identified. Determination of the cell-of-origin in PTCL subsets has already provided more 
accurate prognostic information. Identification of the cell-of-origin has led to better 
understanding of the mechanism of T cell activation and improved patient management 
through targeted therapeutic options. Dogs are an excellent natural model for studying 
lymphoid neoplasia and T zone lymphoma is the second most common T cell tumor in dogs. TZL 
is a slowly progressive disease with unique phenotypic features allowing for early identification 
and rich investigation into the mechanisms of pathogenesis at various stages of this disease. 
We intended to answer fundamental questions related to TZL cellular function as it contributes 
to pathogenesis. We asked: 
1. What is the cell-of-origin for TZL? 
2. What is the driving mechanism for proliferation in this disease? 
3. Is there in vitro evidence for immunosuppression in this disease? 
4. Is there a pre-neoplastic state in TZL and are Golden retrievers predisposed to carry a 
pre-neoplastic phenotype?  
We were ultimately able to characterize a molecular signature for TZL which is suggestive of 
Th2-like cells with highly expressed regulatory molecules. Further, TZL’s proliferative capacity is 
TCR independent, with lacking CD45. Despite expression of immunosuppressive molecules and 
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clinical evidence of immunosuppression in TZL, suppression of normal T cells within the tumor 
microenvironment was not observed in vitro. Lastly, while Golden retrievers do have an increased 
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CHAPTER 1: DETERMINING THE CELL-OF-ORIGIN OF TZL 
Summary  
Gene expression profiling in human lymphoproliferative disorders has identified targets 
for therapy as well as beginning to differentiate subtypes of peripheral T cell lymphoma by cell-
of-origin. T zone lymphoma (TZL) is a subtype of peripheral T cell lymphoma and is the second 
most common T cell lymphoma in dogs. We sought to investigate the cell-of-origin of TZL by 
investigating over 250 genes involved in T cell differentiation. We found increased expression of 
GATA3, the master Th2 transcription, factor and the Th2 specific receptors, CRTh2, CCR3, and 
CCR4 in TZL cases compared to sorted CD4+ and CD8+ T cell controls from healthy dogs. We 
validated gene expression of GATA3 and the expression of immunosuppressive molecules, 
galectin-1 and galectin-3 with immunohistochemistry. These findings suggest that TZL is derived 
from a Th2-like cell with expression of immunomodulatory molecules.  
Background 
Lymphoproliferative disease encompasses a large, assorted group of neoplasms derived 
from normal lymphocyte counterparts. In humans, in lymphoma subtypes in which the cell-of-
origin has been identified, there have been improvements in prognostic information,1,2as well 
as guiding potential interventions for therapy.3,4 Peripheral T cell lymphomas (PTCLs) have 
fewer cytogenetic markers than B cell lymphomas impeding differentiation of this division of 
lymphoid neoplasia.2 In humans, PTCLs are much less common than B cell lymphomas, 
accounting for only ~12% of non-Hodgkin lymphomas internationally.5 There are several 
subtypes of PTCLs within the World Health Organization (WHO) classification scheme of 
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lymphoid neoplasms including: angioimmunoblastic T-cell lymphoma (AITL), anaplastic large 
cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma.6 The majority of PTCLs are 
categorized as PTCL-not otherwise specified (PTCL-NOS) due to inability to further differentiate 
subtypes.6 More recently, gene expression profiling (GEP) of T cell lymphomas has led to 
advances in classification,7 and determination of the cell-of-origin. GEP has identified two major 
categories of PTCL-NOS demonstrating high expression of either GATA3, the master 
transcription factor for Th2 cells or T-BET, 2 the master transcription factor for Th1 cells. 
Further, expression of these transcription factors not only distinguished PTCLs-NOS, but also 
had prognostic significance.2 
T zone lymphoma (TZL) is a neoplasm of the blood and lymph nodes that has an indolent 
clinical course in dogs.8,9 In the lymph node, TZL is associated with an expansion of T cells in the 
paracortex or “T zone” which compresses germinal centers.10 Normally T cells migrate through 
the T zone to interact with dendritic cells as part of the immune response.11 The T cells 
migrating through this area can be of various subtypes. Naive T cells develop in the thymus 
prior to differentiation; immature T cells undergo positive and negative selection in the thymic 
cortex and medulla to become MHC class I or class II restricted.12 Positively selected T cells 
differentiate to become CD4 T helper (Th) or CD8 cytotoxic T lymphocytes (CTLs) and single 
positive cells leave the thymus to circulate in the periphery.13 In the periphery, T cells are 
dormant until they encounter antigens or activating signals.13 T cell survival is dependent on 
activation of the TCR by co-stimulatory molecules and cytokines, including IL-2.13 
In the case of naïve CD4+ T cells, master transcription regulators signal Th cell 
differentiation,14 and cytokine signaling influences the appropriate transcription factor for the 
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optimal immune response. Classically Th1 cells are induced by IFN-γ and IL-12 and produce IFN-
γ participating in elimination of intracellular pathogens along with activating mononuclear 
cells.15 Whereas Th2 cells produce IL-4, IL-5, and IL-13 and are involved in responding to 
parasitic infections and forming the allergic response.16,17  Other, well characterized Th subsets 
include, Th17 cells which utilize several signaling cytokines including: IL-17, IL-21, IL-23, and 
TGF-β; retinoic acid receptor-related orphan receptor gamma-T (RORγt) is the master 
transcription factor of Th17 cells which are involved in inflammation and combating 
extracellular bacteria and fungi.18 TGF-β is the major initiating cytokine and FOXP3 is the major 
transcription factor for T regulatory (Treg) cells which help regulate the immune response.19,20 T 
follicular helper (Tfh) cells signal to B cells in the germinal center and are favored by production 
of IL-6 and IL-21;21,22 BCL-6 is the major transcription factor for this lineage.23 Th17, Treg, and 
Th2 cell are capable of plasticity in differentiation depending on cytokine signals dictating 
conversion to different phenotypes.24 For example, in the presence of TGF-β and IL-6 the 
response can be skewed toward Th17 proliferation, whereas TGF-β in the presence of IL-10 
shifts naïve T cells toward Treg differentiation. Additionally, TGF-β is also involved in Th9 
differentiation in the presence of IL-4,25 which was originally thought to be a reprogramming of 
Th2 cells.26  
In dogs, identifying the cell-of-origin responsible for various lymphoma subtypes has 
been limited. Gene expression profiling of canine diffuse large B cell lymphoma (DLBCL) cells 
has shown a pattern similar to what has been seen with human DLBCL counterparts.27 
Investigations looking at the cell-of-origin of T cell lymphomas in dogs has not been performed 
and there are few studies reporting molecular profiles.28,29  
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We sought to explore the cell-of-origin of TZL lymphoma through the interrogation of 
genes involved in T cell differentiation. Using NanoString technology, we investigated the gene 
expression profile of TZL in comparison to normal sorted CD4+ T cells and CD8+ T cells in dogs. 
We hypothesized that TZL is derived from an activated, mature T cell counterpart based on 
phenotypic aberrancies. 
Methods  
Selection of cases and controls subjected to cell sorting for gene expression analysis 
To investigate the gene expression signature of TZL as it relates to T cell differentiation, 
we compared the expression levels of mRNA from TZL samples and controls. A diagnosis of TZL 
required greater than 60% of the lymphocytes in the lymph node characterized by a TZL 
phenotype (CD5+CD45-) with lymphadenopathy or ≥ 5000 TZL cells/µL in the peripheral blood 
of dogs with lymphocytosis. Case samples included peripheral blood (25 samples; 7 CD4+, 10 
CD4-CD8-, 8 CD8+) and lymph nodes (11 samples; 3 CD4+, 2 CD4-CD8-, 6 CD8+) from dogs 
diagnosed with TZL by flow cytometry through the Colorado State University Clinical 
Immunology (CSU-CI) laboratory during the time period from December 2013 to March 2015 as 
previously described.30 The control samples consisted of CD4+ and CD8+ sorted T cells from the 
lymph nodes (11 samples) and thymus (5 samples) of healthy, hound mix dogs utilized as 
normal controls for a series of gene expression studies aimed at profiling T cell 
lymphoproliferative disease.30  
TZL cells were harvested from blood or lymph nodes of known TZL cases, as previously 
described.30 TZL cells were purified from samples by magnetic depletion of CD45-expressing 
cells based on the Miltenyi Biotec protocol utilizing MACS buffer. The samples were loaded 
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onto an LD column suspended in a MidiMACS separator and unbound TZL cells (CD45- cells) 
were collected.30 Anti-CD45-PE (pan-leukocyte, clone YKIX716.13, Bio-Rad [AbD Serotec], 
Hercules, CA) was the primary antibody and the sample was further depleted by anti-PE beads 
(Miltenyi Biotec, San Diego, CA). Purity of the CD45- unbound cells was then confirmed by flow 
cytometry. For control samples, cells were purified from the lymph nodes and thymus of 
healthy dogs by fluorescence-activated cell sorting on a MoFlo cell sorter (Beckman Coulter, 
Brea, CA) as previously described.30 The cells were stained with the following antibodies 
purchased from Bio-Rad: anti-CD18-PE (Human CD18, clone YFC118.3), anti-CD5-FITC (T cells, 
clone YKIX322.3) and either anti-CD4-Pacific Blue (PB) (CD4 T cells, clone YKIZ302.9), or anti-
CD8-FITC (CD8 T cells, clone YCATE 55.9).   
Gene expression analysis 
To investigate the cell-of-origin of TZL, we measured the expression of 195 genes 
involved in the differentiation of T cell subsets using a custom-designed codeset. An additional 
subset of 68 genes involved in various pathways of Th2 cells, GATA3, galectin, and T cell tumors 
in dogs and humans were subsequently investigated. Expression of these genes was quantified 
by NanoString technology (NanoString Technologies, Seattle, WA) using the nCounter Digital 
Analyzer (4.0), through the University of Arizona Genetic core. These genes were selected 
following literature review of gene expression studies characterizing T cell subsets. Genes of 
interest for this study were identified from investigations characterizing T regulatory cells,31 
differentiation of central and effector memory CD8+ T cells,32 CD4+ and CD8+ T cell 
differentiation,33,34 Tfh cell differentiation,35   and Th17 cell differentiation.36 The additional set 
of 68 genes was included to obtain more information about genes involved in Th2 
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differentiation and signaling,37,38 GATA3 target genes in PTCL in humans,2,39 and canine T cell 
lymphomas.28 Assimilation of these references led us to categorize sets of genes into T subsets 
in order to look at cell type scores and gene set enrichment using nSolver advanced analysis 2.0 
and gene set enrichment analysis (GSEA), respectively. Raw counts were normalized to 6 
housekeeping genes: GUSB, SDHA, HPRT1, EEF1G, TBP, and POLR2A. Counts of +/- 3 standard 
deviations below the negative controls were excluded from heat map analysis.  
Immunohistochemistry 
Immunohistochemistry was performed on lymph node samples from known TZL cases. 
We compared these findings to cases of known lymphoid hyperplasia. We noted the expression 
of GATA3, galectins-1 and -3, and multiple myeloma oncogene 1/interferon regulatory factor 4 
(MUM-1/IRF-4). Immunostaining was performed using the BOND-III Fully Automated IHC and 
ISH stainer. Immunohistochemistry for GATA3 (Invitrogen, Waltham, MA, monoclonal mouse, 
clone 1A12-1d9, 1:500), galectin-1 (Invitrogen, polyclonal rabbit, C-terminal region of galectin-
1, 1:50), galectin-3 (Abcam, Cambridge, MA, polyclonal rabbit, clone synthetic peptide ab31706, 
1:150) and MUM-1/IRF-4 (Biocare Medical, Concord, CA, monoclonal rabbit anti-human MUM-
1, clone BC5, 1:75) was performed on 5 μm paraffin embedded lymph node sections. 
Statistical analysis  
Differential gene expression was determined using nCounter advanced analysis 2.0. The 
Benjamini-Yekutieli test was used to determine the False Discovery Rate. Significant genes were 
determined by an FDR adjusted p-value of < 0.05. The cell type scores were calculated by taking 
the average of log2 expression of the relative characteristic genes for each subtype in TZL cases, 
compared to controls. We also employed GSEA as an additional method looking for substantial 
39 
 
differences in our gene subsets.40 Significant enrichment was identified by FDR < 25% with 
GSEA using a permutation test 1000 times. To determine the significance in Th transcription 
factors and Th2 genes in all samples for the first set of genes and GATA3 expression and CRTh2 
expression in CD8+ cases versus CD8+ controls, the data was analyzed and R and log2 
transformed; a t-test was performed with Benjamini Hockberg adjustment for multiple tests. 
Unsupervised hierarchical clustering was performed with nSolver 4.0 using the Euclidean 
distance which calculates the distance between two samples or genes as the square root of the 
sum of squared differences in their log count values. 
Results 
TZL patients have a unique immunosignature that is distinguishable from healthy dogs and 
independent of phenotype  
TZL cases displayed a common profile that was distinguishable from normal CD4+ and 
CD8+ T cells when samples from the lymph node and thymus were analyzed (see first branching 
in the top of the dendrogram; Fig 1.1). The controls readily clustered based on phenotype 
(CD4+ vs. CD8+ (Fig 1.1). However, the TZL cases were not distinguishable by phenotype and 
were instead intermingled (CD4+ vs. CD8+ vs. CD4-CD8-) (bottom of dendrogram; Fig 1.1). 
Based on dissimilar branching with unsupervised hierarchical clustering of TZL cases and 
controls (CD4+ and CD8+) we pooled control CD4+ and CD8+ T cells compared to all TZL cases to 
determine differential expression. There were 127 genes differentially expressed in all TZL cases 




Figure 1.1. TZL patients have a unique immunosignature. Unsupervised hierarchical 
clustering of control CD4+ and CD8+ T cells compared to all TZL cases. Red indicates 
decreased expression and green indicates increased expression. The controls readily cluster 
based on phenotype (1st branch; CD4+ top vs. CD8+ bottom). The phenotypes of the TZL 
cases are intermingled, failing to cluster (2nd and 3rd branch). This heat map is showing a small 
portion of the genes that were expressed at high levels in cases compared to controls. The 
figure highlights the branching of cases and controls.  
 
Table 1.1. Differential gene expression in TZL. The gene symbol, Log2 fold change of cases 
vs. controls, standard error, P-value, adjusted P-value based on the Benjamini-Yekutiedli 





P-value BY.p.value probe.ID 
PECAM1 6.32 0.622 7.02E-13 1.72E-10 XM_848326.1:1355 
LGALS3 5.65 0.343 5.79E-20 1.14E-16 NM_001197043.1:575 
TIMP1 5.64 0.576 2.15E-12 3.52E-10 NM_001003182.1:145 
S100A4 4.17 0.406 4.95E-13 1.39E-10 NM_001003161.1:247 
LGALS1 3.37 0.243 2.59E-17 2.40E-14 NM_001201488.1:160 
MYCT1 3.12 0.525 4.78E-07 2.19E-05 XM_849728.3:321 
CRTh2 2.74 0.44 1.77E-07 8.68E-06 NM_001048107.1:459 
S100A10 2.53 0.246 4.67E-13 1.39E-10 XM_003432257.2:1075 
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ITGAM 2.46 0.568 8.92E-05 0.00216 XM_005621235.1:3260 
CCR4 2.37 0.504 2.83E-05 0.000795 NM_001003020.1:865 
NFIL3 2.33 0.486 2.16E-05 0.000662 XM_003638793.3:1131 
NELL2 2.24 0.478 2.83E-05 0.000795 XM_005636954.1:2175 
HPGD 2.22 0.462 1.95E-05 0.000627 XM_005635643.1:2135 
IL18RAP 2.16 0.456 2.55E-05 0.000748 XM_538448.2:1835 
LHFPL2 2.05 0.578 0.000971 0.0169 XM_005618223.1:1475 
TNF 1.91 0.487 0.00032 0.00617 NM_001003244.4:185 
CCR3 1.89 0.457 0.000165 0.00364 NM_001005261.1:515 
HLF 1.88 0.38 1.30E-05 0.000434 XM_005624698.1:755 
SLC40A1 1.86 0.407 4.32E-05 0.00113 XM_005640439.1:605 
CD44 1.74 0.162 1.49E-13 7.30E-11 XM_851912.1:453 
PTAFR 1.66 0.392 0.000127 0.00288 NM_001287047.1:1371 
PLD1 1.65 0.527 0.00311 0.0481 XM_005639954.1:2355 
IFIT1 1.64 0.401 0.000195 0.00407 XM_843271.3:260 
BHLHB2 1.56 0.303 6.77E-06 0.000237 XM_541795.4:1920 
TNFRSF1B 1.5 0.346 8.90E-05 0.00216 XM_005617982.1:200 
A2A 1.47 0.32 3.80E-05 0.00101 NM_001003278.1:1525 
GATA3 1.43 0.235 3.06E-07 1.47E-05 XM_844060.1:1148 
FCGRT 1.41 0.165 9.68E-11 1.19E-08 XM_014118885.1:1280 
TNFSF5 1.36 0.392 0.00124 0.021 NM_001002981.1:1037 
MYO6 1.32 0.348 0.000466 0.00866 XM_005627548.1:2255 
IL10RA 1.29 0.236 2.19E-06 8.29E-05 XM_005620306.1:690 
FGR 1.28 0.157 3.30E-10 3.61E-08 XM_544467.4:2847 
NFATC2 1.15 0.117 2.00E-12 3.52E-10 XM_005635184.1:1315 
TGFb 1.15 0.167 2.15E-08 1.51E-06 NM_001003309.1:733 
TGFBR3 1.12 0.318 0.00104 0.018 XM_005621935.1:4115 
RAB27A 1.1 0.136 4.72E-10 4.57E-08 NM_001048130.1:640 
PPARG 1.06 0.325 0.00224 0.0361 NM_001024632.2:1005 
FASLG 1.06 0.341 0.00322 0.0494 XM_848916.2:1315 
PIM1 1.04 0.145 7.68E-09 6.28E-07 NM_001146177.1:710 
ZC2HC1A 0.998 0.173 8.82E-07 3.85E-05 XM_005638063.1:525 
UBXN2B 0.992 0.265 0.000547 0.00995 XM_535083.5:2410 
DBF4 0.876 0.279 0.00307 0.0478 XM_532451.5:1020 
PENK 0.867 0.204 0.00012 0.00273 XM_003640011.3:861 
IFNGR1 0.86 0.202 0.000113 0.00268 XM_003638758.2:1290 
NOTCH1 0.839 0.221 0.00046 0.00866 XM_005625433.1:3623 
XBP1 0.828 0.204 0.000209 0.00432 XM_849540.1:1565 
TRAF1 0.798 0.212 0.000528 0.00969 XM_850435.1:795 
IL2 0.791 0.209 0.000467 0.00866 NM_001003305.1:70 
MAP2K1 0.776 0.167 3.37E-05 0.000908 NM_001048094.1:333 
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TMEM243 0.747 0.178 0.000133 0.00298 XM_014118895.1:479 
SND1 0.712 0.125 1.11E-06 4.66E-05 XM_532436.5:989 
IMPDH1 0.615 0.108 1.10E-06 4.66E-05 XM_014119169.1:1448 
ITPKB 0.574 0.135 0.000119 0.00273 XM_547504.3:5265 
SRI 0.539 0.149 0.000813 0.0144 XM_005628477.2:2419 
MYO5A 0.513 0.125 0.000188 0.00397 XM_005638688.1:3485 
PSMA1 0.509 0.156 0.00221 0.0358 XM_005633695.2:381 
TRIM8 0.507 0.12 0.000118 0.00273 XM_543993.4:933 
AKT1 0.421 0.0875 2.00E-05 0.000632 XM_548000.4:1579 
COX8A 0.411 0.0935 7.50E-05 0.00186 NM_001252370.1:350 
CROT -0.405 0.0984 0.000174 0.00376 XM_014119108.1:1082 
LEF1 -0.482 0.145 0.00181 0.0299 XM_858284.3:955 
CNOT2 -0.482 0.149 0.00245 0.0392 XM_005625628.1:785 
TCF7 -0.492 0.143 0.00132 0.0222 XM_003639372.2:1860 
PTEN -0.501 0.108 3.25E-05 0.000899 NM_001003192.1:721 
CD3e -0.528 0.112 2.52E-05 0.000748 NM_001003379.1:445 
CRLF3 -0.529 0.117 5.18E-05 0.00132 XM_005624833.1:785 
GCC1 -0.538 0.142 0.000458 0.00866 XM_539388.5:2646 
PITPNC1 -0.557 0.152 0.000708 0.0128 XM_005624306.1:2255 
NFIA -0.57 0.158 8.00E-04 0.0143 XM_005620235.1:1970 
SLC25A40 -0.573 0.16 0.000902 0.0158 XM_014118965.1:308 
NFATC3 -0.58 0.113 6.65E-06 0.000237 XM_536809.2:2630 
Canis_TRBC -0.581 0.129 5.17E-05 0.00132 Canis_TRBC.1:255 
SEP6. -0.637 0.115 1.72E-06 6.88E-05 XM_014111690.1:800 
WASL -0.641 0.123 5.47E-06 0.000199 XM_532445.5:4165 
TGFBR2 -0.645 0.134 1.90E-05 0.000623 XM_005634331.1:2775 
DGKA -0.694 0.136 8.03E-06 0.000272 XM_531626.2:1042 
IL6ST -0.727 0.22 0.00199 0.0326 NM_001287021.1:4745 
PRKCA -0.795 0.203 0.000317 0.00617 XM_005624271.1:3050 
DMTF1 -0.796 0.145 2.09E-06 8.16E-05 XM_005628451.2:1009 
FBXO22 -0.892 0.141 1.39E-07 7.16E-06 XM_544796.5:1496 
STAT4 -0.898 0.228 0.000301 0.00592 XM_005640471.1:1410 
MSH6 -0.901 0.192 2.81E-05 0.000795 XM_531814.5:1695 
FKBP5 -0.959 0.234 0.000186 0.00397 XM_005627260.1:1085 
ASB15 -0.961 0.301 0.00265 0.042 XM_014119083.1:1464 
ASPH -0.989 0.31 0.00267 0.042 NM_001003196.1:606 
SATB1 -1.01 0.158 9.99E-08 5.30E-06 XM_005634642.1:1455 
LAG3 -1.07 0.223 2.19E-05 0.000662 XM_005637438.1:130 
HPS3 -1.09 0.15 6.38E-09 5.70E-07 XM_005634557.1:2220 
CCR7 -1.16 0.293 0.000299 0.00592 XM_548131.2:335 
IL17F -1.21 0.307 0.000294 0.00591 XM_538959.1:120 
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RORC -1.38 0.271 7.88E-06 0.000272 XM_005630826.1:1840 
CDK5R1 -1.43 0.213 3.74E-08 2.29E-06 XM_005624820.1:1700 
PRF1 -1.49 0.217 2.28E-08 1.55E-06 XM_005618879.1:1396 
TRPS1 -1.61 0.39 0.00017 0.00371 XM_539139.5:3750 
CXCR7 -1.68 0.306 2.12E-06 8.16E-05 NM_001003281.2:1312 
GCNT1 -1.7 0.32 3.90E-06 0.000145 XM_005615841.1:1346 
PTPN22 -1.7 0.366 3.33E-05 0.000908 XM_005630623.2:1535 
CCR5 -1.76 0.527 0.00174 0.029 NM_001012342.2:1060 
ABCB1 -1.81 0.449 0.000228 0.00466 NM_001003215.1:1425 
ICOS -1.89 0.283 4.00E-08 2.35E-06 NM_001002972.1:635 
CHN1 -1.91 0.319 4.06E-07 1.90E-05 XM_845334.3:570 
IL10 -2.22 0.324 2.38E-08 1.56E-06 NM_001003077.1:555 
ITGAD -2.24 0.502 5.87E-05 0.00148 NM_001110802.1:2061 
CXCR5 -2.32 0.321 6.93E-09 5.92E-07 XM_546496.3:1426 
AKAP2 -2.4 0.605 0.000277 0.00562 XM_005626415.1:3520 
ITGAE -2.57 0.734 0.00113 0.0193 XM_005624962.1:2375 
TIMP4 -2.6 0.251 4.09E-13 1.39E-10 XM_003432743.2:3130 
FOXP3 -2.63 0.263 1.10E-12 2.17E-10 NM_001168461.1:629 
ADAM12 -2.66 0.393 3.25E-08 2.06E-06 XM_005637842.1:845 
TOX -2.78 0.475 6.50E-07 2.90E-05 XM_005638006.1:1300 
EGR1 -2.8 0.583 2.03E-05 0.000634 XM_846145.3:1787 
IFNG -2.96 0.471 1.60E-07 8.04E-06 NM_001003174.1:430 
CD160 -3 0.701 0.000106 0.00253 XM_005630717.1:220 
IL21 -3.01 0.374 4.89E-10 4.57E-08 NM_001003347.1:2360 
PDCD1 -3.17 0.315 8.91E-13 1.95E-10 XM_543338.2:601 
GZMA -3.28 0.496 5.28E-08 2.97E-06 XM_544335.2:140 
PTPRC a -3.37 0.518 7.39E-08 4.04E-06 XM_005622278.1:278 
TNFSF13B -3.55 0.365 2.56E-12 3.86E-10 NM_001161710.2:865 
EOMES -3.59 0.537 4.07E-08 2.35E-06 XM_845645.3:2095 
GZMB -3.7 0.652 1.17E-06 4.79E-05 XM_547752.2:495 
KLRB1 -3.79 0.537 1.19E-08 8.69E-07 XM_005637170.1:325 
CTLA4 -4.19 0.521 4.77E-10 4.57E-08 NM_001003106.1:1370 
CCL4 -4.46 0.463 3.43E-12 4.81E-10 NM_001005250.1:15 
KLRD1 -4.74 0.523 1.98E-11 2.59E-09 NM_001048035.1:169 
TRGC2 -4.85 0.352 3.66E-17 2.40E-14 Canis_TRGC2.1:218 
PTPRC b -5.08 0.709 8.63E-09 6.79E-07 XM_005622278.1:1133 
CCL5 -5.53 0.674 2.91E-10 3.37E-08 NM_001003010.1:69 




GATA3, the transcription factor responsible for Th2 differentiation; and CRTh2, a Th2 
cell specific receptor were significantly upregulated in cases compared to controls (GATA3: 
median cases = 2869, median controls = 1223; CRTh2: median cases = 70, median controls = 12; 
normalized mRNA counts) (Fig 1.2, Table 1.2 and Table 1.3). Furthermore, transcriptions factors 
responsible for differentiation of other Th subsets, including: TBX21 (T-bet, Th1), RORC (RORγt, 
Th17), and FOXP3 (Treg), were significantly down regulated in cases versus controls (Fig 1.2, 
Table 1.2). Th2 specific chemokine receptors, CCR3 and CCR4, were also significantly 
upregulated in cases versus controls (CCR3: median cases = 20, median controls = 2, CCR4: 
median cases = 954, median controls = 284; normalized mRNA counts) (Table 1.3). These 
findings suggest TZL may be derived from a Th2-like cell. However, the cytokines released by 
Th2 cells, and those responsible for Th2 differentiation: IL-4; IL-5; IL-13; and STAT6, an 
important transcription factor downstream of IL-4 signaling,41 were not significantly different 
between cases and controls (Table 1.3). Most cytokines associated with other T helper subsets 
were also not significantly different between cases and controls (Fig 1.3) when thymic controls 
were excluded since cytokine production by differentiated Th cells would occur outside the 
thymus. Surprisingly, TGF-β, the immunosuppressive cytokine, did show significantly increased 




Figure 1.2. The Th2 transcription factor GATA3 is significantly upregulated in TZL. Log2 
transformed gene expression difference between cases and controls for transcription factors 
involved in T helper cell differentiation. GATA3, the Th2 transcription factor, is significantly 
upregulated in TZL cases (n = 34) versus controls (n = 14).  
 
Table 1.2. Transcription factors involved in T helper differentiation. The median 
normalized mRNA counts and interquartile range (IQR) for the transcription factors 
responsible for T helper subset differentiation. The genes with an asterisk were 






2869 (2029 – 4173) 1223 (555 – 
1564) 
1.93E-05 
TBX21 (Th1)* 27 (3 – 800) 239 (72 – 2404) 0.00367 
FOXP3 
(Treg)* 
2 (1 – 16) 89 (2 – 138) 5.00E-08 
RORC 
(Th17)* 
1 (1 – 39) 18 (2 – 52) 0.00014 




Table 1.3. Expression of additional Th2 genes. The median 
normalized mRNA expression values for cases and controls and 
interquartile range (IQR) for the most Th2 specific genes 
investigated in cases versus controls. CRTh2 is a Th2 cell specific 
receptor. CCR3 and CCR4 and chemokine receptors involved in Th2 
cell signaling. STAT6 is a transcription factor downstream of IL-4 
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signaling. The genes with an asterisk were significantly different 





CRTh2* 70 (36 – 246) 12 (9 – 15) 
CCR3* 20 (4 – 51) 2 (1 – 7) 
CCR4* 954 (432 – 2006) 284 (75 – 491) 
IL4 1 (1 – 4) 2 (1 – 17) 
IL5 18 (10 – 22) 9 (5 – 18) 
IL13 3 (1 – 4) 1 (1 – 3) 
STAT6 2056 (1853 – 
22896) 





Figure 1.3. The immunosuppressive cytokine, TGF-β, showed increased expression in TZL 
cases versus controls. mRNA expression values of cytokines involved in T helper cell 
differentiation and activation for TZL cases (red) and controls (black). The cytokines 
associated with T helper subsets were not significantly different in TZL cases vs. controls. 
There was, however, a significant difference in the expression of TGF-β in TZL cases vs. 
controls. Controls in this comparison consisted only of lymph node tissue because we were 
focused on cytokines involved in peripheral differentiation.  
 
When comparing only CD8+ TZL cases, we also saw significantly increased expression of 
GATA3 and CRTh2 compared to CD8+ controls (GATA3 p = 0.0015, CRTh2 p = 3.956 X 10-5) with 
a higher median gene expression than CD4+ controls (Table 1.4). Cases with a CD8+ phenotype 
did show expression of both CD8a and CD8b genes (alpha and beta chains, respectively), but did 
not show expression of CD8 effector granzyme molecules: GMZA, GMZB, GMZK, or other 
effector molecules including perforin and IFN-γ (Fig 1.4). These findings provide evidence that 
expression of CD8 in TZL cases does not correlate with CD8+ T cell function. Furthermore, the 
interspersion of various phenotypes across cases suggests CD4+ and CD8+ subtype molecules 
are not essential to the function of TZL cells.   
Table 1.4. Median mRNA normalized count by phenotype. The median normalized 
mRNA counts for the transcription factor responsible for Th2 differentiation, GATA3 
and CRTh2, the Th2 specific receptor, delineated by phenotype  
CD4+ 
cases 






GATA3 2989.67 2232.77 4102.7 1534.23 500.3 





Figure 1.4. TZL cases can show expression of CD8 but do not show expression of effector 
molecules. mRNA expression of CD8a; CD8b (CD8 alpha and beta chains, respectively); and 
CD8+ effector granzyme A, B, and K molecules (GZMA, GZMB, GZMK); perforin; and INF-γ 
(IFNg). CD8+ TZL cases (red) and CD8+ T cell controls (black).  
 
TZL cells express high levels of immunosuppressive molecules 
There were three immunosuppressive molecules that were highly expressed in TZL 
cases: TGF-β, galectin-1 and galectin-3 (Table 1.5). TGF-β is produced by a number of leukocytes 
and stromal cells,42 but this cytokine has been found to inhibit Th1,43 Th2,44,45 and effector 
functions of CD8+ cytotoxic lymphocytes.46 In tumor bearing mice, TGF-β production was 
associated with Th2 skewing and inhibition of a Th1 response.47 Galectins are produced by a 
wide variety of cells and upregulated in activated lymphocytes.48,49 LGALS1 and LGALS3 
(galectin-1 and galectin-3) are highly expressed in FOXP3+ T regulatory cells suggesting these 
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molecules are markers of Treg cells.31,50 Galectins are also involved in apoptosis of activated T 
cells, suppressing Th1 and Th17 cells along with preferential sparing of Th2 cells promoting a 
Th2 cellular response.51,52 Although there was high expression of these immunosuppressive 
molecules in TZL cases versus controls (Fig 1.5, Table 1.5), FOXP3 (Treg master transcription 
factor) was not identified in our TZL cases (Table 1.2, median = 2). The expression of these 
molecules may be involved in pathogenesis of this disease either creating an 
immunosuppressive environment, or influencing the microenvironment towards a Th2-like or 
Treg-like environment.   
 
Figure 1.5.TZL cells express significantly higher levels of galectin-1 and galectin-3 which may 
contribute to an immunosuppressive environment. Normalized mRNA expression levels of 




Table 1.5. Median normalized mRNA of immunosuppressive molecules. The median 
normalized mRNA expression values for cases and controls and interquartile range 
(IQR) for the immunosuppressive molecules, TGF-β, galectin-1 and galectin-3. All of 
these genes were significantly upregulated (*) in TZL cases versus controls.   
Cases IQR Controls IQR P-value 
TGF-β* 3664 (3067 – 
4229) 
1081 (894 - 2206) 4.14E-10 
Galectin-1* 6768 (4674 - 7517) 351 (236 - 677) 7.05E-18 
Galectin-3* 7436 (4533 - 
10430) 
73 (46 - 247) 7.05E-18 
 
TZL cells have features of Th2 cells and Treg cells  
In an effort to investigate the cell-of-origin associated with TZL, immune cell type scores 
were evaluated by partitioning genes into characteristic T cell subsets. These subset genes were 
loaded into nSolver 4.0 advanced analysis and a raw cell score was obtained for the TZL cases 
versus controls based on the average log2 expression of the genes for a particular subset. The 
possible T cell subsets included:  Th1, Th2, Tfh, Th17, Treg, and CD8+ effector memory cells 
(CD8 EM) (Fig 1.6). CD8+ central memory is not shown because the gene set was only 5 genes. 
The raw cells scores for Th2 and Treg subsets were higher for cases versus controls. These gene 
subsets were also uploaded into GSEA (Fig 1.7). The only subsets to show enrichment with a 
significant FDR were the Th2 subset (FDR = 3.2%, p = 0.01) and the Treg subset (FDR = 7.8 %; p = 
0.04). In the Treg subset, only 6 of 27 genes were responsible for the core enrichment in this 




Figure 1.6. TZL cases have a higher cell score for Th2 cells and Treg cells compared to 
controls. Cell scores for TZL cases compared to controls (cases, grey; ctrl, salmon) derived 
using nSolver 4.0 advanced analysis. The cell score is based on the average log2 expression 
genes associated with each cell subset. TEM CD8: effector memory CD8.   
 
 
Figure 1.7. TZL cells have gene enrichment for Th2 and Treg cells. GSEA Gene set 





Table 1.6. GSEA enrichment score. Gene name, rank in gene list, running enrichment score 
(ES), core enrichment for Treg and Th2 gene list in TZL cases. 


















LGALS1 0 0.10842 Yes FCGRT 8 0.12908 Yes 
LGALS3 1 0.21031 Yes GATA3 15 0.21516 Yes 
S100A4 4 0.29184 Yes MYO6 21 0.28911 Yes 
S100A10 5 0.37519 Yes CRTh2 24 0.37415 Yes 
TGFb 9 0.43073 Yes NFIL3 47 0.34346 Yes 
GATA3 15 0.45761 Yes CCR4 48 0.41356 Yes 
BHLHB2 31 0.42475 No ECM1 52 0.46006 Yes 
TRAF1 34 0.45247 No CCR3 55 0.50958 Yes 
EPSTI1 41 0.45753 No NLRP3 67 0.49885 Yes 
CD25-
IL2RA 59 0.40056 No IL5 68 0.53836 Yes 
FLT1 73 0.35434 No ATF5 82 0.50639 Yes 
TIAF1 75 0.36392 No BATF 83 0.53425 Yes 
HLA-
DRB1 78 0.36790 No IL3 87 0.54518 Yes 
SHMT2 89 0.32996 No IL4R 102 0.49219 No 
GBP5 92 0.32931 No EPAS1 107 0.47634 No 
NINJ2 122 0.19462 No IL24 113 0.45447 No 
TRIB1 134 0.15025 No STAT6 114 0.45634 No 
SDC4 142 0.12849 No MAF 133 0.39086 No 
TFRC 149 0.11374 No IL4 136 0.39970 No 
SLAMF1 155 0.10632 No JUN 175 0.28111 No 
IL2RB 158 0.11396 No     
CEBPA 162 0.11769 No     
CCR5 167 0.11880 No     
TP53INP
1 174 0.11542 No     
AKAP2 182 0.10983 No     
FOXP3 228 -0.04153 No     
CTLA4 231 0.02381 No     
 
Our lab has previously observed that the percentage of CD25 positive cells was higher in 
TZL cells than normal T cells.53 CD25 is the IL-2-receptor-α subunit (IL-2Rα, high affinity IL-2R), 
prompting us to determine if any growth factor receptors were significantly upregulated in TZL. 
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IL-2, IL-4, IL-7, and IL-15 are all considered T cell growth factors.54-58 We ultimately did not see a 
higher expression of any of the growth factor receptors in TZL cases versus controls (Fig 1.8). 
CD25 mRNA expression was also not significantly different between cases and controls, but 
there was a range of expression (TZL cases: median = 1123 range: 21 – 3666.5). IL-7R also had a 
higher median count in cases versus controls, but this was not statistically significant.  
Figure 1.8. T cell growth factor receptor expression is not significantly different in TZL cells. 
Plot of normalized mRNA expression (y-axis) of receptors for T cell growth factors, IL-2, IL-4, 
and IL-7. IL-2 receptors included expression of the subunits α, β, and γ (CD25-IL-2RA, IL-2RB, 
IL-2RG). 
 
GATA3 is diffusely expressed in the nucleus of neoplastic TZL cells 
Protein expression of GATA3 was confirmed by immunohistochemistry (Fig 1.9). In TZL 
lymph nodes, there was compression of follicles to the capsule and intramedullary connective 
tissue by the expanded paracortex (Fig 1.9A). The paracortex was expanded by intermediate 
sized lymphocytes (nuclear size was 1 – 1.5 x RBC); nuclei were round and indented with 
heterochromatin and indistinct nucleoli; there was a moderate amount of homogenous 
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amphophilic cytoplasm and the cells expressed CD3 (not shown). In the expanded paracortex 
there was diffuse nuclear expression of GATA3 in neoplastic TZL cells (Fig 1.9B) Normal lymph 
node tissue displayed multiple primary and secondary follicles (Fig 1.9C) and there was nuclear 
immunoreactivity to GATA3 in cells scattered throughout the paracortex (Fig 1.9D). The diffuse 
nuclear expression pattern of GATA3 was confirmed in three cases of TZL. 
 
Figure 1.9. GATA3 is diffusely expressed in the nucleus of TZL cells. A., B. Lymph node tissue 
from a dog with TZL. A. The paracortex has been expanded by intermediate-sized neoplastic 
lymphocytes that compress follicles (H&E, 100X). B. Within the expanded paracortex, the 
neoplastic lymphocytes have diffuse nuclear immunoreactivity for GATA3. The adjacent 
lymphocytes in the compressed follicle are diffusely negative for GATA3 (IHC, GATA3, 200X). 
C., D. Reactive lymph node tissue from a 2 year-old dog. C. The lymph node is hyperplastic 
with multiple primary and secondary follicles. D. Within the paracortex there is scattered 
variable nuclear immunoreactivity for GATA3 in lymphocytes. The adjacent secondary follicle 
is diffusely negative for GATA3 (IHC, GATA3, 200X). 
 
 
Galectin-1 and Galectin-3 expression  
We anticipated the concordance of galectin protein expression with mRNA expression 
results. Galectins have versatile functions and galectin-3 has been found to be expressed on 
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many inflammatory cells including monocytes and macrophages.59 Normal lymph node 
immunoreactivity toward galectin-3 was identified in the cytoplasm of dendritic cells scattered 
throughout the lymph nodes surrounding follicles (Fig 1.10E and F). There was also occasional 
scattered dim galectin-3 expression in the nucleus of cells found in the paracortex, as well as in 
follicles of cells with lymphocyte morphology. Galectin-1 immunoreactivity in the normal lymph 
node was almost identical to the galectin-3 expression pattern (not shown). In contrast, in TZL 
cases, there was diffuse strong immunoreactivity in the nucleus and cytoplasm of neoplastic 
lymphocytes in the expanded paracortex for both galectin-3 and galectin-1 (Fig 1.10A and B 
(galectin-3) and C and D (galectin-1)).   
Figure 1.10. Galectin expression is abundant in the nucleus and cytoplasm of TZL cells. A., 
B., C., D., Lymph node tissue from a dog with TZL. A. and C. The paracortex is expanded by 
intermediate-sized neoplastic lymphocytes that compress follicles. In the neoplastic cells 
there is diffuse, strong immunoreactivity for galectin-3 (A.) and galectin-1 (C.) (H&E, 100X). B. 
and D. Close-up of a follicle compressed by the expanded TZL population. Within the 
expanded paracortex, the neoplastic lymphocytes have strong diffuse nuclear and 
cytoplasmic immunoreactivity for galectin-3 (B.) and galectin-1 (D.); (IHC, galectin-3 (A. and 
B.) and galectin-1 (C. and D.) 40x and 200X). E., F. Reactive lymph node from a 2 year-old dog. 
E. The lymph node is hyperplastic with multiple primary and secondary follicles. There is 
strong scattered cytoplasmic and dim nuclear immunoreactivity for galectin-3 in both the 
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follicles and paracortex. F. Within the paracortex, there is scattered strong cytoplasmic 
immunoreactivity for galectin-3 within dendritic cells with abundant irregular stellate 
cytoplasm. There are few scattered lymphocytes with dim nuclear immunoreactivity for 
galectin-3 (IHC, galectin-3, 200X). 
  
TZL cells to not express IRF-4/MUM-1 when analyzed with immunohistochemistry 
IL-9 was originally thought to be produced by Th2 cells but further investigation 
revealed a distinct subset of Th cells now called Th9 cells was ultimately responsible for IL-9 
production.26  In the presence of IL-4 and TGF-β, naïve cells differentiate into Th9 cells and 
produce IL-9.60 This process requires several transcription factors including STAT6, IRF-4, and 
GATA3.26,60,61 TGF-β was highly expressed in TZL cases along with GATA3 but our work did not 
investigate gene expression of IL-9 or IRF-4. We decided to determine if the IRF-4 protein was 
expressed. We preformed immunohistochemistry for IRF-4/MUM-1 on three cases of TZL to 
determine if this transcription factor might also be implicated in TZL. In the lymph node, the TZL 
cells were diffusely negative for IRF-4/MUM-1 (Fig 1.11). There were few scattered well 
differentiated plasma cells surrounding follicles that showed immunoreactivity for IRF-4/MUM-






Figure 1.11. TZL cells do not express IRF-4/MUM-1. A., B. Two different TZL cases with 
expanded paracortex by neoplastic TZL cells and few smaller follicles on the periphery. There 
are scattered and peripheral clusters of cells with nuclear immunoreactivity for IRF-4/MUM-1 
while the TZL cells in the expanded cortex are diffusely negative for IRF-4/MUM-1 (IHC, IRF-
4/MUM-1 10X). C. Higher magnification of A. showing the neoplastic TZL cells with 
condensed chromatin and frequently indented nuclei do not express IRF-4/MUM-1. On the 
periphery, well differentiated plasma cells with round nuclei show strong nuclear 
immunoreactivity for IRF-4/MUM-1. 
 
Discussion 
Our investigation sought to identify the cell-of-origin in T zone lymphoma. TZL can 
present as a CD4+, CD4-CD8-, or CD8+ T cell phenotype.53 The TZL cases in our study did not 
cluster by gene expression based on phenotype (Fig 1.1) despite protein and mRNA expression 
of CD4 and CD8 molecules. PTCL-NOS in humans with variable phenotypes showed that 
CD4/CD8 expression did not correspond to an operative lineage by gene expression.62 Similarly, 
in our study, CD8 protein and gene expression did not correspond with expression of CD8 
effector molecules (granzymes, perforin or IFN-γ) (Fig 1.4).   
Regardless of the TZL phenotype, we were able to identify a unique immunosignature 
for TZL. There was significant upregulation of GATA3, the master transcription factor for Th2 
cell differentiation, as well as upregulation of the Th2 specific receptors:  CCR3, CCR4, and 
CRTh2 (Fig 1.2, Table 1.2, and Table 1.3). CRTh2 is a G-protein-coupled receptor, specifically 
expressed by Th2 cells and considered to be the most dependable marker for memory Th2 
cells.63 This receptor is involved in GATA3 upregulation, Th2 cell migration and cytokine 
production.64 CCR4 is the dominate chemokine receptor for Th2 cells, Treg cells, and skin-
homing T cells.65 In polarized T cells CCR3 and CCR4 were found to be expressed in Th2 cells.66,67 




Increased gene expression of some Th2 specific genes in TZL is suggestive of a Th2-like 
cell-of-origin but we did not find a difference in expression of Th2 cytokines including: IL-4, IL-
13, IL-5, or the transcription factor, STAT6 (Table 1.3). Although TZL may be derived from a Th2 
cell, the mechanisms involved in oncogenesis appear to have diverted from normal Th2 cellular 
response since they do not express increased levels of these cytokines. Furthermore, clinically 
dogs with TZL are not reported to present with an eosinophilia.8 Eosinophils are associated with 
a Th2 response and IL-5 is involved in the production of eosinophils.69,70 A subset of human 
PTCL-NOS has been identified to express GATA3 and while these patients predominantly had a 
normal eosinophil count even with increased expression of IL-5, there was a relationship 
between the degree of GATA3 expression and the development of eosinophilia.71 In a separate 
study, the incidence of eosinophilia was not more prominent in patients with GATA3 positive 
PTCL compared to GATA3 negative patients.72 Neither of these studies demonstrated induced 
secretion of Th2 cytokines in neoplastic cells.71,72 It is possible the degree of GATA3 expression 
in TZL cases is not sufficient for cytokine production or eosinophil recruitment.  
Even in the absence of STAT6 with Th1 primed conditions, GATA3 has been shown to 
induce Th2 differentiation.73 GATA3 has been identified to bind to a large number of genes in 
various T cell subsets leading to activation or repression depending on the cellular context.74 
The number of binding sites for GATA3 in various T cell subsets appears to depend on the 
degree of expression.74 GATA3 has shown variable levels of expression in Th1 (low expression) 
and Th2 (high expression) T cell clones, suggesting that the level of GATA3 expression could be 
linked to Th2 cytokine production.75 This theory was further validated by generating antisense 
GATA3 lines from the Th2 cell clones in which all Th2 cytokines were inhibited with decreased 
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GATA3 expression.75 GATA3 was unable to activate the IL-4 promoter alone, needing other 
activation-induced transcription factors such as NFAT or AP-1, for IL-4 promoter activation.75 
Additionally, the level of expression of GATA3 differed depending on the cytokine.75 c-Maf has 
been identified to be a transcription factor necessary for the optimal expression of IL-4 in CD4+ 
T cells and acts synergistically with NFAT.76,77 In our study, c-Maf was not highly expressed in 
TZL cases (TZL median = 246; controls median = 552; data not shown) and there could be other 
genes involved in cytokine regulation that not upregulated TZL cells disrupting cytokine 
production.  
GATA3 expression could also reflect other signaling pathways and transcription factors 
which regulate GATA3 production being disrupted in TZL, rather than representing Th2 cell 
origin. GATA3 expression occurs through different mechanisms including: IL-4 signaling and 
downstream STAT6 activation,78 TCR signaling occurring through PI3K-mTOR,79 IL-33 and STAT5 
activators,80 Notch signaling,81 and Wnt/β-catenin signaling through SATB1.82 However, we did 
not find a significant difference in the expression of STAT6, mTOR, or SATB1 in cases compared 
to controls. The TZL cases did show significantly higher expression of NOTCH. Notch is involved 
in differentiation of many of the T cell subsets,81 but GATA3 has been specifically identified to 
be a transcriptional target of Notch.83 This pathway, along with others involved in GATA3 
regulation, could be involved in the oncogenesis of TZL and the expression of GATA3 in this 
tumor. It would be useful to compare the phosphorylation of these proteins between cases and 
controls to determine if there is a difference in activation. Furthermore, GATA3 has also been 
identified to be critical for thymocyte development,84,85 involved in differentiation and function 
of multiple CD4+ T cell subsets,86 CD8+ T cell maintenance,87 and development of innate like 
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lymphoid cells.88 GATA3 has many functions in T cells and its expression in TZL may not be 
specific for Th2 differentiation.  
Th9 cells also express GATA3 but at lower levels than Th2 cells.89-91 The function of 
GATA3 in Th9 cells is still under investigation25 as some studies have found low levels of GATA3 
present in Th9 cells.89  Th9 cells are characterized by secretion of IL-9 under the influence of 
TGF-β and IL-4.92 STAT6 is an important factor in the downstream pathway of this subset.91 TZL 
cells did show high expression of TGF-β, but did not show an increased expression of IL-4 or 
STAT6. We did not measure the expression of IL-9 in our study. BATF is another transcription 
factor required for Th9 cellular development93 and expression of this transcription factor was 
very low in TZL cases (median = 1.23, data not shown). Through regulation of expression of IL-9, 
IRF-4 has been found to be essential to Th9 development.61 We completed 
immunohistochemistry on two TZL cases to determine if there was protein expression of IRF-
4/MUM-1 but no expression was found in TZL cells (Fig 1.11). Additionally, in cases of TZL of the 
tongue, MUM-1 was not expressed (single case evaluated).94 These findings do not support TZL 
cells stemming from a Th9 T cell subset.  
There were some features of TZL that were suggestive of a regulatory T cell progenitor, 
but we did not find expression of the master transcription factor of Treg cells, FOXP3. GATA3 
has been identified to be important in the function of FOXP3+ Treg cells with co-expression of 
the transcription factors GATA3 and FOXP3.86 Still, we were unable to detect any evidence of 
co-expression of GATA3 and FOXP3 in TZL cases; the median absolute count of FOXP3 
expression in TZL was 2. In TZL cells, there also was not a significant difference in the expression 
of CD25 mRNA (Fig 1.8) when compared with controls or in expression of the Treg cytokine, IL-
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10. There was increased expression of TGF-β, the immunosuppressive cytokine, in TZL cases 
versus controls (Fig 1.3, Table 1.5). TGF-β is an important cytokine for development of Th17 
cells,95 induced Treg cells,19 and it is required for Th9 cell differentiation.96 The involvement of 
TGF-β in various T helper subsets highlights the inherent plasticity of T cells and the myriad of 
complex signaling molecules involved in T cell differentiation. TGF-β expression has also been 
implicated in a variety of cancers associated with tumor immune evasion, metastasis, cellular 
proliferation, and survival.97 TGF-β expression in TZL may be involved in the pathogenesis of 
this disease rather than with the cellular derivation of neoplastic cells.  
Many of the cytokines investigated in this study were expressed at low levels (Fig 1.3). 
Cytokine production primarily occurs through stimulation of the TCR with the help of CD45. It is 
possible the lack of CD45 could be hindering signaling through the TCR and subsequent cytokine 
production then persists at low levels. In other studies, CD45 deficiency was not only associated 
with proliferation defects, but also diminished cytokine production.98 99 CD45 deficient cells 
have been shown to still have the ability to proliferate with IL-2.99 We did find that IL-2 was 
significantly higher in TZL cases (IL-2: TZL median = 470, controls median = 218; p value = 
0.00866) and CD25 (IL-2R) was expressed at higher levels in cases compared to controls 
although this difference was not statistically significant (Fig 1.8). It is possible that TZL cell 
activation/proliferation occurs though the IL-2R since IL-2 is a known T cell growth factor and 
can be produced from many cells besides activated CD4+ Th cells including CD8+ T cells, 
dendritic cells and mast cells.100-103 
Galectin-1 and galectin-3 were also both highly expressed in TZL (Fig 1.5, Table 1.5, and 
Fig 1.10). Galectins show variable expression by all immune cells and are upregulated in 
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activated T cells and FOXP3+ regulatory T cells.104-106 High expression of galectins in TZL 
contributed to the increased Treg score in TZL, however galectins are not specific to Treg cells. 
Galectin-3 may even have an inhibitory role in expansion of the T regulatory cell 
population.107,108  Galectins have been shown to mediate inflammation through apoptosis of 
activated leukocytes105 and conversely amplify inflammation,109-111 which demonstrates the 
multifactorial effects of galectins depending on the cellular and extracellular environment. 
Galectin-1 has also been identified to be activated in many tumors with methylation of the 
galectin-1 promoter suggested to be the primary mechanisms for expression.112 Both galectin-1 
and galectin-3 have been shown to be expressed in neoplastic tissue and in association with 
hypoxic conditions.113-115 Tumor cell secretion of galectins can promote tumor growth by 
tolerogenic effects including cytokine skewing, promotion of T cell anergy, apoptosis of 
cytotoxic lymphocytes and Th1 cells, and expansion of Treg cells.116-118 Galectin expression in 
TZL could have a similar function to that found in other tumors, as a mechanism to regulate the 
immune response; or in the case of TZL, could contribute to a Th2 or Treg-like environment. 
Galectin-1 induced apoptosis in activated T cells preferentially selects Th1 and Th17 
cells, sparing Th2 cells due to differential glycoproteins on the cell surface.51 Galectin-3 has also 
been shown to protect cells from apoptosis when expressed intracellularly119 within Th2 cells 
specifically.120 Galectin-1 produced by Th2 cells has been shown to promote Th1 apoptosis 
similar to reciprocal inhibitory cytokine production in Th1/Th2 cells.120 Furthermore, galectin-1 
predominantly binds to CD45 on Th1 and Th17 cells to cause apoptosis,121,122 and CD45 is 
required for galectin-3 induced cell death.106 TZL cells could be spared from galectin-1 induced 
apoptosis either by lack of expression of CD45 or Th2-type glycans which are resistant to 
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galectin induced cell death. A similar mechanism is described in humans with cutaneous T cell 
lymphoma where cells have lost expression of CD7. CD7 is another important ligand for 
galectin-1 mediated cell death and resistance to galectin-1 induced apoptosis has been 
demonstrated in CD4+CD7- leukemic T cells,123 and is also a hypothesized mechanism for 
development of anaplastic large T cell lymphoma (ALCL) in which the neoplastic cells also do 
not express CD7.124 CD7 expression was measured in TZL cases and was not significantly 
different from controls.     
The results of this study propose that TZL has a unique immunosignature with increased 
expression of GATA3 and immunosuppressive molecules: TGF-β, galectin-1 and galectin-3. 
Genes that were upregulated in TZL overlapped with genes associated with both Th2 cells and 
Treg cells. Although there was not increased expression of Th2 type cytokines, investigation 
into cytokine production associated with pathogenesis may provide more insight into the cell-
of-origin of this disease. Mechanisms involved in the development of TZL could include 
signaling through TGF-β or possibly through the IL-2 receptor. Additionally, identified galectin-1 
and galectin-3 production could be involved in TZL cell resistance to galectin mediated death 
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CHAPTER 2: T ZONE LYMPHOMA CELLS PROLIFERATE THORUGH T CELL RECEPTOR 
INDEPENDENT MECHANISMS 
Summary  
 T zone lymphoma (TZL) has a unique phenotype in which the neoplastic cells lose 
expression of the pan-leukocyte marker, CD45. CD45 is a transmembrane receptor expressed 
abundantly on leukocytes and it is involved in antigen mediated T cell activation. CD45 removes 
inhibiting phosphates from molecules involved in T cell receptor (TCR) signaling and cell 
activation. Since CD45 is required for T cell signaling through antigen stimulation we 
hypothesized that TZL cells would proliferate through mechanisms independent of the TCR. We 
attempted to induce activation and proliferation through two different inducers of TCR 
engagement and we found TZL were unable to proliferate through these methods. TZL cells did 
proliferate when stimulated through mechanisms that by-pass the TCR. IL-2 was found to 
induce proliferation in a subset of cases suggesting IL-2 may contribute to TZL proliferative 
capacity. We also attempted to address resistance to apoptosis in this disease. We found that 
TZL cells were not immune to cell death in long-term culture even in the presence of IL-2. These 
findings suggest other microenvironmental factors may be involved in persistence of neoplastic 
TZL cells in vivo.   
Background  
T zone lymphoma (TZL) is considered a subtype of peripheral T cell lymphoma (PTCL) 
and, in dogs, it is an indolent disease accounting for approximately 10% of all canine 
lymphomas,1,2 and up to 60% of indolent lymphomas.3 Reliable phenotypic abnormalities aid in 
the identification of TZL in dogs, including loss of the pan-leukocyte marker, CD45, increased 
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expression of CD21, and increased expression of CD25 (IL-2 receptor-α, IL-2Rα).4-6 CD21 or 
compliment receptor 2 is commonly expressed on B cells but has been known to be expressed 
by T cells in humans and mice, and may be involved in T cell response or activation.7-9 CD25 is 
considered one of the T cell activation markers in humans.10 These phenotypic features are 
suggestive of TZL cells being derived from an activated T cell (Fig 2.1). Conversely, CD45 is 
essential for T cell receptor (TCR) mediated activation of T cells. CD45 is the most abundant 
transmembrane protein on lymphocytes, and its function is best characterized in T cells.11,12 
CD45 is required for antigen stimulation with subsequent proliferation in T cells.13 Experimental 
studies have found that CD45-deficient cells are unable to proliferate or produce cytokines 
when stimulated through the TCR.13 Because CD45 is absent on TZL cells we questioned how 




Figure 2.1. Flow cytometric features of T zone lymphoma. A. Lymphocyte characteristics of 
normal canine peripheral blood. The lymphocytes (circled) are small and less complex than 
neutrophils and monocytes (grey). The T cells (black) express both CD5+ and CD45+ (CD5 box, 
middle dot plot), and do not express CD21- (third dot plot). The B cells (pink) express CD21+ 
and do not express CD5- (middle and third dot plot). In the final histogram, 1.62% of the 
CD5+CD45+ T cells express CD25. B. Peripheral blood from a dog with TZL. The TZL cells (red) 
are intermediate in size and express CD5+ but do not express CD45- (middle dot plot). There 
are 1.41% of normal T cells (blue) that express both CD5+ and CD45+. The TZL cells also 
express higher levels of CD21 than the normal T cells (third dot plot), and 67.37% express 
CD25 (histogram, far right).  
 
Prior to differentiation of Th subsets, naïve T cells are thought to remain dormant until 
interaction with antigen expressed by an antigen presenting cell (APC).14 T cell activation by the 
TCR results in gene response leading to regulation of multiple pathways.15 TCR engagement 
occurs through two signals, first through CD3, and the second signal through a co-stimulatory 
molecule such as CD28.16,17 Activation through both signals is involved in TCR mediated IL-2 
production,18 which promotes differentiation and proliferation of T cells during an immune 
response.18,19 Antibodies to the TCR-CD3 complex have been shown to cause an initial signal in 
the T cells but proliferation requires co-stimulation often through CD28.20 Anti-CD3 and anti-
CD28 coated beads have proven to provide efficient T cell expansion in humans,21 and this has 
also been demonstrated in dogs.22 Phytohemagglutinin (PHA) is a mitogen that has been 
utilized in many species, including dogs, to cause a rapid and marked T cell expansion,15,23 and it 
has been shown to reflect the gene response of T cell activation through the TCR.24 TCR 
engagement also leads to hydrolysis of membrane phospholipids and production of second 
messengers, resulting in elevations in intracellular Ca2+ concentration and protein kinase C 
(PKC) activation.17 These mechanisms of T cell activation are simulated through exogenous 
compounds in vitro. Phorbol 12-myristate 13-acetate (PMA) and ionomycin are synergistic in 
enhancing the activation of PKC with intracellular Ca2+ influx.25 IL-2 can augment T cell 
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expansion with other mitogens and cause preferential expansion of CD8+ T cells.26,27 Canine T 
cells exhibited expansion with recombinant human IL-2 (rhIL-2) alone or in combination.23,28  
 One of the hallmarks of cancer is uncontrolled cell growth.29 Since TZL cells do not 
express CD45, which impedes proliferation through the TCR receptor, we considered that 
resistance to cell death may be a more prominent pathway of oncogenesis in this disease. 
Normally, upon activation of T cells several mechanisms are in place to regulate the T cell 
response and maintain homeostasis. One pathway includes activation induced cell death (AICD) 
with upregulation of the tumor necrosis factor receptor family (TNFR) resulting in activation of 
the caspase cascade and cell death.30 Fas is a TNFR leading to apoptosis when bound to Fas 
ligand (FasL) in T cells that have been activated.30-32 Another mechanism of cell death in 
activated T cells is through galectins. Galectin-1 is a lectin that is widely expressed and causes 
death in activated T cells in humans.33 Galectin-1 can control T cell fate through binding to 
CD45, CD43, and CD734 or leading to T cell sensitization of Fas mediated cell death.35 Upon T cell 
activation, galectin-1 is upregulated and when bound to CD45 can lead to apoptosis of T cells.33 
Due to the lack of expression of CD45 in TZL cells, resistance to galectin mediated apoptosis 
may be another contributor to lymphomagenesis in this disease.  
 Because of the unique phenotype of TZL we wanted to investigate the mechanism of 
proliferation of TZL cells and determine if there was evidence of resistance to apoptosis in this 
disease. We used in vitro methods of T cell proliferation through the TCR receptor with anti-
CD3/anti-CD28 coated beads and with PHA. Additionally, we investigated TZL proliferation 
through TCR independent pathways utilizing PMA/ionomycin and IL-2. We hypothesized that 
TZL cells would not proliferate when stimulated through the TCR and that IL-2 would cause 
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activation in TZL due to the expression of the IL-2 receptor, CD25. Furthermore, we wanted to 
determine if TZL cells were resistant to death in long-term culture. We hypothesized that TZL 
cells would remain viable for 21 days in culture and given the prolonged time, stimulation with 
IL-2 would induce significant proliferation in the TZL cells.  
Methods 
Selection of cases for in vitro proliferation assays and long-term culture 
Samples that were diagnosed with TZL were obtained through the Colorado State 
University-Clinical Immunology (CSU-CI) laboratory and identified with the standard diagnostic 
flow cytometric panel 2 previous described.4 In samples from 2017 tube 3 and 4 were adjusted 
and combined into tube 3d containing: Class II MHC-FITC/CD34-PE/CD21-APC. Variable 
phenotypes of TZL were examined including CD4+, CD8+, and CD4-CD8-. Non-leukemic canine 
peripheral blood was used for comparison. These ‘normal’ control samples consisted of 
peripheral blood obtained from beagle dogs being utilized for other studies at CSU and housed 
in the veterinary teaching hospital. These dogs were utilized while on various protocols in which 
peripheral blood draws did not interfere with the animal’s health or current studies. These 
procedures were approved through the Colorado State University’s Animal Care and Use 
Committee. Additional normal peripheral blood was obtained through the CSU-CI laboratory 
from samples submitted for a case-control study in Golden retrievers, samples in young dogs 
with heterogeneous lymphocyte expansion and not consistent with a diagnosis of 
lymphoma\leukemia and from samples that were serologically positive for Ehrlichia Canis in a 
study to determine the lymphocyte distribution in dogs with E. canis. Table 2.1 contains the 
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summarized patient data for the cases and controls for this study for each stimulatory method 
and long-term culture.  
Table 2.1. Samples for in vitro cell culture methods. TZL cases (pink, left side); Clinical 
Immunology sample number (CI); phenotype of TZL; lymphocyte count (cells/ul); %TZL cell in the 
sample; breed; age; sex. Controls (Grey, Normal blood, right side); CI number, diagnosis: 
Heterogeneous lymphocyte expansion (hetero), expansion of CD8 T cells (CD8), T cells below 
normal reference range (dimished T cells), normal lymphocyte subsets (Normal), expanison of 
multiple T cell subsets (Hetero T cells); breed; age; sex; notes 
TZL cases  Normal blood  
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73759 CD4 65247 84 LAB 11 FS 74574 6760 MIX 7 F 
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11 FS           
71049 CD8 24300 75 GLDR 9 FS           
84932 
CD4-
CD8-   
10431 57 MINPIN 
5 FS           
85287 CD8 6533 82 GLDR 6 MC           
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57474 CD8 71400 93 GLDR 8 MC 48763 1750 BGL 1 M 




5300 76 GLDR 
11 FS           
71049 CD8 24300 75 GLDR 9 FS           





















CD4    65247 84 





CD8   13000 20 





CD4    32600 87 







GLDR 11 FS 85449 
4710 mix 
1 F 

















n MIX 1 F 
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n MIX 1 M 
83641 CD8  6330 
43.0
2   14 FS 82673 5340 CHI 14 
M
C 
84158 CD4  7750 
12.0
4   8 MC 82677 6000 MIX 3 
M
C 
84160 CD8  18700 
70.6







5 SHTZ 9 FS 83568 10900 BRITT 2 F- 
85287 CD8  6533 
81.9














6 GLDR 13   85449 
4710 mix 
1 F 
85987 CD8 25600 92 SCHN 15 MC           
84932 
CD4-
CD8-   
10431 57 MINPIN 








1 LAB 11 FS 87920 4500 mix 1 M 
86450 
CD4-
CD8-  31500 88.6 BLLDFR 10 FS 88997 18300 mix 5 F 
86803 CD8 57100 91.6 MALT 9 M 90120 7600 mix 5 F 
87348 
CD4-
CD8-  16720 
26.1
1 CCKS 12 FS           
87364 
CD4-
CD8-  28300 
80.7
8 GLDR 13 FS           
 
 
Cell culture methods 
Peripheral blood samples were submitted to the CSU-CI laboratory for suspicion of 
lymphoproliferative disease through the decision of the submitting clinician. Peripheral blood 
was collected in EDTA and prepared as previously described.36 Red blood cells were lysed with 
filter sterilized lysis buffer (0.15M NH4Cl, 1M KHO3, 0.1mM Na2EDTA, 1N HCL at a pH of 7.2-7.4) 
for 5 minutes at room temperature (RT). The samples were washed with HBSS (Milipore Sigma, 
St. Louis, MO) + 5% heat inactivated fetal bovine serum (HI-FBS) (Milipore Sigma). Lysis and 
wash was repeated until the cell pellet did not show any evidence of residual blood. Samples 
were resuspended in HBSS with no FBS. The samples were then labelled for carboxyfluorscein 
succinimidyl ester (CFSE, 5μM, Invitrogen, Waltham, MA) for 5 minutes and washed as 
described.37 Cells were resuspended in RPMI 1640 (Milipore Sigma) media containing: HI-FBS 
10%, 2-mercaptoethanol 0.05μmol/ml (Milipore Sigma), 1 x minimum Essential Medium (MEM) 
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non-essential amino acids (Milipore Sigma), 100U/mL penicillin and 100μg/mL streptomycin 
(Milipore Sigma), 1 x Glutamax (Gibco), 10mM Corning HEPES (Media Tech Inc, Manassas, VA) 
and 1mM sodium pyruvate (Gibco). Based on the lymphocyte count from the complete blood 
cell count a total of approximately 6.25 X 105 lymphocytes per well (62.5 X 105 
lymphocytes/mL) were incubated in 96-well round bottom cell culture plates (M9311 Milipore 
Sigma) at 37 degrees Celsius (C) in a humid 5% CO2 atmosphere. Cells were incubated for up to 
7 days for proliferation assays and for 21 days for long-term culture. For long-term 
experiments, the cells were not stained with CFSE and the media was replaced every 7 days 
with fresh media. Samples were plated in duplicate wells for harvest every 7 days. For 
proliferation assays, cells were harvested at 24 hours, 5 days, and 7 days. All harvested cells 
were stained with surface antibodies by standard protocols. Briefly, the cells were harvested in 
a 96-well plate and washed twice with 150µL of flow buffer (PBS-2% FBS-0.1%NaAZ) and 
resuspended in 25µL of flow buffer and 25µL of a cocktail of antibodies in flow buffer. Surface 
antigens used included: CD5-APC (T cell, clone YKIX322.2, Bio-Rad, Hercules, CA), CD45-PB (pan-
leukocyte, clone YKIX716.13, eBioscience, San Jose, CA), and CD8-A700 (CD8 T cell, clone YCATE 
55.9, Bio-Rad). Samples were incubated for 15 minutes at RT and resuspended in 100µL of flow 
buffer and 100µL of 10µg/mL of propidium iodide (PI) for exclusion of dead cells. To determine 
the total cell count, a known amount of CountBrite beads were added prior to sample 
acquisition, and cells were enumerated based on bead recovery and amount of sample 
remaining at the time of harvest. Cell viability was determined as a percentage of the PI-
CD5+CD45- events divided by the total number of PI+/-CD5+CD45- events. Samples were 
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acquired on a 3-laser Coulter Gallios and analyzed with Kaluza software (Beckman Coulter, 
Brea, CA).  
Stimulatory methods  
To stimulate and activate T cells, approaches included TCR-dependent and TCR-
independent methods (summarized in Table 2.2). TCR-dependent methods included anti-
CD3/anti-CD28 (TCR crosslinking) and PHA (lectin mitogen, non-specific TCR cross-linking). TCR-
independent methods included PMA/ionomycin (bypass TCR, intracellular stimulation), and 
hrIL-2 (IL-2 receptor, IL-2R). For stimulation with anti-CD3/anti-CD28 beads, the manufacturer’s 
protocol was followed. Briefly, Anti-canine CD3 (clone CA17.2A12, Bio-Rad) and mouse anti-
canine CD28 (clone 5B8, eBioscience) were conjugated to magnetic Goat anti-Mouse IgG 
Dynabeads (Invitrogen). Primary antibody concentration was recommended at 0.1-1µg/25µl of 
beads. CD3 was our primary antibody and 0.1µg of CD3 and 0.5µg of CD28 were incubated with 
25µL of Dynabeads (107 beads) for 30 min at 4 C, mixing every 5 minutes in filtered sterilized 1% 
bovine serum albumin (BSA) (w/v) (Milipore Sigma) in phosphate-buffered saline (PBS) 
(Milipore Sigma). Following incubation, the beads were washed with 3mL of 1% BSA in PBS 
three times using a magnet particle concentrator (MPC). The dynabeads were suspended for 1 
minute with the MPC and the wash was discarded. The dynabeads were finally resuspended in 
the original volume of 1% BSA in PBS and stored at 4 C.  Peripheral blood was cultured at a 1:1 
or 1:4 ratio of beads: lymphocytes. For lectin-induced proliferation PBMCs were cultured with 
2.5µg/mL of PHA (Milipore Sigma). For stimulation through the IL-2R, 1U/mL of recombinant 
human IL-2 (rhIL-2, Gibco) was used. Units per mL of hrIL-2 was calculated based on the 
reciprocal of the dilution of supernatant that resulted in half-maximal proliferation of the CTLL-
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2 cells.23,38 Finally, stimulation with PMA and ionomycin (Milipore Sigma) was performed at a 
final concentration of 10ng/mL and 134ng/mL, respectively.   
 
Table 2.2 Stimulatory conditions for cell culture. The condition, final culture concentration, 
method of stimulation, source and location. *the source is referring to the Dynabeads; 
antibody sources and concentrations are listed in the text.  





4 X 108 beads/mL TCR Invitrogen Waltham, 
MA 




PMA/ionomycin 10 ng/mL PMA/134 
ng/mL iono 




hrIL-2 1U/mL IL-2R Gibco Waltham, 
MA 
 
Intracellular Ki-67 for proliferation  
TZL cases were identified through submission to CSU-CI laboratory from February 15, 
2018 to April 8, 2018. The samples were handled as previously described4 and the standard flow 
cytometry panel used at the CSU-CI laboratory was performed. Following diagnosis, cases with 
sufficient sample were processed for intracellular Ki-67 expression using Foxp3/Transcription 
Factor Staining buffer set (eBioscience) adapted from the previously reported protocol.39 
Zombie violet (ZV) dye (BioLegend, San Diego, CA) was used to identify dead cells. The ZV was 
diluted 1:1000 in PBS (0.1%) and the cell suspension was washed with 1 ml 1 x PBS. Samples 
were resuspended in 200µL of diluted ZV and incubated in the dark at RT for 30 minutes. 
Subsequently, cells were washed with flow buffer and the standard surface antibody staining 
protocol was performed. Surface antigens included: anti-CD5-PerCP-eFluor710 (T cell, clone 
YKIX322.2, Bio-Rad); anti-CD45-eFluor405 (pan-leukocyte, clone YKIX716.13, eBioscience); anti-
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CD8-A700 (CD8 T cell, clone YCATE 55.9, Bio-Rad); and CD18 (human neutrophils, clone 
YFC118.3, Bio-Rad). Following surface staining and washing with flow buffer, the samples were 
resuspended in diluted fix and perm from the buffer set (1:4 dilution of eBioscienceTM 
Fixation/Permeabilization concentrate to eBioscienceTM Fixation/Perm diluent) and incubated 
overnight in the dark at 4 C. The next day, samples were pelleted and washed twice with 
diluted perm buffer (eBioscienceTM Permeabilization buffer 10X in a 1:9 dilution with deionized 
water) and then resuspended in 200µL of diluted perm buffer. The samples were split into 2 
tubes and blocked with 5µL of rat immunoglobulin and 5µL of canine Fc receptor binding 
inhibitor (eBioscience) for 10 min at RT. After blocking, 5µL of Isotype-FITC (Rat IgG2a, clone 
SeLA15, eBioscience) or 5µL of Ki-67-FITC (rat IgG2a Ki-67, cell cycle, clone SolA15, eBioscience) 
was added to each tube and incubated at RT for 30 minutes. Samples were washed twice with 
diluted perm buffer and resuspended in flow buffer and placed in cluster tubes to be analyzed. 
Dead cells were excluded by ZV and neutrophils were excluded by the expression of CD18. The 
percentage of Ki-67 positive cells was determined based on the isotype control.  
Statistical analysis  
Differences between non-stimulated and stimulated cells for each group, TZL, normal T 
cells in TZL, and normal peripheral blood were analyzed in R using a paired Wilcoxon rank sum 
test with significant values having a p-value of < 0.05. For Ki-67 data, a correlation matrix was 
computed in Prism 7.0 (Graphpad, La Jolla, CA) with nonparametric Spearman correlation. 
Significance was determined at a p-value of < 0.05, two-tailed. The difference in the percentage 
of Ki-67 positive TZL cells between blood and lymph node was analyzed using the Mann-
Whitney test because the data did not pass normality. The Kruskal-Wallis test was used to 
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determine if there was a significant difference in the %Ki-67 TZL cells comparing TZL 
phenotypes, CD4+ vs. CD8+ vs. CD4-CD8-.  
Results  
TZL cells do not proliferate through the T cell receptor (TCR)  
Canine peripheral blood mononuclear cells (PBMCs) in TZL cases and in dogs with no 
evidence of lymphoproliferative disease were labeled with CFSE and stimulated with either PHA 
(upper middle panel) or anti-CD3/anti-CD28 coated beads (Beads) (Fig 2.2, lower middle panel). 
Both stimuli triggered cell division by day 5 in the normal T cells (CD5+CD45+, Fig 2.2, blue) 
identified by loss of CFSE and increased cell size. The TZL cells (CD5+CD45-, Fig 2.2, red) did not 
show a decreased expression of CFSE with no stimulation or stimulation with PHA or beads and 
the cells remained intermediate in size (Fig 2.2, left, red). We analyzed proliferation by 
identifying the percentage of cells that were negative for CFSE, contained within the last 
decade, indicated by the orange line shown in Fig 2.2A. top panel and graphically represented 
in Fig 2.2B. The difference in the percentage of cells that were negative for CFSE in TZL cells 
with no stimulation (Fig 2.2, right side) versus PHA did reach significance but this difference was 
not meaningful and very low in both conditions (0.73 versus 0.27 %, Fig 2.2, right side, red). 
These findings support the hypothesis that because TZL cells lack CD45, they are not activated 
in a TCR-dependent manner. 
At 5 -7 days of culture, there was a significant difference in the percentage of cells that 
lost expression of CFSE in TZL cells when stimulated with PMA, compared to TZL when not 
stimulated (Fig 2.2, right, p = 0.004). The TZL cells in culture with PMA also got much larger 
based on forward scatter (Fig 2.2, left side, bottom panel). These findings indicate that 
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stimulation through the TCR did not cause proliferation in TZL cells but stimulation could be 
provoked by bypassing the TCR in TZL cells.  
Figure 2.2. TZL cells do not proliferate when stimulated through the TCR. A.T cell 
proliferation in normal T cells and TZL cells in a dog after 5 days of culture measured by the 
loss of CFSE. Top panel: no stimulation, the normal T cells are small and the majority express 
high levels of CFSE after 5 days (blue). The TZL cells are intermediate in size and show 
consistent high expression of CFSE (red). Upper middle panel: in stimulation with PHA 
(stimulation through the TCR), the TZL cells show similar consistent and high expression for 
CFSE (red). The normal T cells are large by forward scatter and a large portion have lost 
expression of CFSE indicating cellular division (blue). Lower middle panel: in stimulation with 
anti-CD3/anti-CD28 conjugated beads (stimulation through the TCR), the TZL cells are positive 
for CFSE and do not show evidence of proliferation. The normal T cells (blue) have increased 
in size by forward scatter and a large portion have lost expression of CFSE. Bottom panel: in 
stimulation with PMA (bypass the TCR), the TZL cells have increased in size and have lost CFSE 
indicating proliferation at day 5 in culture (red). The normal T cells have also increased in size 
and lost expression of CFSE (blue). The area in grey on the histograms shows the starting level 
of CFSE in each condition at 24 hours after culture. B. The % of CFSE negative cells that are 
TZL cells (red) and normal T cells in the same culture (blue), and in T cells in normal blood 
(black) after 5 – 7 days of culture. Each point represents a different dog. There was a 
significant difference in the cellular proliferation of normal T cells stimulated with PHA, beads 
and PMA compared to no stimulation (blue, asterisk). There was only a significant difference 
in TZL stimulated with PMA versus no stimulation (red, asterisk). The orange bar in A. 
indicates the gate for determining the % for the CFSE negative cells (last decade). Red: TZL 
cells (CD5+CD45-); Blue: normal T cells in TZL cases (CD5+CD45+); Black: normal peripheral 
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blood with only CD5+CD45+ T cells. The error bars show the mean (horizontal line) and 
standard deviation of each set of data.  
 
Normal T cells in a TZL environment maintain ability to activate through the TCR  
There was an increase in the percentage of CFSE negative normal T cells (CD5+CD45+) in 
TZL cases and normal canine blood T cells between stimulated cells (beads, PHA, and PMA) 
compared to no stimulation and this difference was significant in all three conditions for the 
normal T cells in culture with TZL cells (beads p = 0.0078, PHA p = 0.0078, PMA p = 0.0039). The 
normal T cells in TZL and in normal blood also increased in size with stimulation compared to no 
stimulation (Fig 2.2, left, bottom three panels, blue). In the completely normal blood there was 
not a significant difference between no stimulation and PMA or beads (Fig 2.2, right side, black 
triangle); there was however a significant difference between no stimulation and PHA (p = 
0.03). These results show that stimulation through the TCR is possible in canine T cells in normal 
blood and in canine T cells that express CD45 in TZL.  
IL-2 signaling may be an alternative stimulatory method for TZL 
IL-2, along with other mitogens, has been shown to augment T cell expansion with 
favored expansion of CD8+ T cells.26,27 Canine T cells have also been shown to expand with IL-2 
(rhIL-2).23,28TZL has previously been identified to express CD25, the IL-2α receptor (IL-2Rα).4,6 
We also found that CD25 mRNA was variably expressed in TZL cases (Chapter 1) and although 
not significantly different, the median count was higher in cases versus controls.   
Canine peripheral blood mononuclear cells (PBMCs) in TZL cases and in dogs with no 
evidence of lymphoproliferative disease were labeled with CFSE and stimulated with hrIL-2 1U 
for 7 days. Samples were also stimulated with PHA as positive control for stimulation in the 
normal CD5+CD45+ T cells. hrIL-2 did cause loss of CFSE expression in both the TZL cells and the 
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normal T cells in many cases, but not all. The cases that often showed the most evidence for 
stimulation with hrIL-2 in TZL were cases that also had a higher percentage of cells expressing 
CD25 or showed a median fluorescence intensity of CD25 of ≥ log1.0 (Fig 2.3B, red boxes). For 
both TZL cells and normal T cells in culture, we analyzed the fold change of the median 
fluorescent intensity (MFI) of CFSE in cells with no stimulation over the MFI of CFSE in 
stimulated cells (either PHA or hrIL-2) (Fig 2.3B). There was not a significant difference in the 
MFI of CFSE fold change in TZL cells when comparing hrIL-2 versus PHA. However, there were 8 
cases in which the cell count increased from day 1 to day 7 (range +297 to +473424, Table 2.3, 
pink), while in 3 cases the cell count decreased from day 1 to day 7 (range -39833 to -531826). 
In only 6 cases, the cell count increased with hrIL-2 stimulation compared to no stimulation 
(Table 2.3, pink).  
Figure 2.3. TZL cells can proliferate when stimulated with IL-2. A. Dot plot and histograms of 
a representative case of TZL at day 7 of culture identifying the normal T cells (CD45+ T cells) 
in blue and the TZL cells (TZL) in red. The TZL cells are CD5+ but do not express CD45- and the 
normal T cells express both CD5+ and CD45+. The histograms show the loss of expression of 
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CFSE, indicating proliferation, in the TZL cells in red middle panel, and the normal T cells in 
blue right panel. The area in grey is an overlay of the expression of CFSE at day 7 in cells that 
were not stimulated. There is evidence of proliferation in both the TZL cells and the normal T 
cells when stimulated with hrIL-2. B. The graph indicates the fold change (FC) of the median 
fluorescence intensity (MFI) of CFSE in non-stimulated cells/MFI of CFSE in stimulated cells at 
day 7 for both PHA (circles) and hrIL-2 (squares) stimulatory methods. The graph on the left is 
the FC of TZL cells and the red squares highlight the TZL cases with high CD25 expression (≥ 
log1.0). The second graph is the FC in the normal T cells in culture with TZL cases. The error 




Figure 2.4 The total cell count of TZL cells in culture for 7 days with hrIL-2 (left) and with no 
stimulation (right). The grey dot is the total cell count 24 hours after plating and the black dot 
is the total cell count after 7 days in culture. The red lines connect each TZL case from day 1 
to day 7.  
 
Table 2.3. Total cell count in TZL cells stimulated with IL-2. The average total cell count 
and difference in duplicate wells for day 1 and day 7 of culture with no stimulation and 
stimulation with hrIL-2. The boxes highlighted in red identify cases with increased cell 
count at 7 days with IL-2 stimulation compared to no stimulation. *the cell count for day 






















in cell count 
with IL-2 
81852*       214306 153000 -61306 
81867 37307 83859 -1048315 595269 63443 -531826 
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83533 228502 220915 97764 131649 178041 46391 
83536 401562 405780 41228 362306 835730 473424 
84158 185440 147084 53346 98923 147689 48767 
84160 316615 342777 88970 312835 511126 198290 
84187 655909 685201 46289 706926 667094 -39833 
84932 49539 49539 -49403 90359 90656 297 
85287 121648 134421 17255 117093 157270 40177 
85372 29801 31972 -15470 36703 103665 66962 
85413 3641 3233 -1208 5245 8103 2857 
 
TZL cells express low levels of Ki-67 in vivo 
Ki-67 is a commonly used method to determine the growth fraction in neoplasia. This 
antigen detects a nuclear protein that is expressed in all stages of the cell cycle but is not 
present in resting cells (G0).40,41 In human lymphoma Ki-67 has been employed as an 
independent prognostic determinant.42-44 Recently, Ki-67 has been used in canine lymphoma to 
differentiate high and low-grade lymphomas by flow cytometry.45 
The median % Ki-67 expressing TZL cells was 4.3 (interquartile range (IQR): 2.0 – 4.9). 
This was actually lower than the median % Ki-67 expressing CD45+ T cells in TZL cases, median = 
8.3, IQR: 4.9 – 13.5 (Fig 2.5A) There was a significant difference in the %Ki-67 expressing TZL 
cells in lymph node versus blood samples (blood median %Ki-67 = 2.5; lymph node median %Ki-
67 = 7.06; p < 0.0001, Fig 2.5B), but there was a not a significant difference in expression of Ki-
67 based on phenotype (Fig 2.5C). There was a positive correlation between the size of the TZL 





Figure 2.5. TZL cells express low percentages of Ki-67 overall. A. %Ki-67 expressing TZL cells 
(red) and normal T cells (CD45+CD5+ T cells, blue). B. %Ki-67 expressing TZL cells in lymph 
node (tan) samples versus peripheral blood (red) samples. C. %Ki-67 expressing TZL cells 
segregated by phenotype, CD4+(green), CD8+(purple), CD4-CD8-(aqua). 
 
TZL cells do not appear resistant to cell death  
We wanted to investigate if resistance to cell death could be a more prominent 
contributor to persistence of TZL cells above uncontrolled proliferative capacity. Cell viability in 
TZL cells remained high at 7 days of culture with no stimulation and stimulation with hrIL-2 (Day 
7 median % viable: 93% with no stimulation and 93% with hrIL-2). Figure 2.6 graphically 
represents the % viable in TZL cells at day 7 in varying conditions. The 2 cases with the lowest 
viability with no stimulation were the same cases with the lowest viability when stimulated with 
hrIL-2. For one of these cases the viability was the lowest point for all conditions suggesting this 
case had an inherent cause for decreased viability. This was also the cases with the largest 
decrease in TZL cell number from day 1 to day 7 (Table 2.3). When reviewing this case, the 
sample was cultured the day after it was received but the peripheral blood appeared to be 
obtained at least 3 days prior and was shipped from the British Columbia. Because all of the 
samples were not treated exactly the same prior to arriving at our lab, there could be many 
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factors affecting cell viability including time in transit. However, the high percentage of viability 
in no stimulation and stimulation with hrIL-2 suggests the possibility for reduced susceptibility 
to cell death in TZL cells in these conditions.  
 
Figure 2.6. TZL cells have high viability after 7 days of culture with no stimulation and when 
stimulated with hrIL-2. The % viable of TZL cells (PI- TZL cells/Total TZL cells) after 7 days of 
culture in the following conditions: no stimulation (no stim), hrIL-2 (IL-2), PHA, and 
PMA/ionomycin (PMA).  
 
In the case of IL-2 stimulation, there was proliferation with IL-2 in some cases 
determined by the loss of CFSE. The increase in TZL cell count was not remarkable and did not 
occur in every case. We theorized that the TZL cell count might increase more significantly if 
there were more time for a response. TZL cells were cultured for 21 days in media with no 
stimulation, as well as in media with hrIL-2 added every 7 days. In this system, every 7 days 
media was removed and replaced with fresh media with or without hrIL-2. The cells were 
harvested every 7 days and TZL cells were enumerated by flow cytometry. In two dogs with TZL, 
there was an increase in TZL cells with  hrIL-2 stimulation at day 7; both of these cases were 
CD4-CD8- cases with the first expressing high levels of CD25, whereas the second expressed low 
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levels of CD25, MFI CD25= log4.3 and log0.1, respectively (Fig 2.7,  magenta, 87364 and blue, 
86450). In all 5 TZL cases, by day 21, the number of TZL cells had dropped significantly from the 
initial total cell count, and in every case there was at least one of the duplicate wells with less 
than 1000 total TZL cells in both non-stimulated and hrIL-2 conditions.  
 
Figure 2.7. TZL cell do not persist in long-term culture. The total TZL cell count for 5 different 
cases. The cell count was measured in conditions of no stimulation (N, solid line) and 
simulation with hrIL-2 (IL-2, dotted line). All cases have decreased total cell numbers by 21 
days in culture. D0 = day 0, D7 = day 7, D14 = day 14, D21 = day 21. 
 
Discussion 
In normal T cell function the TCR recognizes antigen presented by MHC class I or II46 on 
the APC leading to the activation of signaling cascades, T cell differentiation and effector 
function, and immune response. This robust response is very specific for the inciting antigen 
and requires multiple checks and balances, including upregulation of numerous T cell surface 
receptors. These include but are not limited to CD4 and CD8 co-receptors that can initiate or 
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support TCR-MHC interaction,47-49 CD2 and LFA-3 for adhesion,50,51 and CD28 which binds to B7 
molecules on APCs.52,53 The TCR complex includes CD45, which is a transmembrane receptor 
that is expressed heavily on immune cells and is a necessary co-factor for T-cell activation by 
antigen,54-57 and may be involved in the co-stimulating process of other co-factors.58,59 
TZL is consistently identified by the lack of CD45 protein and gene 
expression.4,5,60,61Since CD45 has been shown to be necessary for T cell activation, we wanted 
to investigate mechanisms for TZL cell activation. As predicted, TZL cells did not show evidence 
of proliferation when stimulated through the TCR by two methods, anti-CD3/anti-CD28 beads 
or PHA, which causes cross-linking of the TCR (Fig 2.2). We were able to induce proliferation in 
TZL cells with PMA and ionomycin; this method bypasses the TCR and directly activates PKC and 
causes an influx of calcium.25 However, in vivo, these second messengers are not a primary 
source of activation and require a signal from transmembrane receptors first.62 Since this 
method does not normally occur in vivo we wanted to determine if there was a more 
biologically relevant method for TZL activation and proliferation. TZL cells have been described 
to express CD25,4,6 the IL-2-receptor-α subunit and a marker of activation. In CD45-deficient cell 
lines, proliferation did not occur in response to antigen but IL-2 was still able to elicit a 
dampened response.55 We hypothesized that TZL cells may be sensitive to stimulation with 
hrIL-2 because of increased expression of CD25. Activated T cells rapidly produce and express 
IL-2Rα which complexes with other IL-2R subunits to form a high affinity receptor with 
increased sensitivity to IL-2.63,64 We often saw the most evidence for proliferation in TZL cases 
that showed increased expression of CD25, MFI ≥ log1.0 (Fig 2.3). hrIL-2 did not appear to 
induce a greater degree of proliferation than PMA/ionomycin based on the expression of CFSE 
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and did not induce proliferation in every case. Although, IL-2 may be involved in the 
proliferation in TZL cells, other unidentified factors are expected to be implicated in the 
pathogenesis of proliferation in this disease. For instance, macrophages and/or B cells may 
provide signals to TZL to cause proliferation. Interestingly, from the data in Chapter 1, the TZL 
cases had significantly increased expression levels of CD40 ligand (CD40L) compared to controls 
(TNFSF5; Fold change = 2.59; adj P-value = 4.6X10-6). CD40-CD40L interactions are vital for CD4 
T cell effector functions including B cell differentiation and class switch, macrophage activation 
and cytokine production, and activation of T cells.65 The interaction of CD40L on TZL cells and 
CD40 on B cells or monocytes/macrophages could be another mechanism to explore in the 
activation of TZL and pathogenesis of this disease.  
We also measured intracellular Ki-67 in TZL cases for a better understanding of in vivo 
proliferative capacity. Previously, low Ki-67 in canine diffuse large B cell lymphoma has been 
defined as ≤ 20% by flow cytometry.66 In human lymphomas a value of 45% or less was useful 
to distinguish indolent from aggressive lymphoma by histopathology.44 In TZL, the Ki-67 
expression was much lower with a median of 4.3 in TZL cells (CD5+CD45-) (Fig 2.5). In vitro, 
proliferation of TZL was variable and difficult to induce. The % of Ki-67 expression of TZL also 
does not suggest robust cell proliferation in this disease, which is similar to culture findings and 
may reflect the indolent nature of the disease. 
Since there was some evidence for activation by hrIL-2 in TZL cells we wanted to 
determine if prolonged exposure to hrIL-2 would lead to more profound proliferation and 
increase in TZL cell number compared to what we found with 7 days of culture (Fig 2.4; Table 
2.3). We also wanted to subject TZL cells to prolonged culture time to see if there was any 
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evidence for TZL cell resistance to apoptosis. We identified that in short term culture (7 days 
total), TZL cell had high viability when stimulated with hrIL-2 (Fig 2.6). The TZL cells in culture 
for 21 days consistently decreased in number by day 14, and by day 21 many cells were dead 
and there was only a small population of TZL cells remaining (Fig 2.7). IL-2 has been implicated 
in enhancement of AICD in T cells,67 and has shown to activate transcription of FasL.68 hrIL-2 
may have led to enhancement of cell death in our culture system but the TZL cells also 
decreased in number in conditions with no stimulation. Furthermore, IL-2 priming has been 
show to sensitized T cells to AICD when activated with anti-CD3 antibody but not with PMA and 
ionomycin.69 Since we have identified disruption of TCR signaling in TZL, IL-2 sensitization of 
AICD may not be a factor in these cells. Regardless, we were unable to maintain TZL cells in the 
presence of hrIL-2 in vitro. These findings further support the notion that there are likely other 
signaling factors that are necessary for TZL proliferation and maintenance. These factors could 
be produced in vivo within the tumor microenvironment and may involve other immune cells 
such as macrophages or B cells.  
In conclusion, TZL cells were able to proliferate through TCR-independent mechanisms. 
In some cases of TZL, hrIL-2 was able to induce proliferation, however the cell count did not 
consistently increase in every case. With prolonged exposure to hrIL-2, we found that TZL cells 
did not increase in cell number after 7 days and TZL cells did not show evidence for resistance 
to cell death in 21 days of culture. Although IL-2 may be involved in TZL activation, it is likely 
that other factors are involved as well. Signaling from other cells in the lymph node could be 
involved in TZL proliferation. We did not investigate B cell signaling or inflammatory cell 
signaling in TZL cultures. Investigating TZL cell proliferative mechanisms in the lymph node may 
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provide more insight. Lymph node aspirates would contain cells of the microenvironment, such 
as B cells and dendritic cells, which might be involved in TZL cell activation. Alternatively, the 
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CHAPTER 3: T ZONE LYMPHOMA CELLS DO NOT SHOW EVIDENCE FOR IMMUNOSUPPRESSION 
IN VITRO 
Summary  
T zone lymphoma (TZL) is not an aggressive disease but there is evidence for both 
genetics and environmental influence in disease development. There is also evidence for 
immunosuppression in at least a subset of dogs. Demodicosis is a follicular mite that can cause 
opportunistic infection in adult dogs and has been associated with immunosuppression. In TZL, 
about 10% of dogs present with demodicosis or an additional neoplastic condition. Although 
this disease is indolent, its influence on comorbidities has only begun to be examined, which 
would influence patient management. We investigated how TZL cells influence the tumor 
microenvironment in vitro. We characterize proliferation, and cytokine production in normal T 
cells within TZL microenvironment. We hypothesized that TZL cells would suppress normal T 
cells within the microenvironment. Contrary to what we expected, normal T cells in dogs with 
TZL proliferated at similar rates as normal T cells in dog without TZL. Additionally, IFN-γ 
production was not suppressed in normal T cells, and there was no difference between TGF-β 
production in peripheral blood TZL cases when compared with normal canine peripheral blood 
in vitro.  
Background  
Molecular profiling of neoplastic cells has greatly advanced the understanding of 
lymphomagenesis, but the interaction between the microenvironment and the tumor has also 
been demonstrated to be involved in pathogenesis and prognosis of cancer. Identifying 
functions of the neoplastic cell, as well as the interaction with the tumor stroma and non-
102 
 
neoplastic cells, provides a more thorough understanding of the pathogenesis of disease in 
addition to more opportunities for targetable intervention. The tumor microenvironment has 
proven not only to be involved in preventing cancer development, but has been found to 
contribute to cancer progression.1 In the tumor microenvironment, CD8+ cytotoxic T 
lymphocytes (CTLs) and CD4+ helper T  (Th) cells combat cancer through production of IFN-γ 
and cytotoxic molecules such as granzymes and perforin.2 During cancer development a state of 
equilibrium is reached in which there is a balance between the immune system and the cancer 
cells, with no appreciable growth of the cancer.3 With progression, the tumor escapes the 
immune system through several mechanisms leading to clinical disease. In lymphomas several 
strategies of immune evasion have been identified, including loss of surface molecules that the 
immune system would normally use to recognize neoplastic cells such as MHC class I. For 
instance, in diffuse large B cell lymphoma, the loss of MHC I has been associated with fewer 
infiltrating CD8+ CTLs.4 Tumor cells can also acquire surface molecules to dampen the immune 
response, for example, programmed cell death protein 1 (PD1) can be upregulated which 
inhibits T cells.5,6 Immune evasion can also occur as a result of shifting the microenvironment 
toward a tolerant state, including promotion of regulatory T (Treg) cells.7 TGF-β, produced by 
Treg cells or tumor cells, can lead to differentiation of naïve CD4+ cells to Treg cells, 
perpetuating immune suppression.8 TGF-β inhibits proliferation of lymphocytes while IL-10 
inhibits activation of macrophages and expression of co-stimulatory molecules.9 In addition, 
tumors have been shown to alter the immune response from a Th1 to a Th2 reaction through 
TGF-β and IL-10 production.10  
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A number of small signaling molecules have also been implicated in regulation of the 
tumor microenviroment. Specifically, galectins have been investigated in numerous tumors due 
to immunosuppressive functions leading to tumor progression or immune escape. Galectin-1 
and galectin-3 can bind to several T cell surface molecules including CD45, CD7, CD43, CD2, and 
CD3 leading to apoptosis.14-17 Many different types of tumors have been shown to upregulate 
galectin expression and this is likely due to tolerogenic affects. For instance, in Hodgkin’s 
lymphoma, neoplastic Reed-Sternberg cells have been shown to have increased galectin-1 
levels resulting in an immunosuppressive Th2/Treg dominated microenvironment.18 
Additionally, in patients with leukemic cutaneous T cell lymphomas, increased galectin-1 levels 
have been demonstrated to promote a Th2 response leading to weakening of the anti-tumor 
response.19 Th2 cytokines were found to be overproduced in patients with leukemic, cutaneous 
T–cell lymphoma (L-CTCL) with a strong Th2 bias.20 The Th2 bias identified in T cells in L-CTCL 
was suggested as an underlying mechanism in patients’ susceptibility to infection.20 These 
patients not only have characteristics of a Th2-driven immune state, but they also have 
increased infection rates of Staphylococcus aureus, and increased susceptibility to cutaneous 
infections.20  
Galectins promote a Th2 type environment through preferential cell death of Th1 and 
Th17 cells.21 Specific modifications of oligosaccharides of CD45 are responsible for the control 
of T cell vulnerability to death.22 In T cell activation, galectin-1 signaling and cell death were 
shown to be specific to surface glycans on Th1 and Th17 differentiated cells. In contrast, Th2 
cells were protected from galectin-1 induced cell death by differential sialylation of N- and O-
glycan on the cell's surface.21 Galectin-1 has also been shown to promote production of the Th2 
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cytokines, IL-4, IL-5, and IL-10 with TCR induction,23 causing suppression of chronic 
inflammation.21 Furthermore, Th2 cells have been shown to promote Th1 cell apoptosis 
through secretion of galectin-1, thus behaving like an inhibitory cytokine.23 Interestingly, 
upregulation of galectin-3 is cytokine specific and occurs with IL-2 and IL-4 but not with IFN-γ.24 
Not only does galectin-3 upregulation occur with Th2 cytokine production, but higher levels of 
galectin-3 were identified in Th2 cells compared to Th1 cells.23 Galectin-3 can also bind to CD45 
to modulate TCR signaling and survival.25,26 Surprisingly, galectin-3 can act both extracellularly 
and intracellularly and can protect cells from death.27,28 Intracellular galectin-3 has been shown 
to protect Th2 cells from apoptosis.23 In another cancer-promoting mechanism, galectin-3 has 
been found to concentrate on CD45 on DLBCL cells and unexpectedly promote resistance to 
apoptosis.29     
We have shown in Chapter 2 that TZL cells express high levels of galectins-1 and -3. TZL 
cells also express GATA3, the Th2 transcription factor and TGF-β. These features could support 
an immunosuppressive environment within the tumor. Interestingly, in TZL, 10-50% of dogs 
present with demodicosis.30,31 Demodicosis is an opportunistic skin infection of hair follicle 
mites in dogs and in adult dogs the infection is often associated with an immunosuppressive 
state.32 Another study reported 10% of TZL cases developing a second unrelated neoplasm.33 
These findings suggest that there is a degree of immunosuppression in a subset of dogs with 
TZL. 
Given the unique phenotypic features of TZL, specifically the loss of CD45 in neoplastic T 
cells, we were able to isolate normal T cells and TZL cells in the same sample. Using these 
isolates we investigated whether the TZL cells could suppress CD45+ T cells. First, we wanted to 
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characterize cytokine production in TZL serum and TZL cell culture in order to compare in vivo 
and in vitro cytokine production in this disease. We also wanted to further investigate the 
increased expression of TGF-β identified in Chapter 2, to determine if there was increased 
production of TGF-β in TZL cell culture. Because of increased gene expression of TGF-β and 
galectins, we hypothesized that normal T cells in TZL cases would have hindered proliferation 
rates and IFN-γ production which we investigated through in vitro methods.  
Methods 
Cell culture methods 
Peripheral blood cell culture as described in Chapter 2 was used for cytokine 
measurements and proliferation assays. For intracellular flow cytometry, lymph node aspirates 
were used with the same culture methods as described for blood in Chapter 2. The procedures 
for flow cytometry acquisition and analysis described in Chapter 1 were the same for initial 
diagnosis and case identification using the CSU-CI laboratory standard diagnostic panel. The 
antibodies used for surface staining of cells harvested from cell culture were the same as those 
used in Chapter 2. Surface staining included: CD5-APC (T cell, clone YKIX322.2, Bio-Rad, 
Hercules, CA), CD45-PB (pan-leukocyte, clone YKIX716.13, eBioscience, San Jose, CA), and CD8-
A700 (CD8 T cell, clone YCATE 55.9, Bio-Rad). Normal T cells were identified by the expression 
of both CD5+ and CD45+, and TZL cells were identified by the lack of CD45 expression 
(CD5+CD45-). A known amount of CountBrite beads were added prior to sample acquisition, 





Serum and culture cytokine measurement using canine multiplex  
Serum cytokines were measured in dogs with TZL, dogs with small numbers of TZ (CD45-
CD5+) cells, and control dogs with no TZ cells. Serum was provided from peripheral blood of 
Golden retrievers that was submitted for a case-control study of risk-factors for TZL through the 
CSU-CI laboratory. Dogs with small numbers of TZ cells did not have any clinical signs associated 
with lymphoproliferative disease such as lymphocytosis and lymphadenopathy, and these dogs 
are referred to as TZCUS (T zone cells of unknown significance; Labadie et al. in review JVIM) 
dogs. The TZCUS dogs had at least 1% TZ cells of the total lymphocyte population in their 
peripheral blood. If dogs had less than 1% TZ cells of the total lymphocyte population then they 
were considered negative for TZ cells and categorized as control dogs.  
Culture supernatants were extracted from peripheral blood cell culture of both dogs 
with TZL and control dogs after 24 hours of culture with stimulatory methods described in 
Chapter 2. Using a 13-plex Milliplex MAP canine-specific assay the following cytokines and 
chemokines were measured in both serum and culture samples: GM-CSF, IFN-γ, KC, IP10, IL-2, 
IL-6, IL-7, IL-8, IL-10, IL-15, IL-18, MCP-1, and TNF-α (CCYTOMAG-90K, Millipore Sigma, 
Burlington, MA). Harvested serum and culture supernatants were stored at -80 C for a 
maximum of two years. Freeze-thaw cycles were limited to a maximum of two at the time of 
cytokine analysis. Analytes were measured in duplicates using the manufacturer’s protocol. 
Briefly, 12.5μL from each duplicate sample was incubated with the panel of microspheres 
coupled to the capture antibodies listed above. Sample were then incubated with biotinylated 
secondary antibodies and streptavidin-conjugated PE. Following incubation a Bio-Plex 200 
reader (Bio-Rad, Munich, Germany) with Luminex xMAP technology was used to quantify 
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cytokines, and calculation was performed with the Bio-Plex Manager Software 4.1.1. (Bio-Rad), 
which analyzes the Median Fluorescent Intensity (MFI) using a 5-parameter logistic regression 
curve fitting method to determine the concentration of each cytokine. The sensitivity limit for 
IFN-γ was 2.44pg/mL with a seven-point standard curve from 2.44 – 10,000pg/mL; for the 
remaining cytokines the sensitivity limit was 12.2pg/mL with a seven-point standard curve from 
12.2pg/mL – 50,000pg/mL. Values below the detection limit were assigned a value equal to the 
minimum detectable concentration of each cytokine.   
Cytokine measurement by ELISA  
A DuoSet ELISA development kit (R&D systems, Minneapolis, MN) was used for 
quantitative analysis of IL-4 in culture supernatants following the manufacturer’s protocol. 
Briefly, a 96-well microplate was incubated overnight with 100μL per well of diluted Capture 
Antibody (R&D systems). The next day, the plate was washed (5X) using an automated plate 
washer with wash buffer (0.05% Tween 20 in PBS, pH 7.2-7.4, R&D systems). The plate was then 
blocked with 300μL of Reagent Diluent (R&D systems) at room temperature (RT) for 1 hour. The 
plate was washed and then 100μL of sample or standards in and Reagent Diluent (1% BSA in 
PBS, pH 7.2-7.4, R&D systems) were added to each well in duplicates, then covered and 
incubated for 2 hours at RT. The plate was washed and 100μL of 200-fold dilution of 
Streptavidin-HRP was added to each well, then incubated for 20 minutes at RT while protected 
from light. After incubation, 100μL of the Substrate Solution (1:1 mixture of Color Reagent A 
[H2O2] and Color reagent B [Tetramethylbenzidine], R&D systems) were added to each well. 
When there was evidence of color titration in the standard curve (~20 minutes), 50μL of Stop 
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Solution (2 N H2SO4, R&D Systems) was added to each well. The optical density (OD) of each 
well was determined immediately using a microplate reader set to 450 nm. 
Following the manufacturer’s protocol, the canine IL-2 VetSet, ELISA Development Kit 
(Kingfisher Biotech, Inc; Saint Paul, MN) was used for determination of canine IL-2 in cell 
culture. The 96-well plate was coated with canine IL-2 and 50μL of standard or sample was 
added to each well in duplicate, covered and incubated at RT for 1 hour. The plate was washed 
with 0.05% Tween-20 in DPBS using an automated plate washer (5X). After washing, 50μL of 
Detection Antibody was added at a 1:23 dilution and incubated at RT for 1 hour, then the plate 
was washed. 50μL of streptavidin-HPR was added to the wells at a 1:20 dilution and incubated 
at RT for 30 minutes. After washing the plate, 50μL of TMB (3.3’.5.5’-tetramethylbenzidine, 
KingFisher Biotech, Inc.) substrate solution was added to each well and incubated in the dark at 
RT for 30 minutes. At this point, 50μL of the Stop solution (0.18 M Sulfuric Acid, KingFisher 
Biotech, Inc.) was added to each well and the absorbance was measured on a microplate reader 
at 450 nm.  
TGF-β ELISA measurement  
Following the manufacturer’s protocol, the mouse/rat/porcine/canine TGF-β1 
Quantikine ELISA (R&D systems) was used for measuring TGF-β in culture supernatants. Latent 
TGF-β1 was activated to detect immunoreactive TGF-β1 by adding 20µL of N HCl to 100µL of 
sample and incubated for 10 minutes at RT. The samples were then neutralized with 20µL of 1.2 
N NaOH/0.5 M HEPES and assayed immediately. 50µL of Assay Diluent RD1-21 (R&D systems) 
was added to each sample’s well, followed by 50µL of Standard, Control or activated sample. 
Each well was then incubated for 2 hours at RT, after which the plate was washed with an 
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automated washer (5X) and then blotted dry on paper towels. Following washing, 100µL of 
TGF-β1 Conjugate (R&D Systems) was added to each well and incubated for 2 hours at RT. The 
plate was then washed again and 100µL of Substrate Solution (R&D Systems) was added to 
each well and incubated for 30 minutes at RT while protected from light. Following this 
incubation 100µL of Stop Solution (R&D Systems) was added to each well with gentle mixing, 
after which the OD of each well was determined using a microplate reader at 450 nm. Since 
there was fetal bovine serum within the media, we measured the culture media by itself to 
determine background TGF-β1. We subtracted this background OD from the sample OD.  
Intracellular flow cytometry  
After lysis of lymph node aspirates the cells were resuspended in complete RPMI media 
as described in Chapter 2, and cells were manually counted using trypan blue to distinguish live 
cells. The samples were cultured at 5 x 105 cells/well (50 X 105cells/mL) in duplicate. Cells were 
either not stimulated or stimulated with PHA (2.5mg/mL, Millipore Sigma, St. Louis, MO) for 
three days. After 72 hours, PMA and ionomycin (10ng/mL and 1460ng/mL respectively; 
Millipore Sigma) in the presence of Brefeldin A (5μg/mL, Millipore Sigma) was added to half the 
stimulated wells and Brefeldin A alone was added to the other half of the stimulated wells and 
to the non-stimulated wells for 4 hours. After incubation, the cells were processed using the 
eBioscience Foxp3/Transcription Factor Staining Buffer set (eBioscience, San Jose, CA) adapted 
from the protocol described in Chapter 2 and previously reported34 with the exclusion of 
Zombie violet dye. Briefly, the cells were first washed with flow buffer (PBS-2% FBS-0.1%NaAZ) 
and stained with surface antigens as previously described.35 Cell surface antigens included: anti-
CD5-PerCP-eFluor710 (T cell, clone YKIX322.2, Bio-Rad); anti-CD45-PB (pan-leukocyte, clone 
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YKIX716.13, eBioscience); and anti-CD8-A700 (CD8 T cell, clone YCATE 55.9, Bio-Rad). Following 
surface staining and washing with flow buffer, the samples were resuspended in diluted fix and 
perm from the buffer set (1:4 dilution of eBioscienceTM Fixation/Permeabilization concentrate 
to eBioscienceTM Fixation/Perm diluent) and incubated overnight in the dark at 4 C. The next 
day, samples were pelleted and washed twice with diluted perm buffer (eBioscienceTM 
Permeabilization buffer 10X in a 1:9 dilution with deionized water) and then resuspended in 
200µL of diluted perm buffer. The cells were blocked with 5% mouse serum (Jackson 
ImmunoResearch Laboratories, West Grove, PA) for 15 minutes at RT and subjected to 
intracellular staining with IFN-γ-Alexa488 (titrated to 1µL/reaction, 0.00001mg/μL, mouse anti 
bovine, clone CC302, Bio-Rad) for 15 minutes at RT. The cold-compete control was incubated 
with IFN-γ with no label, 10μL (0.0001mg/μL, mouse anti bovine IFN-γ purified, clone CC302, 
Bio-Rad) for 15 minutes prior to all samples receiving labelled IFN-γ. Blocking and intracellular 
staining were performed in 1x permeabilization buffer. After incubation the cells were washed 
twice with 1x permeabilization buffer and resuspended in 200µL of flow buffer. Gates were set 
using the cold-compete for each sample and confirmed with the fluorescence minus one 
control (FMO), which included all antibodies in the staining panel except IFN-γ-A88.  
Statistics 
For cytokine measurements, the data was analyzed by Prism 7.0 (Graphpad, La Jolla, 
CA). The data was assessed for normality using the Shapiro Wilk test, and was found not to be 
normally distributed. The non-parametric Kruskal-Wallis test was used to determine the 
significance across groups for each analyte and % IFN-γ production and the p-value was 
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adjusted for multiple comparisons by using the Dunn’s multiple comparisons. A p-value of <0.05 
was considered to be significant.  
Results 
Dogs with TZL do not express different cytokines in their serum than control dogs or dogs with 
TZCUS 
Serum cytokine measurement was performed on 35 dogs with TZL, 45 dogs with TZCUS, 
and 32 control dogs with no evidence of TZ cells in their peripheral blood. For a number of 
cytokines, less than 50% of the dogs tested had detectable serum cytokine levels. This included 
GM-CSF, IFN-γ, IP10, IL-2, IL-6, IL-7, IL-10, and TNF-α. For IL-15, IL-18, KC and MCP-1, the cases 
had detectable levels of cytokines in over 50% of dogs within this group, while in all three 
groups more than 90% of dogs had detectable levels of IL-8. IL-8 is a specific neutrophil 
chemoattractant cytokine36 that has been shown to be expressed and produced by 
neutrophils.37 Since the sample was from peripheral blood, the neutrophils, rather than T cells, 
are likely responsible for production of this cytokine. The median and range (min and max) of 
cytokines for all three groups is summarized in Supplemental Table 3.1. There was no significant 
difference between cases, TZCUS dogs or controls for any of the measured 
cytokines/chemokines. In this system there was no evidence of increased IL-10 production in 
TZL, which if increased would be a possible mechanism of immunosuppression.   
Inflammatory cytokines can be induced in TZL cell culture 
In cell culture supernatants, detectable production of all cytokines was found in over 
50% of samples in at least one of the conditions (no stim vs. stim). Interestingly, TNF-α was 
detectable in 100% of the cases that were stimulated and 92% of cases with no stimulation. In 
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examining culture supernatants from dogs with TZL we were unable to detect IL-2, IL-6, and IL-8 
above the limits of detection for this assay, and production of IL-7, IP10 and IL-15 was just 
above the limits of detection with any of the conditions. The other cytokines that T cell can 
produce, and that we were able to detect, included INF-γ, IL-10 and TNF-α. Cytokine 
concentrations for these three cytokines in normal dogs and dogs with TZL are summarized in 
Supplemental Table 3.2. The fold change (cytokine concentration in the stimulated sample over 
cytokine concentration in the non-stimulated sample) for each condition is shown in Fig 3.1. 
There were no significant differences in IL-10 production in TZL cases in any of the conditions. 
The median concentration of TNF-α of TZL cases with no stimulation was significantly lower 
than in TZL cases stimulated with PMA (p < 0.0001) (Supplemental Table 3.2). Similarly, there 
was a significant difference in the median concentration of IFN-γ in TZL cases with no 
stimulation, or stimulation with beads, compared to TZL cases stimulated with PMA (no stim vs. 
PMA: p = 0.0005 and beads vs. PMA: p = 0.03) (Supplemental Table 3.2). There was no 
difference in PMA stimulated TZL cells with any of the cytokines compared to control cells 
stimulated with PMA. In the control dogs there was a significant difference in TNF-α production 
with PMA stimulation versus no stimulation (p = 0.0013) but no other significant differences. 
There was high variability in dogs both in the TZL cases and control cases, and there were fewer 
samples stimulated with PHA or PMA compared to no stimulation and stimulation with beads. 
A wide range of cytokine production has been previously detected in the serum of normal dogs, 
as well as many disease states including lymphoma.38,39 There was no evidence for 
immunosuppression in TZL cases through the production of IL-10 in vivo or in vitro. IFN-γ and 
TNF-α production could be induced in TZL dogs with PMA. These are considered inflammatory 
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cytokines, and these cytokines have been shown to be induced with PMA/ionomycin in other 
species.40 TNF-α production was also induced in control dogs with PMA/ionomycin. It is 
uncertain if the production of these cytokines in TZL cases is specific to TZL cells. Since the 
samples were not sorted originally, we are unable to determine if the production of these 
cytokines is from neoplastic TZL cells or normal CD45+ T cells in the sample.  
Figure 3.1. The production of IFN-γ and TNF-α in TZL cases is induced by stimulation with 
PMA. The fold change (concentration of stim/concentration of no stim) for TZL cases (red) 
and control (CTRL, black) peripheral blood cell culture. The stimulatory methods included 
anti-CD3/anti-CD28 beads (Beads, blue), PHA (PHA, orange), and PMA/ionomycin (PMA, 
purple). The supernatants were collected and assayed at 24 hours of culture.  
 
 
With the canine multiplex the median IL-2 production was 12pg/mL, which is at the 
lower limits of detection for that assay. We attempted to get a better indication of IL-2 
production with the use of an IL-2 specific ELISA. The lower limits of detection for the IL-2 
VetSet, ELISA Development Kit (Kingfisher Biotech, Inc.) was only 60pg/mL. We assayed 2 
samples of cultured, fresh, normal, control lymph node (LN), 2 samples of control peripheral 
blood cultures harvested at days 1 and day 3, and 3 TZL peripheral blood cultured samples 
harvested at days 1 and day 3. These samples included no stimulation, stimulation with PHA (LN 
only) and stimulation with anti-CD3/anti-CD28 beads. All samples were below the limits of 
detection. The concentration in LN control samples ranged from 19 – 40pg/mL; the 
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concentration in control peripheral blood samples ranged from 12 – 20pg/mL; and the 
concentration in TZL peripheral blood samples ranged from 12.5 – 48.4pg/mL. Since our 
samples were not within the lower limits of detection of these assays we did not continue to 
attempt to measure these cytokines with this ELISA  
IL-4 was not an available cytokine in the canine multiplex; we attempted to measure this 
cytokine by ELISA. IL-4 is a Th2 cytokine and has been shown been shown to inhibit IFN-γ gene 
expression.41,42 The canine IL-4 ELISA we pursued was not sensitive enough for our culture 
conditions. The assay has a reported sensitivity of about 100pg/mL. We made several attempts 
at a standard curve with a sensitivity of less than 100pg/mL, but were unsuccessful at getting a 
sensitivity reading below 300pg/mL. Even with these efforts, the OD readings for our samples 
were within the range of background OD readings. The samples we tested included cultured 
canine peripheral blood and lymph node in control dogs, in addition to dogs with TZL in both 
stimulated and non-stimulated conditions (Table 3.3). Only 5 samples had an OD in which a 
concentration could be calculated and these OD readings were at the limits of detection of this 
assay. Further, these samples were for control lymph nodes only; none of the cultured TZL 
cases had OD readings within the limits of detection (300pg/ml). 
Table 3.3. IL-4 is below the limits of detection in TZL cases and controls. Samples of 
controls and TZL cases in conditions of non-stimulation and stimulation at 24 and 72 
hours, the optical density (OD) at 450 nm, and concentration of IL-4 in pg/mL.*The 
concentration was calculated based on the standard curve obtained from the date the 
samples were run. Samples with a concentration below zero were not determined 
(ND). 
CI 
number sample type condition 
time of 
harvest 
(hr) OD 450 nm 
Concentration* 
pg/mL  
66813 CTRL LN  no stim 24 0.06 308.01 
66813 CTRL LN  PHA 24 0.04 189.53 
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66813 CTRL LN  Beads 24 0.05 269.24 
66813 CTRL LN  no stim 72 0.02 124.92 
66813 CTRL LN  PHA 72 0.01 70.36 
66813 CTRL LN  Beads 72 -0.01 ND 
55354 
CD4-CD8- 
TZL  no stim 72 -0.01 ND 
55354 
CD4-CD8- 
TZL  Beads 72 0.05 236.04 
62932 CTRL BLD no stim 24 0.00 ND 
62932 CTRL BLD Beads 24 0.00 ND 
62933 CTRL BLD no stim 24 -0.02 ND 
62933 CTRL BLD Beads 24 -0.03 ND 
62932 CTRL BLD no stim 72 -0.05 ND 
62932 CTRL BLD  Beads 72 -0.04 ND 
62933 CTRL BLD no stim 72 -0.04 ND 
62933 CTRL BLD  Beads 72 -0.02 ND 
55395 
CD4-CD8- 
TZL  no stim 24 -0.04 ND 
55395 
CD4-CD8- 
TZL  Beads 24 0.02 114.20 
55395 
CD4-CD8- 
TZL  no stim 72 -0.05 ND 
55395 
CD4-CD8- 
TZL  Beads 72 -0.06 ND 
 
TGF-β production is not induced in TZL  
TGF-β gene expression was found to be significantly increased in TZL cases and 
discussed in Chapter 1. We wanted to measure TGF-β expression in TZL culture supernatants to 
determine if production of this immunosuppressive molecule could be a mechanism for 
immunosuppression in this disease. There were no significant differences in TGF-β production 
in TZL cases with multiple stimulatory methods including PHA, PMA/ionomycin and IL-2 (Fig 
3.2), nor were there significant differences in TGF-β production in TZL cases versus the controls. 
Moreover, there was no correlation between TGF-β concentration and the total lymphocyte 
count, the white blood cell count, or the TZL cell count. Although we detected increased gene 
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expression of TGF-β in TZL cases we were unable to confirm induced production of this cytokine 
in vitro.  
 
Figure 3.2. TGF-β production is not induced in vitro in TZL. The concentration measured by 
ELISA in pg/mL in cell culture supernatants of TZL cases (red) and control cases (black). These 
concentrations were adjusted for background TGF-β from culture media containing %10 FBS. 
 
IFN-γ expression by normal T cells is not suppressed by TZL  
IFN-γ is a pro-inflammatory cytokine that is produced by Th1 cells and is involved in Th1 
differentiation, which can be repressed by GATA3.43,44 First, we wanted to determine if the 
induced IFN-γ production identified by the cytokine multiplex was produced by the normal T 
cells, or the TZL cells. In order to answer this question, we used intracellular flow cytometry to 
identify which population of cells produced IFN-γ in the presence of PMA/ionomycin. Second, 
we wanted to determine if TZL cells were able to suppress IFN-γ expression in normal T cells, 
which would support our hypothesis of an immunosuppressive environment for this disease. 
We found that stimulation for three days with PHA, followed by 4 hours of stimulation with 
PMA/ionomycin, produced appreciable levels of IFN-γ in lymph node samples from control 
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dogs. The expression of IFN-γ was much higher after three days of stimulation compared with 1 
or 2 days in two different control canine lymph nodes (Fig 3.3). 
 
Figure 3.3. IFN-γ production is induced with PMA/ionomycin after 3 days of stimulation in 
normal canine lymph node tissue culture. Two normal canine lymph nodes that were 
stimulated for 24, 48, and 72 hours with PHA. At each of these time points the samples were 
stimulated with PMA/ionomycin for 4 additional hours prior to processing in the presence of 
Brefeldin A. The y-axis is the %IFN-γ expressing CD5+CD45+ T cells as determined by flow 
cytometry.  
    
In TZL cases we found very little production of IFN-γ in CD45+ T cells and TZL cells with 
no stimulation, or with stimulation by PHA alone after three days. There was production of IFN-
γ in the CD45+ T cells in all TZL cases when stimulated with PHA followed by PMA/ionomycin 
(Fig 3.4). There was a statistically significant difference in the CD45+ T cells that received 
additional stimulation with PMA/ionomycin, compared with those that received no stimulation 
(Fig 3.4; p = 0.0009). In three of the TZL cases there was also production of IFN-γ with the 




Figure 3.4. IFN-γ production is not inhibited by TZL cells. The percentage of CD45+ T cells 
(CD45+CD5+, blue) and TZL cells (CD5+CD45-, red) that express IFN-γ (y-axis) after 3 days in 
culture with no stimulation or stimulation with PHA. After 72 hours the wells were spiked 
with Brefeldin A (no stim and PHA) for 4 hours, or Brefeldin A and PMA/ionomycin 
(PHA+PMA) for 4 hours, and then harvested and processed for intracellular IFN-γ by flow 
cytometry. The % of T cells expressing IFN-γ in two normal lymph nodes (black) with PHA and 
PMA/ionomycin is shown for reference of the potential IFN-γ production in normal dogs 
without TZL. The y-axis is the %IFN-γ expressing cells as determined by flow cytometry.  
 
There is an example IFN-γ production after three days of stimulation with PHA, followed 
by stimulation with PMA/ionomycin for 4 hours prior to harvest in a TZL case in Fig 3.5. The 
percentage of CD45+ T cells producing IFN-γ in TZL cases was higher than in the normal lymph 
nodes; for CD45+ T cells expressing IFN-γ: mean = 14.9% in TZL lymph nodes versus mean = 
9.8% in normal lymph nodes (Fig 3.4). These findings suggest that TZL cells do not suppress the 
production of IFN-γ in CD45+ T cells in vitro. 
TZL cells do not inhibit cell proliferation of CD45+ T cells  
TZL cells were found to express high levels of TGF-β which has been found to inhibit IL-2 
induced T cell proliferation.45 We have previously shown in Chapter 2 that normal CD45+ T cells 
are still able to proliferate within culture with TZL cells (CD45- T cells). In proliferation 
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experiments described in Chapter 2, we noted that the proportion of normal CD45+ T cells 
within culture conditions increased with stimulatory conditions. Fig 3.6 is an example of one of 
the stimulatory experiments performed in Chapter 2. The normal T cells were also able to 
proliferate in all stimulatory conditions, unlike TZL cells which only proliferated in conditions 
independent of the TCR (Chapter 2, Fig 2.2).  
Figure 3.5. Gating strategies for identification of IFN-γ production in normal T cells and TZL 
cells in vivo. An example of IFN-γ production in a TZL case after 3 days of culture with PHA 
followed by 4 hours of stimulation with PMA/ionomycin. The CD45+ T cells and TZL cells are 
isolated based on expression of CD45. The CD45+ cold and TZ cold controls are shown and set 
to less than 1%. These gates are linked to the gates with colored events (blue and red). The % 
of CD45+ T cells (blue) and TZ cells (red) that are expressing IFN-γ are determined by the 
percent of cells within the gates set to the cold controls (Normal T cells IFN-γ = 16.30%; TZ 




Figure 3.6. Normal T cell proliferation does not appear to be inhibited by TZL cells. Normal T 
cells (CD5+CD45+) are identified in blue and TZL cells (CD5+CD45-) are identified in red. The 
proportion of normal T cells increases from 5 to 32% with stimulation by PHA, and to 21% 
with stimulation by PMA and ionomycin. The top panel shows the complexity of cells on the 
y-axis and the size on the x-axis. The normal T cells enlarge with stimulation by both PHA and 
PMA/ionomycin whereas TZL cells only enlarge with PMA/ionomycin.  
 
These findings suggest that TZL cells do not inhibit normal T cells from proliferating in 
culture. We wanted to investigate this assumption by determining the total cell count of normal 
T cells in culture. The total cell count of normal T cells increased in 4 of 5 cases stimulated with 
PHA, and in 8 of 12 cases stimulated with IL-2 (Fig 3.7). In normal peripheral blood, normal T 
cells increased in total cell count in 2 of 4 cases when stimulated with PHA and 2 of 6 cases 
stimulated with IL-2. Based on this information we do not have evidence that TZL cells suppress 




Figure 3.7. TZL cells do not show evidence for suppression of proliferation in normal T cells 
in vitro. The total cell count for normal CD45+ T cells in culture with TZL cells (top) and 
normal T cells in normal peripheral blood (bottom). The total cell count was determined at 24 
hours (day 1) and 7 days after stimulating with either PHA (left) or hrIL-2 (right). The dot plots 
in the right-most panel are showing the identification of normal T cells that are CD5+CD45+ 
in TZL cases (top, blue) and CD5+CD45+ in normal blood (bottom, black) with no TZL cells. 
 
Discussion 
We did not find differences in serum cytokines in dogs with TZL versus TZCUS dogs or 
control dogs without TZL (Supplemental Table 3.1). Detection of serum cytokines can be 
difficult as sample handling can also affect detection. Serum samples are best kept on ice and 
spun down as soon as possible because many cytokines will begin degrading as soon as the 
sample is drawn.48 Time of day, cortisol levels, and nutritional status can all affect serum 
cytokine concentration.48 The accuracy of cytokine quantification in serum ELISA and multiplex 
assays was found to be poor, depending on the cytokine.49 In serum samples, the detection of 
IL-2 was low at several tested concentrations;49 one explanation for this is the presence of 
soluble IL-2 receptors in circulation.50 Some of these factors could have affected detection of 
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cytokines in our samples. In a study of atopic dermatitis, IL-2 was detected in plasma in 9 out of 
20 dogs with disease, but the values were below the limits of detection in 6 of those dogs.51 The 
T cell growth factor cytokines, IL-2, IL-7, and IL-15 were also difficult to detect in the serum of 
dogs that received a single IV dose of Escherichia coli lipopolysaccharide.52 We had similar 
difficulty in detecting T cell growth factor cytokines in TZL cases, TZCUS and control serum 
samples.  
In vitro we did identify that IFN-γ and TNF-α could be induced with stimulation by PMA 
and ionomycin (Fig 3.1, Supplemental Table 3.2). These are considered inflammatory cytokines 
and in other mammals, PMA/ionomycin has been shown to induce Th1, inflammatory cytokines 
more efficiently.40,53,54 We also attempted to measure IL-2 and IL-4 production in TZL but we did 
not have a sensitive enough method. IL-4 was detected in the serum in a study of dogs with 
atopy with no differences between disease and control dogs, and concentrations were in the 
100 -200pg/mL range,51 which is below the limits of detection of the assay we attempted to 
use. We were unable to optimize our assay to limits of detection below 300pg/mL which was 
not sensitive enough for expected production in cell culture. It would be interesting to 
determine if we could detect intracellular IL-4 in TZL cells; however, intracellular IL-4 has been 
measured in PBMCs of dogs with Leishmania infection with very low production (< 5%).55 In 
normal dogs, the maximal expression of IL-4 of PBMCs stimulated with PMA/ionomycin was a 
mean of < 2% of CD4+ and CD8+ T cells.56 IL-2 activity in dogs has also been measured using 
bioassays with canine IL-2 –dependent T cell blasts or murine interleukin-2 dependent T cell 
lines.57,58 IL-4 and IL-2 were also detected in dogs with semi-quantitative RT-PCR with mitogen 
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stimulation, which is a sensitive method to detect cytokine levels.58,59 These methods may be 
more successful at detecting IL-2 or IL-4 in our system.  
The stimulatory methods can also have an effect on the cytokines produced. For 
instance, PMA/ionomycin has been shown to increase production of certain cytokines including 
IFN-γ, TNF-α, IL-2 and IL-6; however, IL-4 and IL-10 production were unaltered and produced at 
low concentrations.53 Other studies have had similar findings with respect to stimulation with 
PMA/ionomycin and production of IFN-γ,54 TNF-α and IL-10.60 We were unable to confirm 
evidence of production of Th2 cytokines or immunosuppressive cytokines with ELISA and canine 
multiplex methods in vivo or in vitro.  
Our original hypothesis was that TZL may induce immunosuppression in a subset of 
cases, based on the observation that demodicosis is present in at least 10% of TZL cases.30,31 
TGF-β expression has been found to be higher in the serum of dogs with demodicosis,61 and we 
found high gene expression of TGF-β in TZL cases in Chapter 1. However, we were unable to 
induce TGF-β in our TZL cell culture system, and we did not find a difference in production of 
this cytokine in TZL cases versus control dogs (Fig 3.2). TGF-β expression in TZL may be affected 
by post-transcriptional regulation. TGF-β1 has been reported to have evidence for post-
transcriptional and/or post-translational regulation as the message levels are not correlated 
with protein secretion.62 Increased TGF-β1 expression is quickly induced in activated B and T 
cells yet secretion increases over several days.63,64 We measured TGF-β production at 24 hours 
and we may find more significant differences if measured at a later time point. Alternatively, 
the in vitro culture conditions may not have accurately mimicked the tumor microenvironment 
124 
 
to induce cytokine production. Using serum free media might also aid in detection of small 
differences in TGF-β production in this disease. 
Some of the most effective contributors of Th1 and Th2 differentiation are cytokines. 
Common examples are IFN-γ potentiating Th1 cells65 and IL-4 leading to differentiation of Th2 
cells.66-68 Th1 and Th2 subsets potentiate their own differentiation with mutual inhibition of the 
other subset. For example, IFN-γ suppresses Th2 cell function while IL-4 and IL-10 inhibit 
development of Th1 cells.41,69-71 TGF-β has also been shown to inhibit IFN-γ production.72,73 
Furthermore, GATA3 can inhibit IFN-γ production in Th1 cells.74  Finally, exogenous galectin-1 
and galectin-1 condition media has been shown to reduce production of IFN-γ.19,23 We had 
previously identified that TZL cell express GATA3, TGF-β, and galectin-1 in Chapter 1. This gene 
expression profile led us to believe that TZL cells would inhibit the production of IFN-γ in cell 
culture and this could be a possible mechanism of immunosuppression in this disease. Contrary 
to what we expected, CD45+ T cells were able to produce IFN-γ in TZL culture, and we didn’t 
find any difference in production of IFN-γ in CD45+ T cells in normal lymph nodes versus TZL 
lymph nodes (Fig 3.5). In some cases, TZL cells did express IFN-γ but this was not significantly 
different from cases with no stimulation. Additionally, the percentage of TZL cells expressing 
IFN-γ was lower than CD45+ T cells. In cutaneous T cell lymphoma in humans, the neoplastic T 
cells express increased Th2 cytokines and low levels of IFN-γ.20 In this disease benign T cells, 
when removed from malignant T cells, show enhanced Th1 responses and decreased Th2 
response. Similarly, T cells from healthy individuals that were co-cultured with neoplastic CTCL 
cells exhibited markedly decreased IFN-γ production.20 Although the TZL cells did not suppress 
the phenotypically normal T cells in culture, it is possible that TZL cells would suppress T cells 
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from normal dogs and this could be a path to explore in the future. The ‘normal’ T cells in TZL 
may not be functionally normal and so we may be missing the possible immunosuppressive 
effects of TZL cells. However, the neoplastic CTCLs have been shown to produce Th2 
cytokines,20,75,76 which we have not been able to confirm in TZL cells.  
As mentioned above TZL cells were found to express high levels of galectins in Chapter 
1. Galectin-1 can cause death in activated T cells, whereas galectin-3 can also act intracellularly 
to prevent apoptosis in T cells.27,28 Galectin-1 treatment has been shown to shift the immune 
response toward a Th2 phenotype with inhibition of T cell proliferation.77-79 These features of 
galectins suggested that TZL might be able to suppress CD45+ T cells by decreasing proliferation 
and increasing galectin mediated cell death of these cells. To the contrary, CD45+ T cells were 
able to proliferate in the presence of TZL cells (Fig 3.6 and Fig 3.7). In this in vitro system we 
found no significant evidence for suppression of CD45+ T cells by TZL cells. Differential 
sialylation of N-and O-glycans on cell surface is related to susceptibility to galectin induced cell 
death.21 Glycotransferases, such as a-2,6 sialyltransferase (ST6Gal1) may modify N-acetyl-
lactoasmine sequences and prevent galectin-1 binding.80 It is possible that TZL cells produce 
glycotransferases responsible for these additions, and that by-standard T cells are also 
glycosylated and protected from galectin-1 induced apoptosis. We did measured expression of 
ST6Gal1 in Chapter 1 and it was increased in TZL cases compared to controls, but not 
significantly.  
We were unable to confirm immunosuppression of normal T cells in TZL using an in vitro 
model, despite clinical evidence and gene expression suggestive of immunosuppression in this 
disease. It is possible that rather than TZL inducing immunosuppression, chronic inflammation 
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and an immunosuppressive environment are involved in TZL development. Associations 
between inflammation and cancer development have been established in mammals, including 
vaccine-induced soft tissue sarcomas in cats83 and implant-associated osteosarcoma in dogs.84 
In humans, there is also evidence of unresolved chronic inflammation being involved in 
promoting tumors though initiation and metastasis in several types of cancer.11 Non-steroidal 
anti-inflammatory drugs (NSAIDs) have been shown to reduce the risk of colon cancer 
development in patients with a genetic predisposition,85 as well as the incidence of lung cancer 
in patients that were smokers.86 Interestingly, a risk factor study of TZL found that dogs that 
were administration of omega-3 fatty acids were 3 times less likely to develop TZL (Labadie et 
al., manuscript under review). Since omega-3 supplements decrease inflammation, the 
protective association of this in TZL might support a role for inflammation in the development 
of TZL.  
 In conclusion, we did not find a difference in serum cytokine production in dogs with 
TZL. In vitro we were able to induce production of IFN-γ and TNF-α when stimulated with 
PMA/ionomycin in TZL cases. Based on lymph node cell culture in TZL the primary source of IFN-
γ appears to be from the normal T cells in culture; however we were able to induce lower levels 
of IFN-γ production in TZL cells. Most strikingly, we did not see inhibition of IFN-γ production in 
the normal T cells in culture with TZL cells. Additionally, in TZL we did not find evidence for 
suppression of proliferation in normal T cells. TZL showed increased expression of 
immunosuppressive molecules, TGF-β, galectin-1 and -3, that are reported to be involved in 
suppression of proliferation, IFN-γ production, and causing apoptosis of Th1 and Th17 cells; 
despite the reported consequences of these molecules, we were unable to confirm any of these 
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features of immunosuppression in our cell culture system. We may need to enhance our in vitro 
system to more closely mimic the in vivo microenvironment or immunosuppression in this 
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CHAPTER 4: INCREASED FREQUENCY OF CD45 NEGATIVE T CELLS (T ZONE CELLS) IN OLDER 
GOLDEN RETRIEVER DOGS1 
Summary 
T zone lymphoma (TZL) is characterized by the clonal expansion of T cells lacking 
expression of the pan-leukocyte antigen CD45 (TZ cells). A strong breed predisposition is 
observed in Golden retrievers. This study aimed to confirm aberrant CD45 mRNA expression 
and determine if Golden retrievers without clinical lymphoma have an increased frequency of 
circulating TZ cells. Gene expression analysis on confirmed TZL cases showed a significant 
decrease in CD45 expression compared to normal dogs. Peripheral blood samples from senior 
dogs, 242 Golden retrievers and 42 non-Golden retrievers, without evidence of 
lymphoproliferative disease were assessed for the presence of TZ cells by flow cytometry. 
Thirty-one percent of Golden retrievers had TZ cells compared to 14% of non-Golden retrievers. 
Thirty-four percent of Golden Retrievers with TZ cells had a clonal T cell receptor gamma (TRG) 
gene rearrangement. Interestingly 20% of Golden retrievers without TZ cells also had a clonal 
TRG rearrangement. Golden retrievers may have an increased risk of TZL due to an increased 
frequency of TZ cells.  
Background 
 Canine lymphoproliferative disease characterization has improved with the use of 
ancillary diagnostics including immunocytochemistry, immunohistochemistry, flow cytometry, 
PCR for antigen receptor rearrangement (PARR) and, more recently, gene expression profiling.  
1Chapter published as: Hughes KL, Labadie JD, Yoshimoto JA, Dossey JJ, Burnett RC, Avery AC. 
Increased frequency of CD45 negative T cells (T zone cells) in older Golden retriever dogs. Vet 
Comp Oncol. 2018.16(1):E109-E116 
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Many of the canine lymphoproliferative diseases mimic human disorders and efforts have been 
made to utilize the World Health Organization scheme when classifying canine lymphoma.1,2 As  
these subtypes become more completely defined, some marked breed-specific predilections for 
different subtypes have become evident. For example, Boxers3,4 and Golden retrievers4 are 
highly represented amongst the group of dogs that develop an aggressive form of T cell 
lymphoma, histologically characterized as lymphoblastic lymphoma or peripheral T cell 
lymphoma not otherwise specified (PTCL-NOS).3 Another example includes a recent study in 
which small breed dogs were found to be over-represented in the group of dogs that develops 
B cell chronic lymphocytic leukemia.5 Breed-specific tendencies to develop particular disorders 
indicate a high likelihood for genetic risk factors underlying these diseases, and position the dog 
as a useful model for studying the role of genes in the development of lymphoproliferative 
disease.    
T zone (or clear cell) lymphoma (TZL) is a variant of PTCL-NOS that is described in both 
humans and dogs.6,7 TZL is characterized by neoplastic T cells expanding the paracortex and 
medullary cords and compressing the fading germinal centers.1 The cells are small to 
intermediate in size with very rare mitoses.1,8  
The prevalence of TZL is estimated as 3-14% of all canine lymphomas in two different 
large-scale studies1,2 and there is a striking breed predilection in dogs, with 40% of all TZL cases 
being diagnosed in American Golden retrievers.9  European Golden retrievers, which represent 
a discreet genetic group10 do not appear to be over-represented in TZL.11,12 The median age of 
dogs diagnosed with TZL is 10 years old in multiple studies.9,11 Lymphadenopathy and 
lymphocytosis are both commonly associated with TZL, and the presence of TZL in the blood 
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does not appear to indicate a more aggressive clinical course.9,11,13 The overall median survival 
time is reported to be 76011 to 1022 days,13 consistent with an indolent nature.  The disease is 
often detected as an incidental finding of lymphocytosis and/or lymphadenopathy; interestingly 
10 – 50% of cases present with or develop demodectic mange,13,14 suggesting that the TZL may 
cause immunosuppression in a subset of cases.   
TZL exhibits a unique phenotype: the neoplastic T cells do not express the pan-leukocyte 
antigen CD45, allowing for reliable diagnosis by immunophenotyping.9 Recently this was 
corroborated with immunohistochemistry.15  Additionally, real-time PCR for CD45 transcript 
and DNA showed almost complete lack of CD45 gene expression but presence of CD45 DNA.15  
CD45 is a transmembrane protein tyrosine phosphatase that has multiple isoforms that are 
abundantly expressed on the cell surface of all leukocytes.16-18 Two major isoforms of CD45 
have been recognized in canine T cells, with expression varying based on phenotype and 
activation status.19  The T cell receptor (TCR) is closely associated with CD45, and CD45 
expression is necessary for T cell response to antigen.16  
TZ cells express increased levels of the complement receptor CD21,9,20 which is 
commonly used to identify B cells in dogs. In previous studies, CD21 expression has been 
identified by flow cytometry9,20 and with microarray in TZL,21 however, expression was not 
compared to normal T cells in these studies. The neoplastic cells can express CD4+, CD8+, 
neither subset antigen,9 or, rarely, both.11   
Our laboratory is conducting a study of environmental and genetic risk factors for TZL in 
Golden retrievers. While screening control Golden retrievers (dogs > 9 years old with no clinical 
evidence of lymphoma of any type) we discovered that many dogs had small but detectable 
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numbers of CD5+CD45- cells (TZ cells) in their peripheral blood. This observation caused us to 
ask if TZ cells are equally frequent in all dogs over the age of 9, or if this is a breed-specific 
phenomenon. 
The objectives of this study are two-fold. First, we wanted to further validate the 
phenotype of TZ cells by examining mRNA levels for the proteins that characterize these cells: 
CD45 and CD21. Then, we wanted to determine the frequency of TZ cells in non-lymphoma 
bearing older Golden retrievers and other purebred dogs. We hypothesized that TZ cells would 
be found more frequently in Golden retrievers than other breeds reflecting the breed 
predilection observed for this form of lymphoma. Validation of this hypothesis would suggest 
that an early event in the development of TZL is loss of CD45 expression, and would pave the 
way for mechanistic studies of oncogenesis. 
Methods 
Selection of cases and controls for gene expression analysis 
To investigate the aberrant antigen expression seen in TZL, we measured the levels of 
CD45 and CD21 mRNA from case and control samples. Case samples included blood or lymph 
node aspirates from 34 dogs diagnosed with TZL by flow cytometry through the Colorado State 
University Clinical Immunology (CSU-CI) laboratory between December 2013 and March 2015. 
These cases were not breed restricted. A diagnosis of TZL included greater than 60% of the 
lymphocytes characterized as TZ cells (CD5+CD45-cells) in lymph node samples or the presence 
of ≥5,000 TZ cells/µL in the peripheral blood of dogs with lymphadenopathy or lymphocytosis 
respectively. These criteria were based on previous publications in which the minimum criteria 
for the diagnosis of lymphoid malignancy was 60% or greater aberrant cells in a lymph 
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node,22,23or 5000 cells/μL or greater phenotypically homogeneous expansion of lymphocytes in 
peripheral blood.5 The control group consisted of T cells purified from lymph node and thymic 
tissue collected from 8 young, healthy, hound mix dogs that were being utilized for a surgical 
continuing education course. All of these procedures were approved by the IACUC committee 
at Colorado State University. 
Cell sorting for gene expression studies 
  TZL cases: TZ cells were purified from blood or lymph node of TZL cases by negatively 
selecting CD45-expressing cells. Briefly, based on the Miltenyi Biotec protocol, the nucleated 
cells were re-suspended in MACS buffer (PBS-0.5% BSA-2mM EDTA) resulting in a total volume 
of 100 µL after addition of the primary antibodies. All antibodies were purchase through Abd 
Serotec/Bio-Rad. Anti-CD45 PE (Pan-leukocyte, clone YKIX716.13) at a concentration of 0.01 
µg/µL was added and the samples were incubated for 10 minutes in the dark at 4oC, and then 
washed with MACS Buffer. The supernatant was removed and samples were resuspended in 
80-90 µL of MACS Buffer and 10µL of anti-PE beads (Miltenyi Biotec, San Diego, CA). The 
samples were incubated for 10 minutes in the dark at 4oC and washed with MACS Buffer. The 
supernatant was removed and the cells were resuspended in 500 µL of MACS buffer. For 
magnetic depletion of CD45+ cells, the 500µL cell suspension was loaded onto an LD column 
that had been placed into a MidiMACS separator. CD45- cells that were not bound by beads 
were collected and tested for purity by flow cytometry. Fig 4.1 shows an example of sorted 
CD5+CD45- (TZ) cells purified by this method. The median purity of the sorted TZ cells was 98%, 
and only one sample had lower than 90% purity (82%).   
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 Controls: CD4+ and CD8+ T cells were purified from the lymph nodes and thymus of 8 
healthy control dogs to be used as normal controls in a series of studies of gene expression 
profiling in T cell lymphoma. Cells were stained with anti-CD18-PE (Human CD18, clone 
YFC118.3), anti-CD5-FITC (T cells, clone YKIX322.3) and either anti-CD4-PB (CD4 T cells, clone 
YKIZ302.9) or anti-CD8-FITC (CD8 T cells, clone YCATE 55.9) and sorted by fluorescence 
activated cell sorting on a MoFlo cell sorter (Beckman Coulter, Fort Collins, CO). All samples 
were analyzed for purity, and only those samples with >90% of the desired cells were used for 
RNA purification. 
 
Figure 4.1. Example of TZ cells purified from one dog for gene expression. A. B., Plots 
from the peripheral blood in a TZL case before sorting for TZ cells, and C.D., are plots 
from the same sample of peripheral blood after purification of TZ cells. The TZ cells are 
in the TZ gate, normal T cells are in the CD5 gate. A. C., depict light scatter properties. B. 






Gene expression using NanoString technology 
Expression of CD45 and CD21 was measured using NanoString technology. NanoString 
technology was employed because it does not require high quantity or quality of RNA, such as 
RNA derived from convenience clinical samples that have been shipped and then further 
manipulated once arriving in the laboratory. Only 100ng or less of total RNA is needed, the 
detection method has a 0.1-0.5 fM detection limit and the assay is reproducible (R2 = 0.999 
average for replicates).24  Gene expression is measured by counting the number of transcripts 
for each gene of interest, rather than using relative expression as is done with microarrays, and 
there is no PCR amplification step. 
After sorting, the cell fractions were suspended in RNA lysis buffer prepared according 
to the Purelink RNA mini kit (Life Technologies, Carlsbad, CA) and stored at -80o C until analysis. 
RNA samples were analyzed for degradation and concentration using Agilent RNA ScreenTape 
assay (Agilent Technologies, Santa Clara, CA). Samples had concentrations ranging from 1250 – 
129000pg/µL and RNA integrity numbers (RIN) ranging from 2.6 to 7.6. Approximately 100ng of 
purified RNA per sample was hybridized overnight to the mRNA custom built probes and 
hybridized reactions were loaded into the nCounter Digital Analyzer (NanoString Technologies, 
Seattle, WA) through the University of Arizona Genetic Core.   
Probes were designed based on the predicted sequence of Canis lupus familiaris CD45. 
While multiple CD45 isoforms have been annotated in the dog, only two isoforms have been 
shown to be expressed in the dog. The difference in these two isoforms is the presence or 
absence of exon 4, which is included in the larger molecular weight form of CD45.19 Exon 4 is 
expressed by naïve T cells, but not expressed in the majority of activated and memory T cells in 
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humans.16,25 Therefore, two probes were designed to detect CD45 expression (Fig 4.1, Table 
4.1). The probe designed for PTPCRb was a pan-CD45 probe predicted to bind to both 
demonstrated canine isoforms19 as well as all predicted possible canine isoforms by analogy 
with mouse and human studies.18  The second probe, PTPRCa, was predicted only to bind to the 
higher molecular weight isoform of CD45 (Fig 4.2).   
The CD21 probe was designed to detect all three predicted canine isoforms of this 
protein (Table 4.1). Gene expression was normalized using 6 housekeeping genes (Table 1) 
which were chosen from a group of 15 housekeeping genes because they exhibited low 
variability between dogs. 
 
 
Figure 4.2. CD45 splice variants. Graphic depiction of CD45 mRNA, predicted splice 
variants and mapping of designed probes for PTPRCa and PTPRCb. Each red arrow 
represents an exon, and the first 4 exons are enumerated.  
 
Table 4.1. Probe design for CD45, CD21, and housekeeping genes. 
Gene Symbol 
NCBI reference 
sequence  Target region of sequence  
PTPRC (CD45b) XM_005622278.1 1134-1233 
PTPRC (CD45a) XM_005622278.1 279-378 
CR2 (CD21) XM_005622319.1 2436-2535 
Housekeeping genes 
GUSB NM_001003191.1 1363-1462 
SDHA XM_535807.4 1641-1740 
HPRT1 NM_001003357.1 177-276 
EEF1G XM_848484.3 1066-1165 
TBP XM_005627736.1 666-765 
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POLR2A XM_852751.1 671-770 
 
Selection of dogs for quantifying CD45-negative T cells in peripheral blood 
The frequency of TZ cells in the peripheral blood was assessed in two populations of 
dogs: Golden retrievers (GRs) and non-Golden retrievers (non-GRs). GR samples were obtained 
from the control group of a case-control study of risk factors for TZL being conducted by the 
CSU-CI laboratory. Samples from dogs recruited June 2013 to April 2015 were utilized. Criteria 
for controls for this study included Golden retrievers, 9 years of age or older, with no suspicion 
or history of lymphoproliferative disease and no lymphocytosis. Other medical conditions, 
including cancers other than lymphoma/leukemia, did not exclude dogs from the study. Clinical 
signs were reported by veterinarians based on physical exam findings and history obtained 
during sample submission. Non-GR dogs were selected from dogs presenting to the Colorado 
State University Veterinary Teaching Hospital (CSU-VTH) between April 2014 and January 2015. 
Shih tzus, which were reported to be the second most frequent breed to develop TZL,9 were 
excluded from this study and will be part of a separate investigation.  Medical records were 
reviewed to identify purebred dogs, 9 years and older. Dogs with prior diagnosis or evidence of 
lymphoma/leukemia (lymphocytosis, etc.) were excluded from the study. Age for all dogs was 
calculated from the date of birth provided to the date of sample received and were rounded to 
the nearest year. Since we were detecting small numbers of TZ cells, we wanted T cell numbers 
to be adequate. In order to avoid small numbers of T cells leading to false negatives, absolute 
lymphopenia identified on the complete blood cell count (CBC) resulted in exclusion from the 





Routine CBCs were performed by the Clinical Pathology Laboratory at the CSU-VTH and 
included both automated cell counts (Advia 120 Hematology Analyzer, Siemans, Tarrytown, NY) 
and blood smear evaluation for assessment of cell morphology and a manual white blood cell 
differential count.   
Immunophenotyping by flow cytometry was performed on peripheral blood collected in 
EDTA tubes with a panel of antibodies used for cellular labeling, as previously described9 and 
listed in Table 2. Antibodies included CD45 (pan-leukocyte), CD21 (B cells) and CD5 (pan-T cell). 
CD45 expression was assessed in the same staining reaction as CD5 and CD21. All data analysis 
for flow cytometry was performed with Kaluza software (Beckman Coulter, Brea, CA). Samples 
were considered positive for TZ cells if the percentage of TZ cells was greater than 1% of the 
total population of all lymphocytes (T and B cells). If 1% or fewer of the lymphocytes were TZ 
cells the dog was considered to be negative for TZ cells and was categorized as such in both the 
GR and non-GR populations. 
Table 4.2. Antibody panel for flow cytometry analysis. Unless otherwise noted, all antibodies were 
purchased from AbD Serotec. Clones are as follows: CD45 = YKIX716.13, CD18 = YFC118.3 (human 
CD18), CD4 = YKIX302.9, CD8 = YCATE 55.9, CD5 = YKIX322.3, CD21 = CA2.1D6, CD22 = RFB4 
(human CD22, purchased from AbCam), CD3 = CA17.2A12, CD14 = TUK4 (human), class II MHC = 
YKIX334.2, CD34 = 1H6, CD25 = P2A10 (purchased from eBiosciences). 
Tube Antibody Specificity and Fluorochrome 
1 
M IgG1-FITC/M IgG1-PE/M IgG1-Alexa 647/M IgG1-Alexa 700/M IgG1-PE-750/M IgG1-
Pacific Blue 
2 CD3-FITC/CD25-PE/CD5-APC/CD8-Alexa 700/CD4-Pacific Blue 
3 Class II MHC-FITC/CD22-PE/CD21-Alexa 647 
4 Class II MHC-FITC/CD34-PE/CD5-APC—CD14-PE-Alexa 750 
5 Class II MHC-FITC/CD18-PE/CD5-APC/CD14 PE-Alexa 750/CD4-Pacific Blue 





The presence of a clonally expanded lymphocyte population was detected by PARR for 
the TRG as previously described26 with modifications noted in supporting information (Table 4.3 
and Fig 4.3).  The presence of a clonally expanded lymphocyte population was detected by 
PARR (PCR for clonal antigen receptor rearrangements) as originally described in Burnett et al,9 
but with substantial changes that were established in 2012.  These changes reflect increased 
knowledge of the structure of the T cell receptor gene and gene usage. 27-29 
Genomic DNA was extracted from clinical samples with the QIAamp DNA Mini Kit 
(Qiagen, Valencia, CA) according to the manufacturer’s instructions. A “touchdown PCR” 
protocol was utilized. Initial denaturation and polymerase activation were at 95° for 15:00. 
Cycling conditions were: 10 cycles of 94° for 0:30, 64-59° for 0:30 (annealing temperature 
decreased by 0.5° every cycle) and 72° for 1:30, and 30 cycles of 94° for 0:30, 59° for 0:30 and 
72° for 1:30 with a final extension of 72° for 7:00. Genescan analysis was carried out on an ABI 
3130xl system calibrated for use with Applied Biosystem’s five-dye chemistry, the DS-33 Dye 
Set (G5 filter set)(Life Technologies/Applied Biosystems, Carlsbad, CA). One µL of a ten-fold 
diluted PCR product was mixed with 14.5µL HiDi formamide and 1µL of GS600LIZ standard for 
each reaction to be analyzed. Data were analyzed with GeneMarker software (Softgenetics, 
State College, PA).      
The PARR assay was carried out in two separate reactions. The primers for each reaction 
are shown in Table 4.3. The amplification reaction containing the immunoglobulin gene primers 
also includes amplification of the rhodopsin gene in order to verify the presence of amplifiable 
DNA.   
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The amplification reaction containing the TCR gene primers was carried out in a second 
reaction. This reaction results in the amplification of 3 V gamma gene families, which are 
distinguishable by the size of the PCR product and the dye attached to each primer (Table 4.3). 
A result was considered clonal if amplification of any given family resulted in from 1 – 4 clonal 
peaks that were 3x the height of the baseline. Examples of results are shown in Fig 4.3. This 
assay detects clonal T cells in 88% of flow cytometrically9 confirmed T zone lymphomas (n = 
193, unpublished results). 
The amount of blood used for each reaction was 200μL and a result was considered 
clonal if one or two peaks were seen in the electropherogram that were greater than 3x the 
baseline. Equivocal clonal TRG gene rearrangements were identified when the peak height did 
not quite reach the 3x threshold, but was nonetheless prominent. 







JGG1 VG2 CCCTCCTGTTTCCCGGTA Fam (large product) 
DPD VG7 ARGCCATGTACTACTGTKCCTG Fam (small product) 
JGG12 VG3 CCCCAGGCACTTCAGTCTAC Ned 
JGG7 JG TAACCCTGAGMAYTGTGCCA 
 
DPG JG TAACCMTGAGCTTTGTGCCA 
DPF JG CCTTGTCCAAATATCTTGATCCA 






Figure 4.3. Examples of polyclonal (negative) and clonal (positive) PARR results. A. 
Amplification of a reactive lymph node using the primers described in Table 4.3. The 
low molecular weight PCR products in the 60 nucleotide range are amplified with V 
gamma 7 primer and the higher molecular weight PCR products (blue) in the 470 
nucleotide range are amplified with V gamma 2 primer. The PCR products in the 420 
range (black) are amplified with V gamma 3 primer. B. Blood from a GR with TZ cells in 
the peripheral blood revealing clonal products detected by all three V gamma primer. 
 
Statistical analysis 
 nCounter software (NanoString technologies) was used to carry out the normalization of 
mRNA levels in the gene expression study. To compare gene expression between cases and 
controls, a Student’s t test was performed (Prism 6; Graphpad, La Jolla, CA). The gene 
expression value was reported as the absolute number of transcripts, which was transformed to 
the signal log2 ratio (a signal log2 ratio of 1 is equal to a fold change of 2) to determine the p-
value. To compare the prevalence of TZ cells in the peripheral blood of GRs versus non-GRs and 
the percentage of GRs (with and without TZ cells) with a TRG clonal result, a Pearson’s Chi-
squared test was performed. The difference in CD21 expression between TZ cells and normal T 
cells in the same dog was calculated using a paired Wilcoxon test of the log median 
fluorescence intensity. The scatter size of each population was compared using a paired t-test. 
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Differences in breed, sex, and hematological characteristics were analyzed using Pearson’s Chi-
squared tests (Prism 6; Graphpad) Median age between groups was compared using the Mann-
Whitney test. Statistical significance was defined as p< 0.05.   
Results  
Gene expression of CD45 and CD21 
 We first wanted to validate the observation that TZ cells downregulate CD45 and 
upregulate CD21 by measuring mRNA levels, since expression of these two proteins has been 
described as unique features of TZL,9,15,20,21Forty-eight samples (14 sorted T cell controls and 34 
TZL cases) from lymph node, peripheral blood, and thymus (controls only), were analyzed for 
mRNA counts using NanoString technology.   
 The results showed that the mean log2-transformed CD45 mRNA counts in TZ cells was 
5.2-8.4 fold (log2 fold change) lower than in controls (p < .0001, Table 4.4) depending on the 
isoform detected. CD21 mRNA counts were more variable among TZL cases, but the median 
value was 3.3 fold higher than CD21 mRNA counts in controls (Table 4.4) (p < .0001). These 
findings indicate that mRNA levels reflect protein expression, and verify that the antibodies 
used for these studies are recognizing the appropriate corresponding proteins. Furthermore, 
the results support previous findings that no variant of CD45 is expressed by the TZ cells.   
Table 4.4. Expression of CD45 and CD21 in T zone lymphoma cases and controls. 











CD45a 168.8 129.3-491.3 6113.0 4840-7476 -5.2 <.0001 
CD45b 124.3 32.75-1165 43190.0 40740-48800 -8.4 <.0001 




Frequency of TZ cells in senior GRs and non-GRs purebred dogs 
We enumerated TZ cells in 242 peripheral blood samples from GRs. Seventy-four of 
these dogs (30.6%) had variable numbers of TZ cells in their peripheral blood. This was 
significantly higher than the percentage of non-GRs with TZ cells in the peripheral blood (p = 
0.03). The percentage of TZ cells varied from 2–95% of all T cells, median = 18.1% (Fig 
4.4A.,B.,E). The median fluorescence intensity (MFI) of CD21 in TZ cells (MFI = 12) compared to 
normal T cells in the same dog (MFI = 0.55) was significantly higher (median difference = 7.0, p 
< 0.0001) (Fig 4.5). In GRs, the size of TZ cells (median size = 361) was also significantly larger 
than normal T cells (median size = 342) with a median difference of 15.21 (p = 0.0003, not 
shown). 
Of the 42 non-GRs, there were 6 (14%) dogs with small numbers of TZ cells identified by 
flow cytometry and 36 dogs without TZ cells. Among the 6 dogs with TZ cells, the proportion of 
TZ cells ranged from 6-20% of all T cells, median = 17.4% (Fig 4.4C.,D.,E.). In dogs with TZ cells, 
the MFI of CD21 in TZ cells (MFI = 7.3) compared to normal T cells (MFI = 0.37) was significantly 
higher (median difference = 11.5, p < 0.03) (Fig 4.5). There was no significant difference in the 
size of TZ cells versus normal T cells in non-GR dogs. There was no significant difference in age, 
sex, presence of anemia, or presence of thrombocytopenia between the dogs with TZ cells and 





Figure 4.4. Older dogs have variable percentages of TZ cells in their peripheral blood. 
A.,B. TZ cells from a healthy GR. In this sample the number of TZ cells represented 95% 
of the total T cell population, the highest percentage of TZ cells detected in non-
lymphoma bearing GRs. C.,D. TZ cells in a non-GR, the highest percentage TZ cells 
detected in the blood of non-GRs. In this sample the number of TZ cells represented 
20% of the total T cell population. E. The range of TZ cells in GRs (n = 74, median = 
18.1%) versus non-GRs (n = 6, median = 17.4%). The whiskers are set at the minimum 




Figure 4.5. TZ cells express higher levels of CD21 than normal T cells. The median 
fluoresce intensity (MFI) of CD21 in CD45+ T cells (normal T cells) versus CD45- T zone 
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T cells (TZ cells) in Golden retrievers (GRs) and non-Golden retrievers (non-GRs). In 
both the GR and non-GR samples, TZ cells express higher levels of CD21 than the 
normal T cells. The whiskers are set at the minimum and maximum value.  
 
Clonality assessment 
PARR was performed in 67 of the 74 cases of GRs with TZ cells (Table 4.5). Twenty-three 
(34.3%) of the cases had clonal TRG gene rearrangements, one dog (1.5%) had an equivocal 
result, and 43 (64.2%) were polyclonal. Additionally, 32 (20%) of 157 GRs with no evidence of TZ 
cells in peripheral blood had clonal TRG gene rearrangement. The percentage of GRs with TZ 
cells with a clonal TRG gene rearrangement was significantly higher than the percentage of GRs 
without TZ cells with a clonal TRG result (p = 0.026).   
All 6 non-GRs with TZ cells had PARR performed, and all had polyclonal TRG gene 
rearrangements, demonstrating no evidence for clonality (Table 4.5). The PARR assay was 
performed on 34 of the non-GRs without TZ cells and 2 had a clonal TRG gene rearrangement. 
The clonal TRG gene rearrangements in these dogs may have represented an emerging T cell 
lymphoma/leukemia although this cannot be confirmed because both dogs were euthanized 
shortly after the sample was obtained due to progressive transitional cell tumor of the bladder 
in one dog and progressive immune mediated hemolytic anemia in the other.   
Table 4.5. PARR results for GR and non-GR with and without TZ cells in the blood. n 
indicates the number of samples available for the PARR assay. The percentage is the number 
of samples with that result out of the total samples with a PARR result.  
 
GR with  TZ 
cells 






PARR results n = 67 % n = 157 % n = 6 % n = 34 % 
Clonal TRG gene 
rearrangement 23 34.3 32 20.4 0 0.0 2 5.9 
Equivocal clonal TRG 
gene rearrangement   1 1.5 1 0.6 0 0.0 0 0.0 
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Polyclonal TRG gene 
rearrangement  43 64.2 124 79.0 6 100.0 32 94.1 
 
Follow up studies of GRs with TZ cells 
Sequential peripheral blood samples were available for 50 dogs within the entire 
population of GRs. Twenty-two of these dogs had TZ cells in the first sample, and all of these 
dogs also had TZ cells in the follow up sample. Twenty-eight dogs had no TZ cells in the first 
sample. Of these, 12 had TZ cells in the follow up sample and the remaining 16 did not. At the 
time of this manuscript, none of these dogs had developed evidence of clinical disease, in 
particular lymphocytosis or peripheral lymphadenopathy. As of August 2018, after a 4 year 
period, the highest lymphocyte count in any of the 34 GRs with follow-up was 3700 cells/μL. 
Two of the 35 dogs (5.7%) progressed to clinical disease with peripheral lymphadenopathy. In 
these two dogs the lymphocyte count has remained within the reference range (dog 1 = 21% of 
lymph node consisting of TZL cells, highest lymphocyte count 2900 lymphocytes/μL; dog 2 = 
43% of the lymph node consisting of TZL cells, highest lymphocyte count 1600 lymphocytes/μL). 
In dog 1 the time from the initial identification of TZ cells to development of peripheral 
lymphadenopathy was 3 years and 6 months. This dog had a polyclonal PARR result for the first 
sample but later developed an identical clonal TRG gene rearrangement in the blood and lymph 
node at the time of clinical disease. In dog 2 the first sample with TZ cells was 2014 and 
lymphadenopathy was identified 3 years and 3 months later. This dog also developed a clonal 




In the remaining dogs, PARR was originally performed on 43 of the 50 dogs and the 
results did not change for 40 of the dogs. In 3 dogs, however, the PARR assay changed from a 
polyclonal to clonal result in the follow up sample. These 3 dogs had TZ cells in their blood on 
both occasions.  
Discussion 
In this study, we have found that the loss of CD45 antigen expression and the increased 
expression of CD21 by TZ cells is reflected in the expression of the relevant genes (Table 4.4). 
These findings indicate that the abnormal antigen expression in TZL is not a function of 
conformational changes in the antigen, or in the case of CD45, differentially spliced protein that 
is not detected by the antibody used in the analysis and support recent findings from another 
group.15 The expression of CD21 in TZL in our study (Fig 4.5) is in concordance with previously 
identified CD21 expression by flow cytometry,9,20 and increased CD21 (CR2) gene expression 
identified in dogs with TZL using the Affymetrix Canine_2.0 gene chip.21 In our study, the 
isolation methods for TZL cases differed from the isolation of normal T cells because of the 
limitations imposed by the use of samples submitted for diagnostic purposes. However, the 
purity and quality of RNA was similar for both cell types and our results are supportive of other 
investigations into phenotypic abnormalities of TZL9,15,20,21 These findings further characterize 
these aberrancies as occurring at both the protein and mRNA level and support the 
characterization of this particular subtype of lymphoma in dogs by immunophenotyping. We 
have demonstrated that 30% of GRs with no evidence of lymphoma/leukemia have circulating 
TZ cells. These cells can be identified in 14% of older dogs of other breeds. These proportions 
reflect the distribution of clinical TZL, where GRs represent almost 40% of all cases.9 A minority 
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of the TZ cell positive GRs (34%) had clonally rearranged TRG genes (Table 4.5). Additionally, 
20% of GRs with no evidence of TZ cells in the peripheral blood had a clonal rearrangement of 
TRG genes. PARR may be a more sensitive test than flow cytometry when there is only a minor 
clonal population within a sample. The clonal T cells in this study are suspected to be the TZ 
cells but since they were not sorted we cannot rule-out a separate emerging T cell 
lymphoma/leukemia or a reactive clonal population. We favor the hypothesis that the clonal T 
cells in these dogs may represent a pre-neoplastic state, similar to pre-neoplastic B and T cell 
disorders in people: monoclonal gammopathy of undetermined significance (MGUS), 
monoclonal B lymphocytosis (MBL), and T cell clonopathy of unknown significance (TCUS).   
MGUS is an asymptomatic plasma cell dyscrasia with low but measurable risk of 
progressing to multiple myeloma (MM).30-32 MBL is a monoclonal gammopathy with no 
evidence of lymphoproliferative disease, but the cells have a chronic lymphocytic leukemia 
(CLL) immunophenotype with rare progression to CLL (1-2% per year).33 Genetic risk factors 
have been identified in both of these disorders and they are thought to represent a pre-
neoplastic state.30,33,34 TCUS may represent a similar process for T cells, but it is difficult to 
equate the process in people with what we have described here in dogs, because T cell clonality 
in people is not defined by DNA based clonality assessment but by expansion of a family of T 
cells that use the same Vb gene, but that do not have identical T cell receptors.35 
In GRs, genetic risk factors may also contribute to increased frequency of TZ cells as well 
as progression to overt lymphoma similar to these human syndromes. If the above hypothesis is 
correct, we might expect to see progression to TZL in a subset of the dogs that carry these cells. 
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Although we only have follow up on a small portion of these GRs, we did not see significant 
expansion of TZ cells in any dog. When multiple samples of peripheral blood were available, TZ 
cells were generally mildly increased and none of these dogs showed progression of disease, 
such as lymphocytosis or lymphadenopathy. In MGUS, patients are monitored throughout their 
life as the risk of transformation is considered to be life-long. The risk for development of MM 
in MGUS is only 1% per year.30 MBL with a low-count (< 500 clonal B cells/µL)36 can be 
identified in about 5% of adults over 40 years old with rare progression to CLL,33 and in one 
study, no individuals with a low-count MBL showed progression to lymphoid neoplasia with a 
median follow-up of 34 months.37 If there was a similar risk of development of TZL in dogs with 
TZ cells, a much larger cohort needs to be identified and followed for a longer period of time in 
order to determine the risk. When we revisited follow-up samples after about 4 years we did 
find progression to clinical disease (lymphadenopathy) in 2/34 dogs (5.7%). These two dogs are 
full siblings. We also received samples from 4 other siblings and they all had small numbers of 
TZ cells. In 2 of the other siblings we have had multiple samples with no evidence of 
progression and in the other 2 siblings we only had one sample. In MGUS in humans, there is an 
increased prevalence of MGUS in families with at least one person with a lymphoproliferative 
or plasma cell disorder.38 Furthermore, the prevalence of MBL in relatives of familial CLL is 2 – 3 
fold higher in individuals over 40 years than the overall population.39-41 These studies are 
supportive of genetic factors and/or shared environmental risk factors in this syndrome which 
is also suggested by our findings. Familial clustering of lymphoma has previously been reported 




development that has yet to be identified. Recently, it was reported that diagnosis of TZL in GRs 
showed differential geographic distribution suggesting a possible environmental risk factor.43      
The ability to recognize potential pre-neoplastic states provides a system in which 
stepwise progression to neoplastic transformation can be investigated. Determining the 
significance of TZ cells in GRs and possible environmental factors or disease states which lead to 
persistence of T cell infiltration and eventual neoplastic development is ongoing. Additionally, 
identifying diagnostics to recognize pre-neoplastic states in dogs may aid in early diagnosis of 
more aggressive subtypes of lymphoma. There has been limited research looking at early 
disease detection markers in dogs with only one study applying clinical screening studies in 
neoplasia.44 In this study, blood ferritin levels showed promise as a biomarker for early 
evidence of disseminated histiocytic sarcoma in Bernese Mountain dogs.44 Further 
development and identification of novel pre-neoplastic markers would be extremely valuable 
since many purebred dogs may have genetic components contributing to higher incidence of 
certain types of cancer. 
The presence of clonal T cells in the blood of older GRs, and a smaller number of non-
GRs should be considered when interpreting the results of clonality assays. First, a positive T 
cell clonality test without supporting clinical data should not be taken to indicate neoplasia, and 
the assay should not be used as a screening test. Second, the presence of a clonal TRG gene 
rearrangement in B cell neoplasms reported by some laboratories45-47 should not necessarily be 
interpreted as aberrant rearrangements; they may in fact reflect the presence of TZ cells, which 
would not be identified without flow cytometry. 
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In conclusion, TZ cells were identified in greater than 30% of GRs, the breed with the 
highest number of dogs to develop TZL. These cells are readily identified by flow cytometry and 
aberrant antigen expression is confirmed at the gene expression level. We have found that a 
higher percentage of GRs without lymphoma have TZ cells in their blood when compared to 
other purebreds, and this reflects the frequency with which GRs develop TZL. Additionally, the 
lack of clinical signs and rare progression to disease in these dogs suggests that this is still a pre-
neoplastic state despite evidence of clonal TRG gene rearrangement. Given these findings, 
clonal TRG gene rearrangements should be interpreted with caution in non-clinical older dogs, 
particularly GRs. Continued prospective analysis of GRs to determine the biological significance 
of TZ cells and possible identification of other genetic and environmental factors involved in the 
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CONCLUSION AND FUTURE DIRECTIONS 
Determining the cell-of-origin leading to lymphoproliferative diseases can enhance our 
understanding of pathogenesis, along with identifying potential therapeutic targets. We were 
specifically interested in characterizing TZL, a subtype of PTCL, by determining the cell-of-origin, 
its proliferative capacity, immunosuppressive activity, and implications for earlier detection of 
disease. There are still gaps following our investigation as to the ultimate cell-of-origin in this 
disease and future endeavors aimed at complete identification of the molecules involved in 
proliferation or immunosuppression would be fruitful. CD45, absent from TZL cells, is necessary 
for the TCR response including cytokine production, effector functions, and proliferation.1-5 
While our work did not include determining the mechanism by which this normally abundantly 
expressed pan-leukocyte protein is lost, certainly future inquiries directed toward this question 
would be informative. Elucidating the mechanism by which this vital protein is lost could apply 
to other lymphoproliferative diseases, including cutaneous T cell lymphoma and anaplastic 
large T cell lymphoma in humans, both of which can lose expression of CD7.6,7  
Cellular Origin of TZL  
Based on our gene expression profiling, TZL is most likely derived from Th2-like cells 
with immunomodulatory functions or an induced Treg cell that does not express FOXP3. Mouse 
IL-10 producing Treg cells have been identified which do not express Foxp3 despite having the 
ability to inhibit proliferation of T cells similar to traditional CD4+ CD25+ Treg cells.9 However, 
we did not detect increased expression of Th2 type cytokines, nor were we able to confirm 





The gene codeset from our investigation was only the beginning; with the inherent 
plasticity of T cells, a more comprehensive understanding of expression in this disease will 
come from exploring numerous other genes of interest. For example, GATA3 and TGF-β have 
been associated with multiple T cell subsets including:  Th2, Treg, and Th9 cells.10-15 Our team 
has submitted TZL samples for RNA sequencing with pending results. This information will 
provide a more global view of gene expression in this disease and may further support a Th2 or 
Treg cellular origin. Still, this data may only complicate the cell-of-origin question while 
suggesting future pathways for investigation.  
There are several pathways which our codeset did not address. For example, we did not 
determine the expression of STAT516 or other transcription factors which have been implicated 
in Th2 differentiation including Dec2 and Gfi-1.17 Furthermore, It could be useful to determine 
the phosphorylation status of transcriptional regulators; exploring their associated pathways in 
TZL. Gene expression could be similar between TZL cases and controls, however 
phosphorylation status of STAT, cJun, AKT, MYC, ERK, and p38 proteins may differ. The BD 
PhosflowTM T cell activation kit is available for flow cytometric assessment of phosphorylation 
status of p38, ERK1/2, Stat1, Stat3, Stat5, Stat6 in humans and antibodies may certainly cross-
react with canine samples. Alternatively, western blot could be used to investigate 
phosphorylation status.  
Functional Pathways in TZL  
We attempted to identify proliferative and functional mechanisms of TZL cells. Gene 
expression analysis revealed increased expression of the immune modulatory molecules TGF-β, 
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galectin-1, and galectin-3, which are involved in suppression of proliferation,18 IFN-γ 
production,18,19 and cause apoptosis of Th1 and Th17 cells.20  However, we were unable to 
confirm any of these features of immunosuppression in TZL cells in vitro. In addition to the 
challenge of identifying effector functions and cytokine production in TZL, we also had difficulty 
inducing proliferation in these cells. We were eventually able to induce proliferation of TZL cells 
through by-passing the TCR. CD25 (IL-2R) expression was variable in our gene expression data, 
but has previously been identified to be increased in TZL21 with IL-2 playing a role in priming 
Th2 cells.22 IL-2 was found to induce proliferation in a subset of cases, suggesting IL-2 may 
contribute to proliferative mechanisms in TZL.  
Future Directions 
Although IL-2 was identified as a potential growth factor for TZL cells, other mechanisms 
may be acting in vivo. Our investigation did not include B cell signaling or inflammatory cell 
signaling in TZL cell cultures. Future studies looking at TZL cell proliferation mechanisms in the 
lymph node may provide some insight. Lymph node aspirates would include the 
microenvironmental B cells and dendritic cells which may play a role in TZL cell activation. From 
gene expression data, we know TZL cells express CD40L (TNFSF5) and Notch at significantly 
higher levels than controls and both of these molecules can be involved in T cell activation.23,24 
Direct interaction between CD40 on APCs and CD40L on TZL cells, or between jagged and delta-
like ligands on APCs and Notch on TZL cells, could be involved in signaling pathways for this 
disease. These interactions could be studied using cell cultures from lymph node samples. 
Adding artificial antigen presenting cells to culture, such as K562 cells which have been used to 
expand T cells in dogs,25 could be another way to enhance proliferation in TZL. Alternatively, 
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culturing TZL cells with additional growth factors such as IL-15 and/or IL-7 may elicit a greater 
response.  
Since CD45 is necessary for T cell proliferation and cytokine production in mice and 
human cell lines,1,5,26 investigating the mechanism by which CD45 is lost in TZL, may provide 
insight into alternative signaling pathways in this disease. Interestingly, CD45 DNA is present 
while the mRNA is absent in TZL,27 which suggests transcriptional regulation may be involved in 
the development of this disease.  Sequencing the CD45 gene could be useful to suggest possible 
mechanisms for decreased transcription, such as a stop codon or splice variant leading to 
termination of transcription. Furthermore, epigenetic changes in transcription could contribute 
to decreased expression in TZL. Bisulfite sequencing to determine the methylation pattern for 
CD45 could elucidate a mechanism for decreased transcription.  
As a result of this work, we identified several molecules which may be involved in the 
pathogenesis of TZL including GATA3, TGF-β, and galectins. IL-2 signaling may be an important 
aspect of cell signaling in this disease. The IL-2 signaling pathway or other signaling pathways 
could be a potential therapeutic target since conventional multidrug chemotherapy may not 
improve survival in this disease. Our studies and future investigations including RNA 
sequencing, protein phosphorylation and epigenetic patterns of CD45 would be consistent with 
prior attempts to determine cellular origin and consider functional implications in human B cell 
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